[{"text": "A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.", "triple_list": [["amiodarone", "mechanism", "indinavir"]]}, {"text": "Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.", "triple_list": [["amiodarone", "advise", "protease inhibitor"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["atropine", "effect", "pralidoxime"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["pralidoxime", "effect", "atropine"]]}, {"text": "Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.", "triple_list": [["probenecid", "effect", "PAH"]]}, {"text": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "triple_list": [["Sonata", "effect", "ethanol"]]}, {"text": "Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.", "triple_list": [["Sonata", "effect", "imipramine"]]}, {"text": "Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.", "triple_list": [["Sonata", "effect", "thioridazine"]]}, {"text": "Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.", "triple_list": [["zaleplon", "mechanism", "promethazine"]]}, {"text": "Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.", "triple_list": [["rifampin", "mechanism", "zaleplon"]]}, {"text": "Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.", "triple_list": [["zaleplon", "mechanism", "erythromycin"]]}, {"text": "Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.", "triple_list": [["Cimetidine", "mechanism", "zaleplon"]]}, {"text": "Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.", "triple_list": [["Sonata", "mechanism", "cimetidine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ", "triple_list": [["atropine", "effect", "pralidoxime"]]}, {"text": "Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.", "triple_list": [["dapsone", "effect", "Lamprene"]]}, {"text": "Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ", "triple_list": [["SYMLIN", "advise", "anticholinergic agents"]]}, {"text": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "triple_list": [["SYMLIN", "mechanism", "human insulin"]]}, {"text": "If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.", "triple_list": [["CEFOTAN", "effect", "aminoglycoside"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestytamine", "mechanism", "thiazide diuretics"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "mechanism", "thiazide diuretics"]]}, {"text": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "triple_list": [["chlorothiazide", "advise", "non-steroidal anti-inflammatory agents"]]}, {"text": "Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.\n", "triple_list": [["glycine", "effect", "glutamate"]]}, {"text": "The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ", "triple_list": [["glycine", "effect", "glutamate"]]}, {"text": "Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. ", "triple_list": [["thiabendazole", "effect", "melarsoprol"]]}, {"text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "triple_list": [["warfarin", "mechanism", "ketorolac tromethamine"]]}, {"text": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.", "triple_list": [["salicylate", "mechanism", "ketorolac"]]}, {"text": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "triple_list": [["TORADOL", "advise", "anticoagulants"]]}, {"text": "Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).", "triple_list": [["TORADOL", "effect", "furosemide"]]}, {"text": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "triple_list": [["TORADOL", "mechanism", "probenecid"]]}, {"text": "Therefore, concomitant use of TORADOL and probenecid is contraindicated.", "triple_list": [["TORADOL", "advise", "probenecid"]]}, {"text": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "triple_list": [["lithium", "mechanism", "TORADOL"]]}, {"text": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "triple_list": [["methotrexate", "mechanism", "NSAIDs"]]}, {"text": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).", "triple_list": [["TORADOL", "effect", "antiepileptic drugs"]]}, {"text": "Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).", "triple_list": [["TORADOL", "effect", "psychoactive drugs"]]}, {"text": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "triple_list": [["metformin", "mechanism", "Acarbose"]]}, {"text": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "triple_list": [["Acarbose", "mechanism", "metformin"]]}, {"text": "Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary", "triple_list": [["hydroxyurea", "effect", "uricosuric medication"]]}, {"text": "Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.", "triple_list": [["anticoagulants", "advise", "thyroid"]]}, {"text": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "triple_list": [["Cholestyramine", "mechanism", "T4"]]}, {"text": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "triple_list": [["Cholestyramine", "mechanism", "T3"]]}, {"text": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.", "triple_list": [["levothyroxine", "mechanism", "estrogens"]]}, {"text": "Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.", "triple_list": [["thyroid", "advise", "estrogens"]]}, {"text": "Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.", "triple_list": [["thyroid", "advise", "contraceptives"]]}, {"text": "Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.", "triple_list": [["thyroid products", "effect", "imipramine"]]}, {"text": "Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.", "triple_list": [["thyroid products", "effect", "tricyclic antidepressants"]]}, {"text": "Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.", "triple_list": [["Thyroxine", "effect", "epinephrine"]]}, {"text": "Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.", "triple_list": [["ARAVA", "effect", "warfarin"]]}, {"text": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "triple_list": [["quinolones", "effect", "warfarin"]]}, {"text": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "triple_list": [["quinolones", "effect", "cyclosporine"]]}, {"text": "Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.", "triple_list": [["sucralfate", "effect", "furosemide"]]}, {"text": "The intake of furosemide and sucralfate should be separated by at least two hours.", "triple_list": [["furosemide", "advise", "sucralfate"]]}, {"text": "Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.", "triple_list": [["furosemide", "effect", "acetylsalicylic acid"]]}, {"text": "Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.", "triple_list": [["indomethacin", "effect", "furosemide"]]}, {"text": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.", "triple_list": [["indomethacin", "advise", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["ibuprofen", "effect", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["ibuprofen", "effect", "thiazides"]]}, {"text": "Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.", "triple_list": [["Ibuprofen", "mechanism", "lithium"]]}, {"text": "Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["ibuprofen", "advise", "lithium"]]}, {"text": "The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.", "triple_list": [["FLUDARA", "advise", "pentostatin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["cholestyramine", "mechanism", "digitalis"]]}, {"text": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "triple_list": [["photosensitizing agents", "effect", "LEVULAN KERASTICK"]]}, {"text": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "triple_list": [["sulfonamides", "effect", "LEVULAN KERASTICK"]]}, {"text": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "triple_list": [["tetracyclines", "effect", "LEVULAN KERASTICK"]]}, {"text": "Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.", "triple_list": [["halothane", "mechanism", "NUROMAX"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["NUROMAX", "effect", "antibiotics"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["NUROMAX", "effect", "magnesium"]]}, {"text": "As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "triple_list": [["NUROMAX", "effect", "phenytoin"]]}, {"text": "Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.", "triple_list": [["tricyclic antidepressants", "mechanism", "cimetidine"]]}, {"text": "Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.", "triple_list": [["tricyclic antidepressants", "effect", "cimetidine"]]}, {"text": "The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.", "triple_list": [["tricyclic antidepressants", "effect", "cimetidine"]]}, {"text": "Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.", "triple_list": [["reserpine", "effect", "tricyclic antidepressant"]]}, {"text": "Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.", "triple_list": [["nortriptyline hydrochloride", "advise", "anticholinergic drugs"]]}, {"text": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "triple_list": [["tricyclic antidepressants", "advise", "antidepressants"]]}, {"text": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "triple_list": [["tricyclic antidepressants", "advise", "Type 1C antiarrhythmics"]]}, {"text": "Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.", "triple_list": [["amprenavir", "effect", "methadone"]]}, {"text": "Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.", "triple_list": [["amprenavir", "mechanism", "methadone"]]}, {"text": "Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.", "triple_list": [["Amprenavir", "effect", "ritonavir"]]}, {"text": "Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.", "triple_list": [["Amprenavir", "advise", "ritonavir"]]}, {"text": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "triple_list": [["spironolactone", "mechanism", "digoxin"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["clarithromycin", "mechanism", "digoxin"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["tetracycline", "mechanism", "digoxin"]]}, {"text": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "triple_list": [["metoclopramide", "mechanism", "digoxin"]]}, {"text": "Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.", "triple_list": [["digoxin", "effect", "sympathomimetics"]]}, {"text": "Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.", "triple_list": [["beta-adrenergic blockers", "effect", "digoxin"]]}, {"text": "Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.", "triple_list": [["calcium channel blockers", "effect", "digoxin"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["XENICAL", "mechanism", "cyclosporine"]]}, {"text": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "triple_list": [["vitamin K", "mechanism", "XENICAL"]]}, {"text": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "triple_list": [["warfarin", "advise", "XENICAL"]]}, {"text": "however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.", "triple_list": [["ranitidine", "mechanism", "ceftibuten"]]}, {"text": "however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.", "triple_list": [["ranitidine", "mechanism", "ceftibuten"]]}, {"text": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ", "triple_list": [["METH", "effect", "SCH-23390"]]}, {"text": "The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.", "triple_list": [["aspirin", "mechanism", "fenoprofen"]]}, {"text": "Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.", "triple_list": [["fenoprofen", "mechanism", "aspirin"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "mechanism", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "advise", "salicylates"]]}, {"text": "When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.", "triple_list": [["phenobarbital", "advise", "Nalfon"]]}, {"text": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "triple_list": [["Nalfon", "advise", "steroid"]]}, {"text": "When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.", "triple_list": [["lansoprazole", "mechanism", "theophylline"]]}, {"text": "Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.", "triple_list": [["theophylline", "advise", "lansoprazole"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["proton pump inhibitors", "mechanism", "sucralfate"]]}, {"text": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "triple_list": [["lansoprazole", "mechanism", "ampicillin"]]}, {"text": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "triple_list": [["lansoprazole", "mechanism", "iron"]]}, {"text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "triple_list": [["Ketoconazole", "mechanism", "terfenadine"]]}, {"text": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "triple_list": [["ketoconazole", "effect", "astemizole"]]}, {"text": "Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.", "triple_list": [["astemizole", "advise", "ketoconazole"]]}, {"text": "Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.", "triple_list": [["ketoconazole", "mechanism", "cisapride"]]}, {"text": "Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.", "triple_list": [["ketoconazole", "effect", "cisapride"]]}, {"text": "Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.", "triple_list": [["ketoconazole", "advise", "cisapride"]]}, {"text": "Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "triple_list": [["NIZORAL", "mechanism", "midazolam"]]}, {"text": "Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "triple_list": [["NIZORAL", "mechanism", "triazolam"]]}, {"text": "Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.", "triple_list": [["ketoconazole", "mechanism", "phenytoin"]]}, {"text": "Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.", "triple_list": [["rifampin", "mechanism", "ketoconazole"]]}, {"text": "After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.", "triple_list": [["ketoconazole", "mechanism", "loratadine"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "mechanism", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "advise", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "advise", "telithromycin"]]}, {"text": "Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ", "triple_list": [["proton pump inhibitors", "advise", "warfarin"]]}, {"text": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ", "triple_list": [["pantoprazole", "mechanism", "ampicillin"]]}, {"text": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ", "triple_list": [["pantoprazole", "mechanism", "iron"]]}, {"text": "The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ", "triple_list": [["DIPRIVAN", "effect", "narcotics"]]}, {"text": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ", "triple_list": [["DIPRIVAN", "advise", "analgesic agents"]]}, {"text": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ", "triple_list": [["DIPRIVAN", "advise", "nitrous oxide"]]}, {"text": "In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.", "triple_list": [["levodopa", "effect", "phenytoin"]]}, {"text": "Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.", "triple_list": [["metoclopramide", "mechanism", "levodopa"]]}, {"text": "Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ", "triple_list": [["neomycin", "effect", "ACTH"]]}, {"text": "Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ", "triple_list": [["opioids", "effect", "levomepromazine"]]}, {"text": "Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ", "triple_list": [["levomepromazine", "effect", "opioids"]]}, {"text": "Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ", "triple_list": [["levomepromazine", "effect", "benzodiazepines"]]}, {"text": "Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ", "triple_list": [["levomepromazine", "advise", "anticholinergic drugs"]]}, {"text": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "triple_list": [["nabumetone", "advise", "warfarin"]]}, {"text": "Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.", "triple_list": [["temazepam", "mechanism", "ethanol"]]}, {"text": "In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ", "triple_list": [["temazepam", "mechanism", "ethanol"]]}, {"text": "The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. ", "triple_list": [["alcohol", "mechanism", "3-hydroxy-1,4-benzodiazepine"]]}, {"text": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "triple_list": [["diphenidol", "effect", "apomorphine"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["VIRACEPT", "advise", "quinidine"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["VIRACEPT", "advise", "terfenadine"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["VIRACEPT", "advise", "ergot derivatives"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["VIRACEPT", "advise", "rifampin"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["VIRACEPT", "advise", "Benzodiazepines"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["VIRACEPT", "advise", "triazolam"]]}, {"text": "therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.", "triple_list": [["VIRACEPT", "advise", "terfenadine"]]}, {"text": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "triple_list": [["indinavir", "mechanism", "VIRACEPT"]]}, {"text": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "triple_list": [["ritonavir", "mechanism", "VIRACEPT"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "mechanism", "VIRACEPT"]]}, {"text": "Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.", "triple_list": [["ketoconazole", "mechanism", "VIRACEPT"]]}, {"text": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "triple_list": [["rifabutin", "mechanism", "VIRACEPT"]]}, {"text": "Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.", "triple_list": [["rifampin", "mechanism", "VIRACEPT"]]}, {"text": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "triple_list": [["VIRACEPT", "mechanism", "OVCON-35"]]}, {"text": "Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. ", "triple_list": [["fluoxetine", "mechanism", "cisapride"]]}, {"text": "In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.", "triple_list": [["Angiomax", "effect", "thrombolytics"]]}, {"text": "In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "triple_list": [["dexmedetomidine", "effect", "ephedrine"]]}, {"text": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "triple_list": [["dexmedetomidine", "effect", "ephedrine"]]}, {"text": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "triple_list": [["aminoglycosides", "advise", "MAXIPIME"]]}, {"text": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "triple_list": [["cephalosporins", "effect", "diuretics"]]}, {"text": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "triple_list": [["clozapine", "advise", "benzodiazepine"]]}, {"text": "Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "triple_list": [["rifampin", "mechanism", "Clozapine"]]}, {"text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "triple_list": [["Clozapine", "advise", "carbamazepine"]]}, {"text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "triple_list": [["carbamazepine", "mechanism", "Clozapine"]]}, {"text": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "triple_list": [["clozapine", "advise", "Type 1C antiarrhythmics"]]}, {"text": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "triple_list": [["clozapine", "advise", "flecainide"]]}, {"text": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "triple_list": [["fexofenadine hydrochloride", "mechanism", "ketoconazole"]]}, {"text": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "triple_list": [["fexofenadine hydrochloride", "mechanism", "erythromycin"]]}, {"text": "These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.", "triple_list": [["ketoconazole", "mechanism", "fexofenadine"]]}, {"text": "These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.", "triple_list": [["erythromycin", "mechanism", "fexofenadine"]]}, {"text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "triple_list": [["ketoconazole", "mechanism", "fexofenadine"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["fexofenadine hydrochloride", "mechanism", "aluminum"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["fexofenadine hydrochloride", "mechanism", "magnesium"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["fexofenadine hydrochloride", "mechanism", "antacid"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "mechanism", "phenytoin"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["valproic acid", "mechanism", "ethosuximide"]]}, {"text": "Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.", "triple_list": [["nifedipine", "effect", "beta-blocking agents"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "int", "nifedipine"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "advise", "nifedipine"]]}, {"text": "Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.", "triple_list": [["digoxin", "mechanism", "digoxin"]]}, {"text": "Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "advise", "nifedipine"]]}, {"text": "Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).", "triple_list": [["quinidine", "mechanism", "nifedipine"]]}, {"text": "Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.", "triple_list": [["coumarin anticoagulants", "effect", "nifedipine"]]}, {"text": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.", "triple_list": [["cimetidine", "mechanism", "nifedipine"]]}, {"text": "Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.", "triple_list": [["amyl nitrite", "effect", "alcohol"]]}, {"text": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "triple_list": [["TOBI", "effect", "dornase alfa"]]}, {"text": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "triple_list": [["TOBI", "effect", "aminoglycosides"]]}, {"text": "Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ", "triple_list": [["diuretics", "effect", "aminoglycoside"]]}, {"text": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "triple_list": [["cephalexin", "mechanism", "metformin"]]}, {"text": "Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.", "triple_list": [["cephalexin", "mechanism", "metformin"]]}, {"text": "Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.", "triple_list": [["cephalexin", "advise", "metformin"]]}, {"text": "The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.", "triple_list": [["Mecamylamine", "effect", "antihypertensive drugs"]]}, {"text": "Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.", "triple_list": [["aspirin", "effect", "valdecoxib"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "thiazides"]]}, {"text": "Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).", "triple_list": [["valdecoxib", "mechanism", "phenytoin"]]}, {"text": "Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.", "triple_list": [["valdecoxib", "advise", "phenytoin"]]}, {"text": "Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.", "triple_list": [["valdecoxib", "mechanism", "dextromethorphan"]]}, {"text": "Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.", "triple_list": [["dextromethorphan", "mechanism", "valdecoxib"]]}, {"text": "Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.", "triple_list": [["Valdecoxib", "mechanism", "lithium"]]}, {"text": "Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.", "triple_list": [["BEXTRA", "advise", "warfarin"]]}, {"text": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "triple_list": [["valdecoxib", "mechanism", "ketoconazole"]]}, {"text": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "triple_list": [["valdecoxib", "mechanism", "fluconazole"]]}, {"text": "Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.", "triple_list": [["valdecoxib", "mechanism", "fluconazole"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["valdecoxib", "mechanism", "glyburide"]]}, {"text": "Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.", "triple_list": [["glyburide", "advise", "valdecoxib"]]}, {"text": "Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.", "triple_list": [["valdecoxib", "mechanism", "omeprazole"]]}, {"text": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "triple_list": [["valdecoxib", "mechanism", "Ortho-Novum"]]}, {"text": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "triple_list": [["diazepam", "mechanism", "valdecoxib"]]}, {"text": "Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.", "triple_list": [["valdecoxib", "effect", "diazepam"]]}, {"text": "Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.", "triple_list": [["TCAs", "advise", "SSRIs"]]}, {"text": "Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.", "triple_list": [["amitriptyline HCl", "effect", "anticholinergic"]]}, {"text": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "triple_list": [["tricyclic antidepressants", "mechanism", "cimetidine"]]}, {"text": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "triple_list": [["HYDROXYZINE", "effect", "CENTRAL NERVOUS SYSTEM DEPRESSANTS"]]}, {"text": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "triple_list": [["HYDROXYZINE", "effect", "NON-NARCOTIC ANALGESICS"]]}, {"text": "Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.", "triple_list": [["central nervous system depressants", "advise", "hydroxyzine"]]}, {"text": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.", "triple_list": [["lymecycline", "mechanism", "iron"]]}, {"text": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.", "triple_list": [["lymecycline", "mechanism", "zinc"]]}, {"text": "In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.", "triple_list": [["AED", "mechanism", "oxcarbazepine"]]}, {"text": "1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.", "triple_list": [["phenytoin", "mechanism", "Trileptal"]]}, {"text": "Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.", "triple_list": [["Trileptal", "advise", "phenytoin"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["Trileptal", "mechanism", "contraceptive"]]}, {"text": "Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.", "triple_list": [["Trileptal", "effect", "hormonal contraceptives"]]}, {"text": "Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.", "triple_list": [["diazoxide", "effect", "hydralazine"]]}, {"text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "triple_list": [["phenytoin", "mechanism", "alcohol"]]}, {"text": "- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine", "triple_list": [["phenytoin", "mechanism", "alcohol"]]}, {"text": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "triple_list": [["phenytoin", "effect", "valproic acid"]]}, {"text": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "triple_list": [["phenytoin", "effect", "valproate"]]}, {"text": "- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted", "triple_list": [["tricyclic antidepressants", "effect", "Cerebyx"]]}, {"text": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "triple_list": [["cholestyramine", "mechanism", "hydrochlorothiazide"]]}, {"text": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "triple_list": [["colestipol", "mechanism", "hydrochlorothiazide"]]}, {"text": "Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "triple_list": [["Hydrochlorothiazide", "advise", "non-steroidal anti-inflammatory agents"]]}, {"text": "When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ", "triple_list": [["methyldopa", "advise", "lithium"]]}, {"text": "Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ", "triple_list": [["methyldopa", "mechanism", "ferrous sulfate"]]}, {"text": "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ", "triple_list": [["methyldopa", "advise", "ferrous sulfate"]]}, {"text": "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ", "triple_list": [["methyldopa", "advise", "ferrous gluconate"]]}, {"text": "Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.", "triple_list": [["irbesartan", "mechanism", "aliskiren"]]}, {"text": "Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.", "triple_list": [["atorvastatin", "mechanism", "aliskiren"]]}, {"text": "Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.", "triple_list": [["ketoconazole", "mechanism", "aliskiren"]]}, {"text": "Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.", "triple_list": [["aliskiren", "mechanism", "furosemide"]]}, {"text": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "triple_list": [["calcium", "mechanism", "iron"]]}, {"text": "A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ", "triple_list": [["calcium", "mechanism", "heme iron"]]}, {"text": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "triple_list": [["Robinul", "effect", "anticholinergics"]]}, {"text": "Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.", "triple_list": [["Robinul", "mechanism", "potassium chloride"]]}, {"text": "The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ", "triple_list": [["Sanctura", "effect", "anticholinergic agents"]]}, {"text": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "triple_list": [["Sanctura", "mechanism", "metformin"]]}, {"text": "Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.", "triple_list": [["dobutamine", "effect", "nitroprusside"]]}, {"text": "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.", "triple_list": [["ALFENTA", "effect", "CNS depressants"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["volatile inhalation anesthetics", "mechanism", "ALFENTA"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["erythromycin", "mechanism", "ALFENTA"]]}, {"text": "Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).", "triple_list": [["WELLBUTRIN", "int", "orphenadrine"]]}, {"text": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "triple_list": [["bupropion", "mechanism", "desipramine"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["bupropion", "advise", "antidepressants"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["bupropion", "advise", "antipsychotics"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["bupropion", "advise", "beta-blockers"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["bupropion", "advise", "Type 1C antiarrhythmics"]]}, {"text": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .", "triple_list": [["bupropion", "effect", "phenelzine"]]}, {"text": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.", "triple_list": [["bupropion", "effect", "levodopa"]]}, {"text": "Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "triple_list": [["WELLBUTRIN", "advise", "levodopa"]]}, {"text": "Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "triple_list": [["WELLBUTRIN", "advise", "amantadine"]]}, {"text": "The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)", "triple_list": [["alcohol", "advise", "WELLBUTRIN"]]}, {"text": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "triple_list": [["thiazides", "effect", "vitamin D"]]}, {"text": "Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.", "triple_list": [["agents with b-blocking properties", "effect", "reserpine"]]}, {"text": "Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.", "triple_list": [["clonidine", "effect", "agents with b-blocking properties"]]}, {"text": "When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.", "triple_list": [["agents with b-blocking properties", "advise", "clonidine"]]}, {"text": "Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.", "triple_list": [["cyclosporine", "mechanism", "carvedilol"]]}, {"text": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.", "triple_list": [["cyclosporine", "advise", "carvedilol"]]}, {"text": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.", "triple_list": [["carvedilol", "advise", "cyclosporine"]]}, {"text": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "triple_list": [["digoxin", "mechanism", "carvedilol"]]}, {"text": "Both digoxin and COREG slow AV conduction.", "triple_list": [["digoxin", "effect", "COREG"]]}, {"text": "Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.", "triple_list": [["Rifampin", "mechanism", "carvedilol"]]}, {"text": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "triple_list": [["COREG", "advise", "verapamil"]]}, {"text": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "triple_list": [["COREG", "advise", "diltiazem"]]}, {"text": "Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.", "triple_list": [["Agents with b-blocking properties", "effect", "insulin"]]}, {"text": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "triple_list": [["ENABLEX", "advise", "clarithromycin"]]}, {"text": "Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).", "triple_list": [["ENABLEX", "advise", "thioridazine"]]}, {"text": "Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).", "triple_list": [["ENABLEX", "advise", "tricyclic antidepressants"]]}, {"text": "The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.", "triple_list": [["ENABLEX", "effect", "anticholinergic agents"]]}, {"text": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "triple_list": [["neomycin", "mechanism", "methotrexate"]]}, {"text": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "triple_list": [["neomycin sulfate", "effect", "coumarin"]]}, {"text": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "triple_list": [["neomycin sulfate", "effect", "anticoagulants"]]}, {"text": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "triple_list": [["IOPIDINE", "advise", "CNS depressants"]]}, {"text": "An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.", "triple_list": [["clonidine", "effect", "neuroleptic"]]}, {"text": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.", "triple_list": [["apraclonidine", "advise", "beta-blockers"]]}, {"text": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.", "triple_list": [["apraclonidine", "advise", "cardiac glycosides"]]}, {"text": "A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.", "triple_list": [["FOSCAVIR", "int", "pentamidine"]]}, {"text": "Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;", "triple_list": [["FOSCAVIR", "effect", "pentamidine"]]}, {"text": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "triple_list": [["FOSCAVIR", "advise", "amphotericin B"]]}, {"text": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "triple_list": [["FOSCAVIR", "advise", "pentamidine"]]}, {"text": "DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. ", "triple_list": [["Clarithromycin", "mechanism", "simvastatin"]]}, {"text": "The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. ", "triple_list": [["macrolide antibiotics", "effect", "hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors"]]}, {"text": "Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.", "triple_list": [["probenecid", "mechanism", "acyclovir"]]}, {"text": "Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.", "triple_list": [["Methergine", "advise", "vasoconstrictors"]]}, {"text": "Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.", "triple_list": [["warfarin", "effect", "flutamide"]]}, {"text": "Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.", "triple_list": [["alcohol", "effect", "methyprylon"]]}, {"text": "Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.", "triple_list": [["CNS depression-producing drugs", "effect", "methyprylon"]]}, {"text": "During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.", "triple_list": [["TAMBOCOR", "mechanism", "digoxin"]]}, {"text": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "triple_list": [["TAMBOCOR", "mechanism", "propranolol"]]}, {"text": "The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.", "triple_list": [["TAMBOCOR", "effect", "propranolol"]]}, {"text": "Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.", "triple_list": [["beta blockers", "effect", "flecainide"]]}, {"text": "Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.", "triple_list": [["carbamazepine", "mechanism", "flecainide"]]}, {"text": "In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.", "triple_list": [["cimetidine", "mechanism", "flecainide"]]}, {"text": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "triple_list": [["amiodarone", "mechanism", "flecainide"]]}, {"text": "Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;", "triple_list": [["quinidine", "mechanism", "flecainide"]]}, {"text": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "triple_list": [["disopyramide", "advise", "TAMBOCOR"]]}, {"text": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "triple_list": [["verapamil", "advise", "TAMBOCOR"]]}, {"text": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "triple_list": [["Vardenafil", "advise", "ketoconazole"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Indinavir", "mechanism", "Vardenafil"]]}, {"text": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "triple_list": [["nitrates", "mechanism", "vardenafil"]]}, {"text": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "triple_list": [["Vardenafil", "advise", "nitrates"]]}, {"text": "With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "triple_list": [["Vardenafil", "effect", "terazosin"]]}, {"text": "With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "triple_list": [["Vardenafil", "effect", "terazosin"]]}, {"text": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "triple_list": [["Vardenafil", "effect", "terazosin"]]}, {"text": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "triple_list": [["Vardenafil", "effect", "tamsulosin"]]}, {"text": "Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.", "triple_list": [["Vardenafil", "effect", "tamsulosin"]]}, {"text": "Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.", "triple_list": [["Vardenafil", "advise", "alpha-blocker"]]}, {"text": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "triple_list": [["Vardenafil", "mechanism", "ritonavir"]]}, {"text": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "triple_list": [["Vardenafil", "mechanism", "indinavir"]]}, {"text": "Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.", "triple_list": [["lorazepam", "effect", "pyrimethamine"]]}, {"text": "(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)", "triple_list": [["thiazide diuretics", "effect", "digitalis"]]}, {"text": "for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;", "triple_list": [["hypoglycemic medications", "advise", "thiazide diuretic"]]}, {"text": "Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)", "triple_list": [["hydroflumethiazide", "advise", "nonsteroidal anti-inflammatory agents"]]}, {"text": "Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ", "triple_list": [["GH", "mechanism", "antipyrine"]]}, {"text": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "triple_list": [["dolasetron", "mechanism", "cimetidine"]]}, {"text": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "triple_list": [["dolasetron", "mechanism", "rifampin"]]}, {"text": "Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.", "triple_list": [["HUMORSOL", "int", "succinylcholine"]]}, {"text": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "triple_list": [["procaine hydrochloride", "effect", "anticholinesterase agents"]]}, {"text": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "triple_list": [["anticholinesterases", "mechanism", "procaine hydrochloride"]]}, {"text": "CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ", "triple_list": [["procaine hydrochloride", "effect", "CNS depressant medications"]]}, {"text": "Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ", "triple_list": [["procaine hydrochloride", "effect", "neuromuscular blocking agents"]]}, {"text": "Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ", "triple_list": [["procaine hydrochloride", "effect", "sulfonamides"]]}, {"text": "Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.", "triple_list": [["acetazolamide", "mechanism", "procaine hydrochloride"]]}, {"text": "Elevated plasma levels of theophylline have been reported with concomitant quinolone use.", "triple_list": [["theophylline", "mechanism", "quinolone"]]}, {"text": "Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.", "triple_list": [["quinolones", "mechanism", "cyclosporine"]]}, {"text": "The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.", "triple_list": [["guanfacine", "effect", "CNS-depressant drug"]]}, {"text": "There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).", "triple_list": [["Gleevec", "mechanism", "ketoconazole"]]}, {"text": "Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).", "triple_list": [["rifampin", "mechanism", "Gleevec"]]}, {"text": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "triple_list": [["Gleevec", "mechanism", "simvastatin"]]}, {"text": "Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).", "triple_list": [["Gleevec", "advise", "cyclosporine"]]}, {"text": "Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.", "triple_list": [["ROMAZICON", "effect", "benzodiazepine"]]}, {"text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "triple_list": [["DISULFIRAM", "effect", "PHENYTOIN"]]}, {"text": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "triple_list": [["anticoagulants", "advise", "disulfiram"]]}, {"text": "Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;", "triple_list": [["isoniazid", "advise", "disulfiram"]]}, {"text": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "triple_list": [["disulfiram", "effect", "nitrite"]]}, {"text": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "triple_list": [["disulfiram", "effect", "nitrites"]]}, {"text": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "triple_list": [["LEVSIN", "effect", "tricyclic antidepressants"]]}, {"text": "May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;", "triple_list": [["colestipol", "effect", "thiazide diuretics"]]}, {"text": "There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.", "triple_list": [["buprenorphine", "effect", "benzodiazepines"]]}, {"text": "SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.", "triple_list": [["SUBOXONE", "advise", "benzodiazepines"]]}, {"text": "Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.", "triple_list": [["benzodiazepines", "advise", "SUBOXONE"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["buspirone hydrochloride", "advise", "MAO inhibitors"]]}, {"text": "There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.", "triple_list": [["trazodone hydrochloride", "effect", "buspirone HCl"]]}, {"text": "In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.", "triple_list": [["buspirone HCl", "mechanism", "haloperidol"]]}, {"text": "Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.", "triple_list": [["amphotericin B", "effect", "flucytosine"]]}, {"text": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "triple_list": [["imidazoles", "effect", "amphotericin B"]]}, {"text": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "triple_list": [["ketamine", "effect", "propofol"]]}, {"text": "Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.", "triple_list": [["TNF antagonist", "effect", "ORENCIA"]]}, {"text": "Concurrent therapy with ORENCIA and TNF antagonists is not recommended.", "triple_list": [["ORENCIA", "advise", "TNF antagonists"]]}, {"text": "There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ", "triple_list": [["PURINETHOL", "effect", "TABLOID"]]}, {"text": "As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ", "triple_list": [["aminosalicylate derivatives", "mechanism", "thioguanine"]]}, {"text": "In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.", "triple_list": [["aminoglycoside", "effect", "antibiotics"]]}, {"text": "Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.", "triple_list": [["INVIRASE", "advise", "ritonavir"]]}, {"text": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "triple_list": [["oxyphenbutazone", "mechanism", "androgens"]]}, {"text": "In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.", "triple_list": [["androgens", "effect", "insulin"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["ACE inhibitors", "effect", "lithium"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["antacid", "mechanism", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["antacids", "mechanism", "fosinopril"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["Lomefloxacin", "mechanism", "sucralfate"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["Lomefloxacin", "mechanism", "gelusil"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["Lomefloxacin", "mechanism", "erythromycin"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["Lomefloxacin", "mechanism", "multi-minerals"]]}, {"text": "one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. ", "triple_list": [["DIFLUCAN", "effect", "glyburide"]]}, {"text": "Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. ", "triple_list": [["DIFLUCAN", "advise", "coumarin-type anticoagulants"]]}, {"text": "Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ", "triple_list": [["DIFLUCAN", "advise", "phenytoin"]]}, {"text": "Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. ", "triple_list": [["DIFLUCAN", "mechanism", "cyclosporine"]]}, {"text": "Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ", "triple_list": [["DIFLUCAN", "advise", "cyclosporine"]]}, {"text": "Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ", "triple_list": [["DIFLUCAN", "advise", "theophylline"]]}, {"text": "Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ", "triple_list": [["DIFLUCAN", "mechanism", "terfenadine"]]}, {"text": "The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. ", "triple_list": [["fluconazole", "advise", "terfenadine"]]}, {"text": "The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored. ", "triple_list": [["fluconazole", "advise", "terfenadine"]]}, {"text": "Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. ", "triple_list": [["fluconazole", "effect", "cisapride"]]}, {"text": "A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.", "triple_list": [["fluconazole", "mechanism", "cisapride"]]}, {"text": "The combined use of fluconazole with cisapride is contraindicated. ", "triple_list": [["fluconazole", "advise", "cisapride"]]}, {"text": "Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ", "triple_list": [["fluconazole", "mechanism", "astemizole"]]}, {"text": "Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. ", "triple_list": [["fluconazole", "effect", "rifabutin"]]}, {"text": "Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. ", "triple_list": [["rifabutin", "advise", "fluconazole"]]}, {"text": "Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. ", "triple_list": [["fluconazole", "effect", "tacrolimus"]]}, {"text": "Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. ", "triple_list": [["tacrolimus", "advise", "fluconazole"]]}, {"text": "Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ", "triple_list": [["midazolam", "mechanism", "fluconazole"]]}, {"text": "This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ", "triple_list": [["midazolam", "effect", "fluconazole"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "mechanism", "ethinyl estradiol"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "mechanism", "levonorgestrel"]]}, {"text": "The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.", "triple_list": [["diuretic", "effect", "PRINIVIL"]]}, {"text": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "triple_list": [["PRINIVIL", "effect", "potassium-sparing diuretics"]]}, {"text": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "triple_list": [["PRINIVIL", "effect", "potassium"]]}, {"text": "It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.", "triple_list": [["PRINIVIL", "advise", "lithium"]]}, {"text": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "triple_list": [["heparin", "effect", "TNKase"]]}, {"text": "Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ", "triple_list": [["ketoconazole", "mechanism", "retapamulin"]]}, {"text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "triple_list": [["theophylline", "advise", "erythromycin"]]}, {"text": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "triple_list": [["erythromycin", "mechanism", "digoxin"]]}, {"text": "There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.", "triple_list": [["erythromycin", "effect", "anticoagulants"]]}, {"text": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "triple_list": [["erythromycin", "effect", "ergotamine"]]}, {"text": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "triple_list": [["erythromycin", "effect", "dihydroergotamine"]]}, {"text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "triple_list": [["erythromycin", "effect", "cisapride"]]}, {"text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "triple_list": [["cisapride", "mechanism", "erythromycin"]]}, {"text": "Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;", "triple_list": [["lovastatin", "advise", "erythromycin"]]}, {"text": "Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.", "triple_list": [["sunitinib", "int", "docetaxel"]]}, {"text": "Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ", "triple_list": [["sunitinib", "effect", "docetaxel"]]}, {"text": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "triple_list": [["docetaxel", "effect", "sunitinib"]]}, {"text": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "triple_list": [["TIKOSYN", "mechanism", "verapamil"]]}, {"text": "In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.", "triple_list": [["verapamil", "effect", "dofetilide"]]}, {"text": "In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.", "triple_list": [["HCTZ", "mechanism", "dofetilide"]]}, {"text": "In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.", "triple_list": [["metformin", "advise", "dofetilide"]]}, {"text": "In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.", "triple_list": [["digoxin", "effect", "dofetilide"]]}, {"text": "The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.", "triple_list": [["dofetilide", "mechanism", "thiazide diuretics"]]}, {"text": "Enhanced theophylline clearance secondary to phenytoin therapy.\r\n", "triple_list": [["theophylline", "mechanism", "phenytoin"]]}, {"text": "This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. ", "triple_list": [["theophylline", "mechanism", "phenytoin"]]}, {"text": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "triple_list": [["phenytoin", "effect", "theophylline"]]}, {"text": "Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.", "triple_list": [["D.H.E. 45", "effect", "peripheral vasoconstrictors"]]}, {"text": "Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.", "triple_list": [["Sumatriptan", "effect", "D.H.E. 45"]]}, {"text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "triple_list": [["propranolol", "effect", "ergotamine"]]}, {"text": "Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.", "triple_list": [["Nicotine", "effect", "ergot"]]}, {"text": "SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.", "triple_list": [["5-HT1 agonists", "effect", "SSRIs"]]}, {"text": "Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.", "triple_list": [["ELSPAR", "effect", "methotrexate"]]}, {"text": "These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.", "triple_list": [["methotrexate", "advise", "ELSPAR"]]}, {"text": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "triple_list": [["sulfonylureas", "effect", "nonsteroidal anti-inflammatory agents"]]}, {"text": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "triple_list": [["miconazole", "effect", "hypoglycemic agents"]]}, {"text": "Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.", "triple_list": [["alcohol", "int", "phentermine hydrochloride"]]}, {"text": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "triple_list": [["fentanyl", "mechanism", "ritonavir"]]}, {"text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "triple_list": [["diltiazem", "mechanism", "fentanyl"]]}, {"text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "triple_list": [["erythromycin", "mechanism", "fentanyl"]]}, {"text": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "triple_list": [["DURAGESIC", "effect", "tranquilizers"]]}, {"text": "MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics", "triple_list": [["DURAGESIC", "advise", "MAOI"]]}, {"text": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "triple_list": [["PLETAL", "advise", "ketoconazole"]]}, {"text": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "triple_list": [["PLETAL", "advise", "erythromycin"]]}, {"text": "Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.", "triple_list": [["omeprazole", "mechanism", "cilostazol"]]}, {"text": "Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.", "triple_list": [["erythromycin", "mechanism", "cilostazol"]]}, {"text": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "triple_list": [["tetracyclines", "advise", "anticoagulant"]]}, {"text": "The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.", "triple_list": [["tetracycline", "effect", "Penthrane"]]}, {"text": "Concurrent use of tetracycline may render oral contraceptives less effective.", "triple_list": [["tetracycline", "effect", "contraceptives"]]}, {"text": "- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.", "triple_list": [["bumetanide", "advise", "aminoglycoside antibiotics"]]}, {"text": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "triple_list": [["Lithium", "advise", "diuretics"]]}, {"text": "This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.", "triple_list": [["probenecid", "mechanism", "bumetanide"]]}, {"text": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "triple_list": [["Indomethacin", "mechanism", "bumetanide"]]}, {"text": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "triple_list": [["Indomethacin", "effect", "bumetanide"]]}, {"text": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "triple_list": [["quinidine", "effect", "precocene I"]]}, {"text": "The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.", "triple_list": [["Adenocard", "effect", "digitalis"]]}, {"text": "The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.", "triple_list": [["adenosine", "effect", "methylxanthines"]]}, {"text": "The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.", "triple_list": [["adenosine", "effect", "caffeine"]]}, {"text": "Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.", "triple_list": [["aspirin", "effect", "VIOXX"]]}, {"text": "Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.", "triple_list": [["cimetidine", "mechanism", "rofecoxib"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "thiazides"]]}, {"text": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "triple_list": [["NSAIDs", "mechanism", "lithium"]]}, {"text": "Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["VIOXX", "advise", "lithium"]]}, {"text": "At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.", "triple_list": [["VIOXX", "mechanism", "methotrexate"]]}, {"text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "triple_list": [["methotrexate", "mechanism", "rofecoxib"]]}, {"text": "Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.", "triple_list": [["VIOXX", "advise", "methotrexate"]]}, {"text": "Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.", "triple_list": [["VIOXX", "mechanism", "rifampin"]]}, {"text": "Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.", "triple_list": [["VIOXX", "mechanism", "theophylline"]]}, {"text": "Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.", "triple_list": [["VIOXX", "advise", "theophylline"]]}, {"text": "Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.", "triple_list": [["VIOXX", "advise", "warfarin"]]}, {"text": "A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ", "triple_list": [["megestrol acetate", "mechanism", "indinavir"]]}, {"text": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "triple_list": [["potassium-sparing diuretics", "effect", "ACE inhibitors"]]}, {"text": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "triple_list": [["potassium", "effect", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "triple_list": [["ACE inhibitors", "effect", "lithium"]]}, {"text": "If a diuretic is also used, the risk of lithium toxicity may be increased. ", "triple_list": [["diuretic", "effect", "lithium"]]}, {"text": "Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.", "triple_list": [["digoxin", "mechanism", "conivaptan"]]}, {"text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "triple_list": [["levothyroxine sodium", "mechanism", "cholestyramine"]]}, {"text": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "triple_list": [["levothyroxine sodium", "mechanism", "androgens"]]}, {"text": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "triple_list": [["levothyroxine sodium", "mechanism", "estrogens"]]}, {"text": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "triple_list": [["diclofenac", "advise", "aspirin"]]}, {"text": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "triple_list": [["diclofenac", "mechanism", "aspirin"]]}, {"text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "triple_list": [["NSAIDs", "advise", "warfarin"]]}, {"text": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "triple_list": [["diclofenac", "mechanism", "digoxin"]]}, {"text": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "triple_list": [["diclofenac", "mechanism", "methotrexate"]]}, {"text": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "triple_list": [["diclofenac", "effect", "cyclosporine"]]}, {"text": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "triple_list": [["diclofenac", "effect", "cyclosporine"]]}, {"text": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "triple_list": [["NSAID", "effect", "cyclosporine"]]}, {"text": "Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.", "triple_list": [["Diclofenac", "mechanism", "lithium"]]}, {"text": "Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.", "triple_list": [["Diclofenac", "mechanism", "lithium"]]}, {"text": "In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.", "triple_list": [["diclofenac", "effect", "lithium"]]}, {"text": "There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.", "triple_list": [["insulin", "effect", "diclofenac"]]}, {"text": "There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.", "triple_list": [["hypoglycemic agents", "effect", "diclofenac"]]}, {"text": "A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.", "triple_list": [["diclofenac", "effect", "insulin"]]}, {"text": "Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.", "triple_list": [["phenobarbital", "effect", "diclofenac"]]}, {"text": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "triple_list": [["diclofenac", "mechanism", "salicylic acid"]]}, {"text": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "triple_list": [["diclofenac", "mechanism", "prednisolone"]]}, {"text": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "triple_list": [["lapatinib", "effect", "Herceptin"]]}, {"text": "Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ", "triple_list": [["Herceptin", "effect", "lapatinib"]]}, {"text": "The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.", "triple_list": [["diuretic", "advise", "Lotensin"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["ACE inhibitors", "mechanism", "lithium"]]}, {"text": "If a diuretic is also used, the risk of lithium toxicity may be increased.", "triple_list": [["diuretic", "effect", "lithium"]]}, {"text": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "triple_list": [["Accutane", "effect", "vitamin A"]]}, {"text": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "triple_list": [["Accutane", "advise", "tetracyclines"]]}, {"text": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "triple_list": [["Accutane", "effect", "tetracyclines"]]}, {"text": "Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.", "triple_list": [["progesterone", "effect", "Accutane"]]}, {"text": "Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. ", "triple_list": [["allopurinol", "effect", "cypermethrin"]]}, {"text": "Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. ", "triple_list": [["Vitamin E", "effect", "cypermethrin"]]}, {"text": "Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.", "triple_list": [["cypermethrin", "effect", "allopurinol"]]}, {"text": "(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. ", "triple_list": [["penicillins", "mechanism", "probenecid"]]}, {"text": "(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. ", "triple_list": [["cephaloridine", "mechanism", "probenecid"]]}, {"text": "This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.", "triple_list": [["probenecid", "mechanism", "cloxacillin"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "mechanism", "propantheline"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "mechanism", "propantheline"]]}, {"text": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "triple_list": [["carbamazepine", "mechanism", "clonazepam"]]}, {"text": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "triple_list": [["benzodiazepine class", "effect", "monoamine oxidase inhibitors"]]}, {"text": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "triple_list": [["alcohol", "advise", "LEXAPRO"]]}, {"text": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.", "triple_list": [["psychotropic drugs", "effect", "NSAID"]]}, {"text": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.", "triple_list": [["psychotropic drugs", "effect", "aspirin"]]}, {"text": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.", "triple_list": [["citalopram", "mechanism", "cimetidine"]]}, {"text": "Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.", "triple_list": [["LEXAPRO", "advise", "lithium"]]}, {"text": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "triple_list": [["pimozide", "effect", "citalopram"]]}, {"text": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "triple_list": [["sumatriptan", "advise", "SSRI"]]}, {"text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "triple_list": [["carbamazepine", "mechanism", "escitalopram"]]}, {"text": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "triple_list": [["citalopram", "mechanism", "ketoconazole"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "mechanism", "desipramine"]]}, {"text": "Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).", "triple_list": [["LEXAPRO", "mechanism", "metoprolol"]]}, {"text": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "triple_list": [["escitalopram", "advise", "citalopram"]]}, {"text": "HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.", "triple_list": [["TRICOR", "advise", "HMG-CoA reductase inhibitors"]]}, {"text": "Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.", "triple_list": [["TRICOR", "mechanism", "bile acid binding resin"]]}, {"text": "Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.", "triple_list": [["cyclosporine", "effect", "fibrate drugs"]]}, {"text": "The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed", "triple_list": [["TRICOR", "advise", "immunosuppressants"]]}, {"text": "Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .", "triple_list": [["fenofibrate", "advise", "bile acid binding resin"]]}, {"text": "Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.", "triple_list": [["fenofibrate", "mechanism", "pravastatin"]]}, {"text": "Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.", "triple_list": [["fenofibrate", "mechanism", "atorvastatin"]]}, {"text": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ", "triple_list": [["Nalidixic acid", "effect", "melphalan"]]}, {"text": "Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease", "triple_list": [["melphalan", "effect", "cyclosporin"]]}, {"text": "The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.", "triple_list": [["cromolyn sodium", "effect", "isoproterenol"]]}, {"text": "Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).", "triple_list": [["piperazine", "effect", "phenothiazine"]]}, {"text": "Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.", "triple_list": [["piperazine", "effect", "pyrantel"]]}, {"text": "Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ", "triple_list": [["cinacalcet", "effect", "darbepoetin"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "triple_list": [["phenytoin", "mechanism", "corticosteroids"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "triple_list": [["phenytoin", "mechanism", "corticosteroid"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "triple_list": [["rifampin", "mechanism", "corticosteroids"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "triple_list": [["rifampin", "mechanism", "corticosteroid"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ", "triple_list": [["troleandomycin", "mechanism", "corticosteroids"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ", "triple_list": [["ketoconazole", "mechanism", "corticosteroids"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ", "triple_list": [["salicylate", "effect", "corticosteroid"]]}, {"text": "The effect of corticosteroids on oral anticoagulants is variable. ", "triple_list": [["corticosteroids", "effect", "anticoagulants"]]}, {"text": "Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.\r\n", "triple_list": [["celecoxib", "effect", "anti-cancer drugs"]]}, {"text": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "triple_list": [["celecoxib", "effect", "doxorubicin"]]}, {"text": "Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.", "triple_list": [["sodium nitroprusside", "effect", "INOmax"]]}, {"text": "By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.", "triple_list": [["DIAMOX", "mechanism", "primidone"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["CANCIDAS", "mechanism", "tacrolimus"]]}, {"text": "In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.", "triple_list": [["cyclosporine", "mechanism", "caspofungin"]]}, {"text": "There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.", "triple_list": [["CANCIDAS", "effect", "cyclosporine"]]}, {"text": "A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.", "triple_list": [["rifampin", "mechanism", "caspofungin"]]}, {"text": "Patients on rifampin should receive 70 mg of CANCIDAS daily.", "triple_list": [["rifampin", "advise", "CANCIDAS"]]}, {"text": "In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; ", "triple_list": [["ouabain", "effect", "PTX"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["epinephrine", "effect", "monoamine oxidase inhibitors"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["epinephrine", "effect", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["norepinephrine", "effect", "monoamine oxidase inhibitors"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["norepinephrine", "effect", "tricyclic antidepressants"]]}, {"text": "H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.", "triple_list": [["famotidine", "mechanism", "cefditoren pivoxil"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.", "triple_list": [["probenecid", "mechanism", "cefditoren pivoxil"]]}, {"text": "The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.", "triple_list": [["nevirapine", "int", "warfarin"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["Methadone", "advise", "nevirapine"]]}, {"text": "aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.", "triple_list": [["nevirapine", "effect", "methadone"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["Sucralfate", "mechanism", "lomefloxacin"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["magnesium", "mechanism", "lomefloxacin"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["Videx", "mechanism", "lomefloxacin"]]}, {"text": "Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;", "triple_list": [["antacid", "mechanism", "lomefloxacin"]]}, {"text": "In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.\n", "triple_list": [["prostaglandin F2alpha", "int", "oxytocin"]]}, {"text": "There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.", "triple_list": [["PGF2alpha", "effect", "oxytocin"]]}, {"text": "Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ", "triple_list": [["cholestyramine", "mechanism", "ezetimibe"]]}, {"text": "The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ", "triple_list": [["ezetimibe", "effect", "cholestyramine"]]}, {"text": "Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ", "triple_list": [["ZETIA", "advise", "fibrates"]]}, {"text": "Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ", "triple_list": [["fenofibrate", "mechanism", "ezetimibe"]]}, {"text": "Patients who take both ezetimibe and cyclosporine should be carefully monitored. ", "triple_list": [["ezetimibe", "advise", "cyclosporine"]]}, {"text": "norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ", "triple_list": [["dobutamine", "int", "sodium bicarbonate"]]}, {"text": "For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters", "triple_list": [["anticoagulant", "advise", "Bezalip"]]}, {"text": "For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters", "triple_list": [["anticoagulant", "advise", "Bezalip"]]}, {"text": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "triple_list": [["sulphonylureas", "effect", "Bezalip"]]}, {"text": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "triple_list": [["insulin", "effect", "Bezalip"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip", "advise", "anion-exchange resins"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip retard", "advise", "anion-exchange resins"]]}, {"text": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "triple_list": [["Perhexiline hydrogen maleate", "advise", "Bezalip"]]}, {"text": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "triple_list": [["MAO-inhibitors", "advise", "Bezalip"]]}, {"text": "Therefore, use of zidovudine in combination with ZERIT should be avoided. ", "triple_list": [["zidovudine", "advise", "ZERIT"]]}, {"text": "In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ", "triple_list": [["stavudine", "effect", "doxorubicin"]]}, {"text": "Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.", "triple_list": [["NIMBEX", "effect", "succinylcholine"]]}, {"text": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "triple_list": [["succinylcholine", "effect", "NIMBEX"]]}, {"text": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "triple_list": [["enflurane", "effect", "NIMBEX"]]}, {"text": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "triple_list": [["enflurane", "effect", "NIMBEX"]]}, {"text": "In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.", "triple_list": [["enflurane", "advise", "NIMBEX"]]}, {"text": "In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.", "triple_list": [["isoflurane", "advise", "NIMBEX"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["nondepolarizing agents", "effect", "NIMBEX"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["nondepolarizing agents", "effect", "antibiotics"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["nondepolarizing agents", "effect", "magnesium"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["NIMBEX", "effect", "antibiotics"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["NIMBEX", "effect", "magnesium"]]}, {"text": "Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.", "triple_list": [["nondepolarizing neuromuscular blocking agents", "effect", "phenytoin"]]}, {"text": "While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.", "triple_list": [["phenytoin", "effect", "NIMBEX"]]}, {"text": "While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.", "triple_list": [["carbamazepine", "effect", "NIMBEX"]]}, {"text": "An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. ", "triple_list": [["perchlorate", "mechanism", "pertechnetate"]]}, {"text": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "triple_list": [["acetaminophen", "effect", "tranquilizers"]]}, {"text": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "triple_list": [["caffeine", "effect", "tranquilizers"]]}, {"text": "Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.", "triple_list": [["antihistamines", "effect", "CNS depressants"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["anticholinergic", "effect", "narcotic analgesics"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["anticholinergic", "effect", "phenothiazines"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["anticholinergic", "effect", "antiarrhythmics"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["anticholinergic", "effect", "quinidine"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["AKINETON", "effect", "narcotic analgesics"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["AKINETON", "effect", "phenothiazines"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["AKINETON", "effect", "antiarrhythmics"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["AKINETON", "effect", "quinidine"]]}, {"text": "The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.", "triple_list": [["imipramine", "mechanism", "alprazolam"]]}, {"text": "The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.", "triple_list": [["desipramine", "mechanism", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["fluoxetine", "mechanism", "alprazolam"]]}, {"text": "Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.", "triple_list": [["propoxyphene", "mechanism", "alprazolam"]]}, {"text": "Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.", "triple_list": [["contraceptives", "mechanism", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "int", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "int", "erythromycin"]]}, {"text": "Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.", "triple_list": [["alprazolam", "int", "sertraline"]]}, {"text": "Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.", "triple_list": [["Antizol", "mechanism", "ethanol"]]}, {"text": "Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.", "triple_list": [["ethanol", "mechanism", "Antizol"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["mazindol", "advise", "monoamine oxidase inhibitor"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["mazindol", "advise", "isocarboxazid"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["mazindol", "advise", "tranylcypromine"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["mazindol", "advise", "phenelzine"]]}, {"text": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "triple_list": [["BOTOX", "advise", "aminoglycosides"]]}, {"text": "Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.", "triple_list": [["botulinum toxin", "effect", "botulinum toxin"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["quinolones", "mechanism", "iron"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["quinolones", "mechanism", "multivitamins"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["quinolones", "mechanism", "iron"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["quinolones", "mechanism", "VIDEX"]]}, {"text": "Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.", "triple_list": [["grepafloxacin", "mechanism", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["theophylline", "advise", "grepafloxacin"]]}, {"text": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "triple_list": [["quinolones", "effect", "warfarin"]]}, {"text": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "triple_list": [["quinolone antimicrobial", "advise", "warfarin"]]}, {"text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "triple_list": [["grepafloxacin", "mechanism", "theophylline"]]}, {"text": "Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.", "triple_list": [["nonsteroidal anti inflammatory drug", "effect", "quinolone"]]}, {"text": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "triple_list": [["decamethonium", "effect", "Coly-Mycin M"]]}, {"text": "The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.", "triple_list": [["sodium cephalothin", "advise", "Coly-Mycin M"]]}, {"text": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "triple_list": [["thiazides", "effect", "vitamin D"]]}, {"text": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ", "triple_list": [["morphine", "effect", "CNS depressants"]]}, {"text": "Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ", "triple_list": [["neuroleptics", "effect", "morphine"]]}, {"text": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ", "triple_list": [["sodium salicylate", "mechanism", "teniposide"]]}, {"text": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ", "triple_list": [["sulfamethizole", "mechanism", "teniposide"]]}, {"text": "Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.", "triple_list": [["naproxen sodium", "mechanism", "Neurontin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["morphine", "mechanism", "Neurontin"]]}, {"text": "Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.", "triple_list": [["cimetidine", "mechanism", "gabapentin"]]}, {"text": "Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.", "triple_list": [["cimetidine", "mechanism", "gabapentin"]]}, {"text": "This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.", "triple_list": [["gabapentin", "mechanism", "cimetidine"]]}, {"text": "Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.", "triple_list": [["Maalox", "mechanism", "gabapentin"]]}, {"text": "It is recommended that gabapentin be taken at least 2 hours following Maalox administration.", "triple_list": [["gabapentin", "advise", "Maalox"]]}, {"text": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "triple_list": [["acetylcholine chloride", "effect", "suprofen"]]}, {"text": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "triple_list": [["carbachol", "effect", "suprofen"]]}, {"text": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "triple_list": [["Exjade", "advise", "aluminum"]]}, {"text": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "triple_list": [["indinavir", "mechanism", "SUSTIVA"]]}, {"text": "Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.", "triple_list": [["efavirenz", "advise", "contraceptives"]]}, {"text": "Potential for reduction in anticonvulsant and/or efavirenz plasma levels;", "triple_list": [["anticonvulsant", "mechanism", "efavirenz"]]}, {"text": "Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.", "triple_list": [["Felbatol", "mechanism", "antiepileptic drugs"]]}, {"text": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "triple_list": [["Felbatol", "mechanism", "phenytoin"]]}, {"text": "Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.", "triple_list": [["felbamate", "mechanism", "phenytoin"]]}, {"text": "In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.", "triple_list": [["felbamate", "advise", "phenytoin"]]}, {"text": "Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.", "triple_list": [["Felbatol", "mechanism", "carbamazepine"]]}, {"text": "The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.", "triple_list": [["carbamazepine", "mechanism", "felbamate"]]}, {"text": "Valproate: Felbatol  causes an increase in steady-state valproate concentrations.", "triple_list": [["Felbatol", "mechanism", "valproate"]]}, {"text": "Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.", "triple_list": [["felbamate", "mechanism", "valproate"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["felbamate", "mechanism", "phenobarbital"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "mechanism", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["phenytoin", "mechanism", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "mechanism", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["carbamazepine", "mechanism", "Felbatol"]]}, {"text": "Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.", "triple_list": [["phenobarbital", "mechanism", "felbamate"]]}, {"text": "When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.", "triple_list": [["digoxin", "mechanism", "BREVIBLOC"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["BREVIBLOC", "mechanism", "morphine"]]}, {"text": "Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.", "triple_list": [["BREVIBLOC", "advise", "succinylcholine"]]}, {"text": "Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.", "triple_list": [["BREVIBLOC", "advise", "verapamil"]]}, {"text": "Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.", "triple_list": [["BREVIBLOC", "advise", "norepinephrine"]]}, {"text": "International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.", "triple_list": [["warfarin", "effect", "IRESSA"]]}, {"text": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "triple_list": [["ketoconazole", "mechanism", "gefitinib"]]}, {"text": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "triple_list": [["ketoconazole", "mechanism", "gefitinib"]]}, {"text": "Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.", "triple_list": [["ranitidine", "mechanism", "IRESSA"]]}, {"text": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "triple_list": [["IRESSA", "effect", "vinorelbine"]]}, {"text": "Simultaneous administration of SPRYCEL with antacids should be avoided.", "triple_list": [["SPRYCEL", "advise", "antacids"]]}, {"text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "triple_list": [["H2 blockers", "effect", "dasatinib"]]}, {"text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "triple_list": [["proton pump inhibitors", "effect", "dasatinib"]]}, {"text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "triple_list": [["famotidine", "effect", "dasatinib"]]}, {"text": "The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.", "triple_list": [["H2 blockers", "advise", "SPRYCEL"]]}, {"text": "The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.", "triple_list": [["proton pump inhibitors", "advise", "SPRYCEL"]]}, {"text": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "triple_list": [["H2 blockers", "advise", "SPRYCEL"]]}, {"text": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "triple_list": [["proton pump inhibitors", "advise", "SPRYCEL"]]}, {"text": "The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.", "triple_list": [["lenalidomide", "effect", "CCI-779"]]}, {"text": "Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.", "triple_list": [["linezolid", "int", "adrenergic"]]}, {"text": "Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.", "triple_list": [["ZYVOX", "effect", "vasopressor"]]}, {"text": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "triple_list": [["ZYVOX", "effect", "antidepressants"]]}, {"text": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "triple_list": [["ZYVOX", "effect", "selective serotonin reuptake inhibitors"]]}, {"text": "Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).", "triple_list": [["ZYVOX", "effect", "serotonergic agents"]]}, {"text": "The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see", "triple_list": [["aspirin", "effect", "Streptokinase"]]}, {"text": "Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ", "triple_list": [["diazepam", "effect", "metamizol"]]}, {"text": "Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).", "triple_list": [["danazol", "effect", "lovastatin"]]}, {"text": "Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).", "triple_list": [["amiodarone", "effect", "HMG-CoA reductase inhibitor class"]]}, {"text": "Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).", "triple_list": [["verapamil", "effect", "HMG-CoA reductase inhibitor class"]]}, {"text": "It is recommended that Myfortic and antacids not be administered simultaneously. ", "triple_list": [["Myfortic", "advise", "antacids"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["Myfortic", "advise", "azathioprine"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["Myfortic", "advise", "mycophenolate mofetil"]]}, {"text": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ", "triple_list": [["Myfortic", "advise", "cholestyramine"]]}, {"text": "Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ", "triple_list": [["contraceptives", "advise", "Myfortic"]]}, {"text": "Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ", "triple_list": [["ketoconazole", "effect", "terfenadine"]]}, {"text": "Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ", "triple_list": [["ketoconazole", "mechanism", "terfenadine"]]}, {"text": "Concomitant administration of ketoconazole and terfenadine is contraindicated. ", "triple_list": [["ketoconazole", "advise", "terfenadine"]]}, {"text": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "triple_list": [["terfenadine", "mechanism", "itraconazole"]]}, {"text": "Concomitant administration of itraconazole and terfenadine is contraindicated. ", "triple_list": [["itraconazole", "advise", "terfenadine"]]}, {"text": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ", "triple_list": [["azole-type antifungal agents", "advise", "terfenadine"]]}, {"text": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ", "triple_list": [["erythromycin", "mechanism", "terfenadine"]]}, {"text": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ", "triple_list": [["clarithromycin", "mechanism", "terfenadine"]]}, {"text": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "triple_list": [["terfenadine", "advise", "troleandomycin"]]}, {"text": "However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.", "triple_list": [["SPIRIVA", "advise", "anticholinergic"]]}, {"text": "MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ", "triple_list": [["sympathomimetic pressor amines", "effect", "monoamine oxidase inhibitors"]]}, {"text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "triple_list": [["ergot-type medications", "advise", "naratriptan"]]}, {"text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "triple_list": [["dihydroergotamine", "advise", "naratriptan"]]}, {"text": "Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.", "triple_list": [["naratriptan", "advise", "5-HT1 agonists"]]}, {"text": "If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "triple_list": [["naratriptan", "advise", "SSRI"]]}, {"text": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "triple_list": [["oxyphenbutazone", "mechanism", "androgens"]]}, {"text": "In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.", "triple_list": [["androgens", "effect", "insulin"]]}, {"text": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "triple_list": [["HALDOL", "effect", "CNS depressants"]]}, {"text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "triple_list": [["rifampin", "mechanism", "haloperidol"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["ketoconazole", "advise", "DETROL LA"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["azole antifungals", "advise", "DETROL LA"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["macrolide antibiotics", "advise", "DETROL LA"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["cyclosporine", "advise", "DETROL LA"]]}, {"text": "Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.", "triple_list": [["Tiagabine", "mechanism", "valproate"]]}, {"text": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "triple_list": [["tiagabine", "mechanism", "carbamazepine"]]}, {"text": "Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.", "triple_list": [["tiagabine", "mechanism", "phenytoin"]]}, {"text": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "triple_list": [["tiagabine", "mechanism", "phenobarbital"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["valproate", "mechanism", "tiagabine"]]}, {"text": "Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.", "triple_list": [["antacids", "mechanism", "lactulose"]]}, {"text": "Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.", "triple_list": [["PEGANONE", "advise", "Phenurone"]]}, {"text": "Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.", "triple_list": [["phenytoin", "mechanism", "coumarin"]]}, {"text": "Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.", "triple_list": [["phenytoin", "mechanism", "coumarin anticoagulants"]]}, {"text": "Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.", "triple_list": [["coumarin anticoagulants", "mechanism", "phenytoin"]]}, {"text": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "triple_list": [["CRM197", "effect", "doxorubicin"]]}, {"text": "The combination of minocycline and fosfomycin can be synergistic against MRSA. ", "triple_list": [["minocycline", "effect", "fosfomycin"]]}, {"text": "Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.", "triple_list": [["reserpine", "effect", "ZEBETA"]]}, {"text": "Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ", "triple_list": [["5-FU", "mechanism", "ELOXATIN"]]}, {"text": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "triple_list": [["MAO inhibitors", "advise", "dopamine HCl"]]}, {"text": "Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.", "triple_list": [["dopamine HCl", "effect", "diuretic agents"]]}, {"text": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "triple_list": [["dopamine", "effect", "propranolol"]]}, {"text": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "triple_list": [["phenothiazines", "effect", "dopamine"]]}, {"text": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "triple_list": [["dopamine HCl", "advise", "cyclopropane"]]}, {"text": "Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.", "triple_list": [["phenytoin", "effect", "dopamine HCl"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "int", "Monoamine oxidase inhibitors"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "int", "MAOI"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "effect", "flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "effect", "Ethanol"]]}, {"text": "Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.", "triple_list": [["levamisole", "advise", "warfarin sodium"]]}, {"text": "Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.", "triple_list": [["thiazide diuretics", "effect", "ergocalciferol"]]}, {"text": "The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.", "triple_list": [["alcohol", "effect", "bromocriptine mesylate"]]}, {"text": "Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.", "triple_list": [["bromocriptine mesylate", "advise", "ergot alkaloids"]]}, {"text": "Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.", "triple_list": [["heparin sodium", "advise", "dicumarol"]]}, {"text": "The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.", "triple_list": [["heparin", "effect", "antithrombin III"]]}, {"text": "Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).", "triple_list": [["heparin", "advise", "antithrombin III"]]}, {"text": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "triple_list": [["EPA", "int", "aspirin"]]}, {"text": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "triple_list": [["EPA", "int", "non-steroidal anti-inflammatory drugs"]]}, {"text": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "triple_list": [["EPA", "int", "ginkgo"]]}, {"text": "Antagonism has been demonstrated between clindamycin and erythromycin in vitro.", "triple_list": [["clindamycin", "effect", "erythromycin"]]}, {"text": "Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.", "triple_list": [["short-acting beta adrenergic aerosol bronchodilators", "advise", "MAXAIR AUTOHALER"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.", "triple_list": [["loracarbef", "mechanism", "probenecid"]]}, {"text": "In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ", "triple_list": [["methadone", "mechanism", "PEG-Intron"]]}, {"text": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["troleandomycin", "mechanism", "cisapride"]]}, {"text": "It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.", "triple_list": [["cisapride", "advise", "anticoagulant"]]}, {"text": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["nefazodone", "mechanism", "cisapride"]]}, {"text": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["ketoconazole", "mechanism", "cisapride"]]}, {"text": "A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.", "triple_list": [["cisapride", "effect", "ketoconazole"]]}, {"text": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "triple_list": [["Cimetidine", "mechanism", "cisapride"]]}, {"text": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["indinavir", "mechanism", "cisapride"]]}, {"text": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["ritonavir", "mechanism", "cisapride"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ketamine", "effect", "ouabain"]]}, {"text": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "triple_list": [["ouabain", "effect", "droperidol"]]}, {"text": "Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.", "triple_list": [["ketoconazole", "mechanism", "erlotinib"]]}, {"text": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "triple_list": [["TARCEVA", "advise", "ketoconazole"]]}, {"text": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "triple_list": [["TARCEVA", "advise", "troleandomycin"]]}, {"text": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "triple_list": [["TARCEVA", "advise", "voriconazole"]]}, {"text": "Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.", "triple_list": [["rifampicin", "mechanism", "erlotinib"]]}, {"text": "If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.", "triple_list": [["TARCEVA", "advise", "rifampicin"]]}, {"text": "Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.", "triple_list": [["calcium acetate", "effect", "digitalis glycosides"]]}, {"text": "Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.", "triple_list": [["cimetidine", "mechanism", "mebendazole"]]}, {"text": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "triple_list": [["decongestants", "advise", "tricyclic antidepressants"]]}, {"text": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "triple_list": [["anesthetics", "advise", "tricyclic antidepressants"]]}, {"text": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "triple_list": [["sympathomimetic amine", "advise", "tricyclic antidepressants"]]}, {"text": "Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.", "triple_list": [["L-arginine", "mechanism", "ibuprofen"]]}, {"text": "Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.", "triple_list": [["L-arginine", "effect", "nitrates"]]}, {"text": "Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;", "triple_list": [["Amphetamines", "effect", "tricyclic"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "mechanism", "desipramine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "mechanism", "protriptyline"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "mechanism", "tricyclics"]]}, {"text": "Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.", "triple_list": [["amphetamines", "mechanism", "acidifying agents"]]}, {"text": "Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.", "triple_list": [["propoxyphene", "effect", "amphetamine"]]}, {"text": "Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.", "triple_list": [["Amphetamines", "None", "corticosteroid"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["cyclosporin A", "mechanism", "etoposide"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["Aprepitant", "mechanism", "dexamethasone"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["Aprepitant", "mechanism", "dexamethasone"]]}, {"text": "The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.", "triple_list": [["dexamethasone", "mechanism", "Aprepitant"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "advise", "Aprepitant"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "advise", "Aprepitant"]]}, {"text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "triple_list": [["S(-)warfarin", "mechanism", "Aprepitant"]]}, {"text": "In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.", "triple_list": [["warfarin", "advise", "Aprepitant"]]}, {"text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "triple_list": [["tolbutamide", "mechanism", "Aprepitant"]]}, {"text": "therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.", "triple_list": [["contraceptives", "effect", "Aprepitant"]]}, {"text": "Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.", "triple_list": [["Aprepitant", "advise", "contraceptives"]]}, {"text": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "triple_list": [["Aprepitant", "mechanism", "midazolam"]]}, {"text": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "triple_list": [["Aprepitant", "mechanism", "midazolam"]]}, {"text": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "triple_list": [["Aprepitant", "mechanism", "midazolam"]]}, {"text": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "triple_list": [["Aprepitant", "mechanism", "aprepitant"]]}, {"text": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "triple_list": [["aprepitant", "mechanism", "diltiazem"]]}, {"text": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "triple_list": [["aprepitant", "mechanism", "paroxetine"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "triple_list": [["phenytoin", "mechanism", "corticosteroids"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "triple_list": [["phenytoin", "advise", "corticosteroid"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "triple_list": [["rifampin", "mechanism", "corticosteroids"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "triple_list": [["rifampin", "advise", "corticosteroid"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "triple_list": [["troleandomycin", "mechanism", "corticosteroids"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "triple_list": [["ketoconazole", "mechanism", "corticosteroids"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.", "triple_list": [["salicylate", "effect", "corticosteroid"]]}, {"text": "The effect of corticosteroids on oral anticoagulants is variable.", "triple_list": [["corticosteroids", "effect", "anticoagulants"]]}, {"text": "Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. ", "triple_list": [["estradiol", "effect", "endotoxin"]]}, {"text": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).", "triple_list": [["Kineret", "effect", "etanercept"]]}, {"text": "Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).", "triple_list": [["Kineret", "effect", "etanercept"]]}, {"text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "triple_list": [["doxazosin", "mechanism", "cimetidine"]]}, {"text": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.", "triple_list": [["felodipine", "mechanism", "anticonvulsant"]]}, {"text": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "triple_list": [["neuroleptics", "advise", "Permax"]]}, {"text": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "triple_list": [["thioxanthines", "advise", "Permax"]]}, {"text": "Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.", "triple_list": [["Allopurinol", "mechanism", "mercaptopurine"]]}, {"text": "Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.", "triple_list": [["Allopurinol", "mechanism", "azathioprine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["allopurinol", "advise", "mercaptopurine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["allopurinol", "advise", "azathioprine"]]}, {"text": "The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.", "triple_list": [["uricosuric agents", "mechanism", "allopurinol"]]}, {"text": "Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "triple_list": [["allopurinol", "effect", "thiazide diuretics"]]}, {"text": "Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..", "triple_list": [["thiazide diuretics", "advise", "allopurinol"]]}, {"text": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.", "triple_list": [["ampicillin", "effect", "allopurinol"]]}, {"text": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.", "triple_list": [["amoxicillin", "effect", "allopurinol"]]}, {"text": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.", "triple_list": [["allopurinol", "mechanism", "chlorpropamide"]]}, {"text": "The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.", "triple_list": [["allopurinol", "effect", "chlorpropamide"]]}, {"text": "Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.", "triple_list": [["cyclosporine", "mechanism", "allopurinol sodium"]]}, {"text": "Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.", "triple_list": [["baclofen", "effect", "morphine"]]}, {"text": "Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. ", "triple_list": [["gentamicin", "mechanism", "99mTc-MDP"]]}, {"text": "Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ", "triple_list": [["INVEGA", "advise", "centrally acting drugs"]]}, {"text": "Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.", "triple_list": [["anticonvulsant agents", "mechanism", "cisplatin"]]}, {"text": "Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.", "triple_list": [["L-histidine", "effect", "medroxyprogesterone acetate"]]}, {"text": "Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.", "triple_list": [["aspirin", "mechanism", "flurbiprofen"]]}, {"text": "Concurrent use of flurbiprofen and aspirin is therefore not recommended.", "triple_list": [["flurbiprofen", "advise", "aspirin"]]}, {"text": "Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.", "triple_list": [["flurbiprofen", "advise", "beta-blocker"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["flurbiprofen", "mechanism", "cimetidine"]]}, {"text": "Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.", "triple_list": [["nonsteroidal anti-inflammatory drugs", "effect", "thiazide diuretics"]]}, {"text": "Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.", "triple_list": [["flurbiprofen", "advise", "furosemide"]]}, {"text": "Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.", "triple_list": [["flurbiprofen", "advise", "diuretics"]]}, {"text": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "triple_list": [["TRACRIUM", "effect", "aminoglycosides"]]}, {"text": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.", "triple_list": [["acitretin", "effect", "glibenclamide"]]}, {"text": "However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.", "triple_list": [["acitretin", "effect", "progestin"]]}, {"text": "Consequently, the combination of methotrexate with acitretin is also contraindicated.", "triple_list": [["methotrexate", "advise", "acitretin"]]}, {"text": "Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.", "triple_list": [["acitretin", "mechanism", "phenytoin"]]}, {"text": "Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.", "triple_list": [["acitretin", "effect", "tetracyclines"]]}, {"text": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "triple_list": [["vitamin A", "advise", "acitretin"]]}, {"text": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "triple_list": [["retinoids", "advise", "acitretin"]]}, {"text": "ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ", "triple_list": [["SALICYLATE DRUGS", "effect", "DISALCID"]]}, {"text": "Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ", "triple_list": [["CHEMET", "advise", "CaNa 2 EDTA"]]}, {"text": "Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.", "triple_list": [["L-glutamine", "mechanism", "human growth hormone"]]}, {"text": "Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.", "triple_list": [["L-glutamine", "effect", "indomethacin"]]}, {"text": "Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.", "triple_list": [["methotrexate", "effect", "L-glutamine"]]}, {"text": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "triple_list": [["Matulane", "advise", "tricyclic antidepressant"]]}, {"text": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "triple_list": [["Matulane", "advise", "tyramine"]]}, {"text": "Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.", "triple_list": [["Anafranil", "advise", "anticholinergic"]]}, {"text": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "triple_list": [["tricyclic antidepressants", "effect", "CMI"]]}, {"text": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "triple_list": [["tricyclic antidepressants", "effect", "tricyclic antidepressants"]]}, {"text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "triple_list": [["tricyclic antidepressants", "mechanism", "methylphenidate"]]}, {"text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "triple_list": [["methylphenidate", "mechanism", "CMI"]]}, {"text": "Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.", "triple_list": [["TCAs", "advise", "SSRIs"]]}, {"text": "Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. ", "triple_list": [["TAM", "effect", "1,25(OH)2D3"]]}, {"text": "Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. ", "triple_list": [["1,25(OH)2D3", "effect", "TAM"]]}, {"text": "Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.", "triple_list": [["ABILIFY", "advise", "centrally acting drugs"]]}, {"text": "Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.", "triple_list": [["ketoconazole", "mechanism", "aripiprazole"]]}, {"text": "When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.", "triple_list": [["ketoconazole", "advise", "aripiprazole"]]}, {"text": "Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.", "triple_list": [["aripiprazole", "mechanism", "quinidine"]]}, {"text": "Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.", "triple_list": [["quinidine", "advise", "aripiprazole"]]}, {"text": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.", "triple_list": [["carbamazepine", "mechanism", "aripiprazole"]]}, {"text": "When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.", "triple_list": [["carbamazepine", "advise", "aripiprazole"]]}, {"text": "When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.", "triple_list": [["carbamazepine", "advise", "aripiprazole"]]}, {"text": "Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.", "triple_list": [["Betaseron", "mechanism", "antipyrine"]]}, {"text": "Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ", "triple_list": [["thiabendazole", "advise", "xanthine derivatives"]]}, {"text": "Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ", "triple_list": [["Cholestyramine", "mechanism", "raloxifene"]]}, {"text": "Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.", "triple_list": [["antidiabetic agents", "advise", "VELCADE"]]}, {"text": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "triple_list": [["diflunisal", "effect", "phenprocoumon"]]}, {"text": "This may occur because diflunisal competitively displaces coumarins from protein binding sites.", "triple_list": [["diflunisal", "mechanism", "coumarins"]]}, {"text": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "triple_list": [["diflunisal", "mechanism", "hydrochlorothiazide"]]}, {"text": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "triple_list": [["diflunisal", "mechanism", "acetaminophen"]]}, {"text": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "triple_list": [["diflunisal", "advise", "acetaminophen"]]}, {"text": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "triple_list": [["diflunisal", "effect", "acetaminophen"]]}, {"text": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "triple_list": [["nonsteroial anti-inflammatory drugs", "mechanism", "cyclosporine"]]}, {"text": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "triple_list": [["diflunisal", "mechanism", "indomethacin"]]}, {"text": "In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "triple_list": [["indomethacin", "effect", "diflunisal"]]}, {"text": "Therefore, indomethacin and diflunisal should not be used concomitantly.", "triple_list": [["indomethacin", "advise", "diflunisal"]]}, {"text": "The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "triple_list": [["diflunisal", "effect", "NSAIDs"]]}, {"text": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "triple_list": [["diflunisal", "mechanism", "aspirin"]]}, {"text": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "triple_list": [["diflunisal", "mechanism", "sulindac"]]}, {"text": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "triple_list": [["diflunisal", "mechanism", "naproxen"]]}, {"text": "The drug interaction between warfarin and rifampin is not well known. ", "triple_list": [["warfarin", "int", "rifampin"]]}, {"text": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "triple_list": [["rifampin", "mechanism", "warfarin"]]}, {"text": "Withdrawal of rifampin decreased the warfarin requirement by 50%. ", "triple_list": [["rifampin", "mechanism", "warfarin"]]}, {"text": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "triple_list": [["rifampin", "effect", "warfarin"]]}, {"text": "Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.", "triple_list": [["colestipol hydrochloride", "mechanism", "propranolol"]]}, {"text": "Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.", "triple_list": [["propranolol", "advise", "COLESTID"]]}, {"text": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "triple_list": [["digitalis preparations", "effect", "colestipol hydrochloride"]]}, {"text": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "triple_list": [["colestipol hydrochloride", "mechanism", "digoxin"]]}, {"text": "In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ", "triple_list": [["methadone", "mechanism", "ZIAGEN"]]}, {"text": "Elevated plasma levels of theophylline have been reported with concomitant quinolone use.", "triple_list": [["theophylline", "mechanism", "quinolone"]]}, {"text": "The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.", "triple_list": [["quinolones", "effect", "glyburide"]]}, {"text": "The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.", "triple_list": [["norfloxacin", "effect", "glyburide"]]}, {"text": "Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.", "triple_list": [["probenecid", "mechanism", "norfloxacin"]]}, {"text": "The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.", "triple_list": [["nitrofurantoin", "effect", "Norfloxacin"]]}, {"text": "Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.", "triple_list": [["diuretics", "effect", "enalapril"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalapril", "effect", "diuretic"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalaprilat", "effect", "diuretic"]]}, {"text": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "triple_list": [["enalapril", "effect", "antihypertensive agents"]]}, {"text": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "triple_list": [["enalapril", "effect", "antihypertensive agents"]]}, {"text": "It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.", "triple_list": [["enalapril", "advise", "lithium"]]}, {"text": "Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.", "triple_list": [["Cerubidine", "effect", "doxorubicin"]]}, {"text": "Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.", "triple_list": [["cephalosporins", "effect", "aminoglycoside antibiotics"]]}, {"text": "Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.", "triple_list": [["cephalosporins", "effect", "diuretics"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "int", "FELDENE"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["FELDENE", "advise", "coumarin-type anticoagulants"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["FELDENE", "mechanism", "aspirin"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["FELDENE", "mechanism", "lithium"]]}, {"text": "Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.", "triple_list": [["levetiracetam", "mechanism", "AEDs"]]}, {"text": "Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ", "triple_list": [["ethanol", "effect", "disulfiram"]]}, {"text": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "triple_list": [["ticagrelor", "effect", "aspirin"]]}, {"text": "Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.", "triple_list": [["celecoxib", "int", "fluconazole"]]}, {"text": "Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.", "triple_list": [["nonsteroidal anti-inflammatory drugs", "int", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "thiazides"]]}, {"text": "However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.", "triple_list": [["aspirin", "effect", "CELEBREX"]]}, {"text": "Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.", "triple_list": [["fluconazole", "mechanism", "celecoxib"]]}, {"text": "This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).", "triple_list": [["celecoxib", "mechanism", "fluconazole"]]}, {"text": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "triple_list": [["lithium", "mechanism", "CELEBREX"]]}, {"text": "Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.", "triple_list": [["lithium", "advise", "CELEBREX"]]}, {"text": "However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.", "triple_list": [["CELEBREX", "advise", "warfarin"]]}, {"text": "In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.", "triple_list": [["labetalol HCl", "effect", "tricyclic antidepressants"]]}, {"text": "During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.", "triple_list": [["labetalol HCl", "effect", "halothane"]]}, {"text": "If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.", "triple_list": [["labetalol HCl", "effect", "nitroglycerin"]]}, {"text": "Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ", "triple_list": [["fluoxetine", "mechanism", "endoxifen"]]}, {"text": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "triple_list": [["tamoxifen", "advise", "SSRI antidepressants"]]}, {"text": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "triple_list": [["tamoxifen", "advise", "paroxetine"]]}, {"text": "If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.", "triple_list": [["antidepressant", "advise", "tamoxifen"]]}, {"text": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "triple_list": [["L-methionine", "effect", "acetaminophen"]]}, {"text": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "triple_list": [["L-methionine", "effect", "methotrexate"]]}, {"text": "Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.", "triple_list": [["nelfinavir", "effect", "azithromycin"]]}, {"text": "However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.", "triple_list": [["azithromycin", "advise", "warfarin"]]}, {"text": "Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.", "triple_list": [["macrolides", "effect", "warfarin"]]}, {"text": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "triple_list": [["azithromycin", "mechanism", "theophylline"]]}, {"text": "Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.", "triple_list": [["piperacillin", "effect", "aminoglycoside"]]}, {"text": "Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.", "triple_list": [["probenecid", "mechanism", "PIPRACIL"]]}, {"text": "Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ", "triple_list": [["hemantane", "effect", "doxycycline"]]}, {"text": "In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.", "triple_list": [["serotonin reuptake inhibitor drug", "effect", "monoamine oxidase inhibitors"]]}, {"text": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "triple_list": [["fluvoxamine maleate", "mechanism", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["alprazolam", "advise", "Fluvoxamine"]]}, {"text": "Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.", "triple_list": [["Fluvoxamine", "advise", "diazepam"]]}, {"text": "Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.", "triple_list": [["fluvoxamine", "mechanism", "diazepam"]]}, {"text": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "triple_list": [["fluvoxamine", "advise", "diazepam"]]}, {"text": "Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.", "triple_list": [["diazepam", "advise", "fluvoxamine"]]}, {"text": "Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.", "triple_list": [["fluvoxamine maleate", "mechanism", "warfarin"]]}, {"text": "Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.", "triple_list": [["anticoagulants", "advise", "Fluvoxamine"]]}, {"text": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "triple_list": [["EQUETROTM", "mechanism", "theophylline"]]}, {"text": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "triple_list": [["EQUETROTM", "mechanism", "primidone"]]}, {"text": "Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.", "triple_list": [["carbamazepine", "effect", "lithium"]]}, {"text": "Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.", "triple_list": [["EQUETROTM", "advise", "centrally acting drugs"]]}, {"text": "Therefore, use of lamivudine in combination with zalcitabine is not recommended", "triple_list": [["lamivudine", "advise", "zalcitabine"]]}, {"text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "triple_list": [["cinacalcet", "mechanism", "amitriptyline"]]}, {"text": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "triple_list": [["Probenecid", "mechanism", "nonsteroidal anti-inflammatory"]]}, {"text": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "triple_list": [["VISTIDE", "advise", "aminoglycosides"]]}, {"text": "Interaction of gentamycin and atracurium in anaesthetised horses.\r\n", "triple_list": [["gentamycin", "int", "atracurium"]]}, {"text": "Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). ", "triple_list": [["atracurium", "effect", "gentamycin"]]}, {"text": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "triple_list": [["Levo-Dromoran", "effect", "central nervous system depressants"]]}, {"text": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "triple_list": [["Levo-Dromoran", "effect", "skeletal muscle relaxants"]]}, {"text": "Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.", "triple_list": [["Levo-Dromoran", "advise", "MAO inhibitors"]]}, {"text": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "triple_list": [["captopril", "effect", "diuretic"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "triple_list": [["lithium", "effect", "ACE inhibitor"]]}, {"text": "If a diuretic is also used, it may increase the risk of lithium toxicity.", "triple_list": [["diuretic", "effect", "lithium"]]}, {"text": "Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ", "triple_list": [["ZOLINZA", "effect", "HDAC inhibitors"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "effect", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "effect", "corticosteroids"]]}, {"text": "Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.", "triple_list": [["contraceptives", "mechanism", "vitamin A"]]}, {"text": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "triple_list": [["calcium channel blockers", "effect", "nitrates"]]}, {"text": "At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ", "triple_list": [["sulfamethoxazole", "mechanism", "phenytoin"]]}, {"text": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "triple_list": [["dexamethasone", "effect", "EGF"]]}, {"text": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "triple_list": [["retinyl acetate", "effect", "EGF"]]}, {"text": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "triple_list": [["dexamethasone", "effect", "insulin"]]}, {"text": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "triple_list": [["glucocorticoids", "effect", "insulin"]]}, {"text": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "triple_list": [["trovafloxacin", "mechanism", "opiate"]]}, {"text": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "triple_list": [["ciprofloxacin", "mechanism", "opiate"]]}, {"text": "Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.", "triple_list": [["chloroquine", "mechanism", "cyclosporin"]]}, {"text": "Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.", "triple_list": [["steroids", "effect", "aspirin"]]}, {"text": "Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "triple_list": [["rifampin", "mechanism", "fludrocortisone acetate"]]}, {"text": "Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.", "triple_list": [["Simulect", "mechanism", "azathioprine"]]}, {"text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "triple_list": [["apomorphine", "advise", "5HT3 antagonist class"]]}, {"text": "Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.", "triple_list": [["antihypertensive medications", "effect", "vasodilators"]]}, {"text": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "triple_list": [["ABT-737", "effect", "DZNep"]]}, {"text": "Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.", "triple_list": [["CRIXIVAN", "advise", "atazanavir"]]}, {"text": "Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.", "triple_list": [["CRIXIVAN", "advise", "delavirdine"]]}, {"text": "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.", "triple_list": [["indinavir", "effect", "ritonavir"]]}, {"text": "Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.", "triple_list": [["CRIXIVAN", "advise", "itraconazole"]]}, {"text": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "triple_list": [["rifabutin", "advise", "CRIXIVAN"]]}, {"text": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "triple_list": [["estazolam", "mechanism", "estazolam"]]}, {"text": "Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.", "triple_list": [["estazolam", "advise", "ketoconazole"]]}, {"text": "In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "triple_list": [["INDOCIN", "effect", "diflunisal"]]}, {"text": "Therefore, diflunisal and INDOCIN should not be used concomitantly.", "triple_list": [["diflunisal", "advise", "INDOCIN"]]}, {"text": "In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.", "triple_list": [["aspirin", "mechanism", "indomethacin"]]}, {"text": "The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "triple_list": [["INDOCIN", "advise", "NSAIDs"]]}, {"text": "Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.", "triple_list": [["INDOCIN", "advise", "anticoagulants"]]}, {"text": "Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "triple_list": [["non-steroidal anti-inflammatory drugs", "effect", "cyclosporine"]]}, {"text": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "triple_list": [["INDOCIN", "mechanism", "lithium"]]}, {"text": "As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.", "triple_list": [["INDOCIN", "advise", "lithium"]]}, {"text": "Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.", "triple_list": [["INDOCIN", "advise", "digoxin"]]}, {"text": "It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.", "triple_list": [["triamterene", "effect", "INDOCIN"]]}, {"text": "The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.", "triple_list": [["INDOCIN", "effect", "potassium-sparing diuretics"]]}, {"text": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.", "triple_list": [["beta-adrenoceptor blocking agents", "effect", "non-steroidal antiinflammatory drugs"]]}, {"text": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.", "triple_list": [["beta-adrenoceptor blocking agents", "effect", "INDOCIN"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "effect", "cisplatin"]]}, {"text": "Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.", "triple_list": [["paclitaxel", "mechanism", "doxorubicin"]]}, {"text": "Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.", "triple_list": [["rauwolfia alkaloid", "effect", "MAO inhibitors"]]}, {"text": "The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. ", "triple_list": [["GL", "effect", "antibiotics"]]}, {"text": "Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.", "triple_list": [["GL", "effect", "cefazolin"]]}, {"text": "Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ", "triple_list": [["estradiol", "effect", "noradrenaline"]]}, {"text": "It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .", "triple_list": [["calcium channel blockers", "effect", "Nimotop"]]}, {"text": "In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;", "triple_list": [["Nimotop", "effect", "antihypertensive compounds"]]}, {"text": "A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.", "triple_list": [["cimetidine", "mechanism", "nimodipine"]]}, {"text": "Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.", "triple_list": [["etanercept", "effect", "anakinra"]]}, {"text": "Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.", "triple_list": [["TNFa-blocking agents", "effect", "anakinra"]]}, {"text": "In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ", "triple_list": [["vigabatrin", "mechanism", "phenytoin"]]}, {"text": "When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ", "triple_list": [["ProAmatine", "effect", "cardiac glycosides"]]}, {"text": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ", "triple_list": [["phenylpropanolamine", "effect", "ProAmatine"]]}, {"text": "The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "triple_list": [["cocaine", "effect", "norepinephrine"]]}, {"text": "The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "triple_list": [["desipramine", "effect", "norepinephrine"]]}, {"text": "Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ", "triple_list": [["warfarin", "advise", "FLOMAX"]]}, {"text": "Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.", "triple_list": [["indinavir", "None", "amiodarone"]]}, {"text": "Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.", "triple_list": [["amiodarone", "None", "protease inhibitor"]]}, {"text": "Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.", "triple_list": [["Cimetidine", "None", "amiodarone"]]}, {"text": "Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "This information should be considered when changing from intravenous amiodarone to oral amiodarone .", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "triple_list": [["Cyclosporine", "None", "amiodarone"]]}, {"text": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "triple_list": [["Cyclosporine", "None", "cyclosporine"]]}, {"text": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "triple_list": [["Cyclosporine", "None", "cyclosporine"]]}, {"text": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "triple_list": [["amiodarone", "None", "cyclosporine"]]}, {"text": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "triple_list": [["amiodarone", "None", "cyclosporine"]]}, {"text": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.", "triple_list": [["Simvastatin", "None", "amiodarone"]]}, {"text": "Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.", "triple_list": [["digoxin", "None", "amiodarone"]]}, {"text": "Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.", "triple_list": [["amiodarone", "None", "digoxin"]]}, {"text": "Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.", "triple_list": [["quinidine", "None", "quinidine"]]}, {"text": "Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.", "triple_list": [["procainamide", "None", "procainamide"]]}, {"text": "Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.", "triple_list": [["procainamide", "None", "procainamide"]]}, {"text": "Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.", "triple_list": [["procainamide", "None", "procainamide"]]}, {"text": "because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.", "triple_list": [["flecainide", "None", "drugs"]]}, {"text": "Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.", "triple_list": [["amiodarone", "None", "antiarrhythmic"]]}, {"text": "Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.", "triple_list": [["antiarrhythmic", "None", "amiodarone"]]}, {"text": "The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.", "triple_list": [["antiarrhythmic", "None", "amiodarone"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["Amiodarone", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["Amiodarone", "None", "calcium channel"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["Amiodarone", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["Amiodarone", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["CYP3A4", "None", "calcium channel"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["CYP3A4", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["CYP3A4", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["calcium channel", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["calcium channel", "None", "CYP3A4"]]}, {"text": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "triple_list": [["CYP3A4", "None", "CYP3A4"]]}, {"text": "Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.", "triple_list": [["CYP3A4", "None", "anticoagulant"]]}, {"text": "Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.", "triple_list": [["CYP3A4", "None", "amiodarone"]]}, {"text": "Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.", "triple_list": [["anticoagulant", "None", "amiodarone"]]}, {"text": "Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.", "triple_list": [["warfarin", "None", "amiodarone"]]}, {"text": "Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.", "triple_list": [["warfarin", "None", "anticoagulant"]]}, {"text": "Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.", "triple_list": [["amiodarone", "None", "anticoagulant"]]}, {"text": "Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).", "triple_list": [["amiodarone", "None", "CYP3A4"]]}, {"text": "Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.", "triple_list": [["rifampin", "None", "amiodarone"]]}, {"text": "Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.", "triple_list": [["rifampin", "None", "amiodarone"]]}, {"text": "Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.", "triple_list": [["amiodarone", "None", "Fentanyl"]]}, {"text": "Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.", "triple_list": [["amiodarone", "None", "amiodarone"]]}, {"text": "Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.", "triple_list": [["Fentanyl", "None", "amiodarone"]]}, {"text": "Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.", "triple_list": [["amiodarone", "None", "lidocaine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["atropine", "None", "atropine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["atropine", "None", "pralidoxime"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["atropine", "None", "atropine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["pralidoxime", "None", "atropine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["pralidoxime", "None", "pralidoxime"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["pralidoxime", "None", "atropine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["atropine", "None", "pralidoxime"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "triple_list": [["atropine", "None", "atropine"]]}, {"text": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "triple_list": [["Sonata", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "triple_list": [["Sonata", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.", "triple_list": [["Sonata", "None", "paroxetine"]]}, {"text": "Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.", "triple_list": [["paroxetine", "None", "zaleplon"]]}, {"text": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "triple_list": [["zaleplon", "None", "venlafaxine"]]}, {"text": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "triple_list": [["zaleplon", "None", "zaleplon"]]}, {"text": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "triple_list": [["zaleplon", "None", "venlafaxine"]]}, {"text": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "triple_list": [["venlafaxine", "None", "zaleplon"]]}, {"text": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "triple_list": [["venlafaxine", "None", "venlafaxine"]]}, {"text": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "triple_list": [["zaleplon", "None", "venlafaxine"]]}, {"text": "In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.", "triple_list": [["zaleplon", "None", "venlafaxine"]]}, {"text": "Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.", "triple_list": [["zaleplon", "None", "zaleplon"]]}, {"text": "Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.", "triple_list": [["promethazine", "None", "zaleplon"]]}, {"text": "However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.", "triple_list": [["zaleplon", "None", "promethazine"]]}, {"text": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.", "triple_list": [["zaleplon", "None", "5-oxo-desethylzaleplon"]]}, {"text": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.", "triple_list": [["zaleplon", "None", "zaleplon"]]}, {"text": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.", "triple_list": [["5-oxo-desethylzaleplon", "None", "zaleplon"]]}, {"text": "Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.", "triple_list": [["zaleplon", "None", "zaleplon"]]}, {"text": "Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.", "triple_list": [["erythromycin", "None", "zaleplon"]]}, {"text": "Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.", "triple_list": [["Diphenhydramine", "None", "Diphenhydramine"]]}, {"text": "There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.", "triple_list": [["zaleplon", "None", "diphenhydramine"]]}, {"text": "Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.", "triple_list": [["Cimetidine", "None", "Cimetidine"]]}, {"text": "Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.", "triple_list": [["Cimetidine", "None", "zaleplon"]]}, {"text": "Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).", "triple_list": [["Sonata", "None", "digoxin"]]}, {"text": "Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.", "triple_list": [["Sonata", "None", "warfarin"]]}, {"text": "Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.", "triple_list": [["Sonata", "None", "warfarin"]]}, {"text": "Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.", "triple_list": [["Ibuprofen", "None", "Ibuprofen"]]}, {"text": "There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.", "triple_list": [["zaleplon", "None", "ibuprofen"]]}, {"text": "This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.", "triple_list": [["zaleplon", "None", "zaleplon"]]}, {"text": "May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).", "triple_list": [["central nervous system (CNS) depressants", "None", "alcohol"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ", "triple_list": [["atropine", "None", "atropine"]]}, {"text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ", "triple_list": [["pralidoxime", "None", "atropine"]]}, {"text": "This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed. ", "triple_list": [["atropine", "None", "pralidoxime"]]}, {"text": "To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ", "triple_list": [["arginine", "None", "glucose"]]}, {"text": "To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ", "triple_list": [["arginine", "None", "theophylline"]]}, {"text": "To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ", "triple_list": [["glucose", "None", "theophylline"]]}, {"text": "In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. ", "triple_list": [["sulfonylureas", "None", "biguanides"]]}, {"text": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "triple_list": [["SYMLIN", "None", "Insulin"]]}, {"text": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "triple_list": [["SYMLIN", "None", "SYMLIN"]]}, {"text": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "triple_list": [["SYMLIN", "None", "human insulin"]]}, {"text": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "triple_list": [["Insulin", "None", "SYMLIN"]]}, {"text": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "triple_list": [["Insulin", "None", "human insulin"]]}, {"text": "Thus, SYMLIN and insulin should not be mixed and must be administered separately.", "triple_list": [["SYMLIN", "None", "insulin"]]}, {"text": "Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.", "triple_list": [["Dactinomycin", "None", "antibacterial drug"]]}, {"text": "No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).", "triple_list": [["MAO-B inhibitor", "None", "selegiline"]]}, {"text": "No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).", "triple_list": [["MAO-B inhibitor", "None", "entacapone"]]}, {"text": "No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).", "triple_list": [["selegiline", "None", "entacapone"]]}, {"text": "More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.", "triple_list": [["selegiline", "None", "entacapone"]]}, {"text": "As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.", "triple_list": [["entacapone", "None", "entacapone"]]}, {"text": "These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).", "triple_list": [["antibiotics", "None", "ampicillin"]]}, {"text": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.", "triple_list": [["tricyclic antidepressant", "None", "imipramine"]]}, {"text": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.", "triple_list": [["tricyclic antidepressant", "None", "entacapone"]]}, {"text": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.", "triple_list": [["imipramine", "None", "entacapone"]]}, {"text": "AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation. ", "triple_list": [["insulin", "None", "glucose"]]}, {"text": "Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. ", "triple_list": [["glucose", "None", "insulin"]]}, {"text": "Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. ", "triple_list": [["glucose", "None", "somatostatin"]]}, {"text": "Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. ", "triple_list": [["insulin", "None", "somatostatin"]]}, {"text": "CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation. ", "triple_list": [["Glucose", "None", "insulin"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "colestipol"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "Cholestytamine"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "colestipol"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "thiazide diuretics"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestyramine", "None", "diuretic"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "Cholestytamine"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "colestipol"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "thiazide diuretics"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "diuretic"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "Cholestytamine"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "colestipol"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "thiazide diuretics"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "diuretic"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestytamine", "None", "colestipol"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestytamine", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["Cholestytamine", "None", "diuretic"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "resins"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["colestipol", "None", "diuretic"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "thiazide diuretics"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["resins", "None", "diuretic"]]}, {"text": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "triple_list": [["thiazide diuretics", "None", "diuretic"]]}, {"text": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "triple_list": [["chlorothiazide", "None", "diuretic"]]}, {"text": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "triple_list": [["non-steroidal anti-inflammatory agents", "None", "diuretic"]]}, {"text": "The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ", "triple_list": [["glycine", "None", "glutamate"]]}, {"text": "The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ", "triple_list": [["glutamate", "None", "glutamate"]]}, {"text": "Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ", "triple_list": [["anticoagulant", "None", "Mitotane"]]}, {"text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "triple_list": [["Heparin", "None", "warfarin"]]}, {"text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "triple_list": [["Heparin", "None", "ketorolac tromethamine"]]}, {"text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "triple_list": [["Heparin", "None", "ketorolac"]]}, {"text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "triple_list": [["warfarin", "None", "ketorolac"]]}, {"text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "triple_list": [["ketorolac tromethamine", "None", "ketorolac"]]}, {"text": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.", "triple_list": [["salicylate", "None", "ketorolac"]]}, {"text": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.", "triple_list": [["ketorolac", "None", "ketorolac"]]}, {"text": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "triple_list": [["phenytoin", "None", "ketorolac tromethamine"]]}, {"text": "In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.", "triple_list": [["heparin", "None", "heparin"]]}, {"text": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "triple_list": [["TORADOL", "None", "warfarin"]]}, {"text": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "triple_list": [["TORADOL", "None", "TORADOL"]]}, {"text": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "triple_list": [["TORADOL", "None", "anticoagulants"]]}, {"text": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "triple_list": [["warfarin", "None", "TORADOL"]]}, {"text": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "triple_list": [["warfarin", "None", "anticoagulants"]]}, {"text": "Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).", "triple_list": [["TORADOL", "None", "diuretic"]]}, {"text": "Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).", "triple_list": [["diuretic", "None", "furosemide"]]}, {"text": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "triple_list": [["TORADOL", "None", "ketorolac"]]}, {"text": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "triple_list": [["TORADOL", "None", "ketorolac"]]}, {"text": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "triple_list": [["probenecid", "None", "ketorolac"]]}, {"text": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "triple_list": [["probenecid", "None", "ketorolac"]]}, {"text": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "triple_list": [["ketorolac", "None", "ketorolac"]]}, {"text": "Lithium: Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "triple_list": [["TORADOL", "None", "lithium"]]}, {"text": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "triple_list": [["TORADOL", "None", "lithium"]]}, {"text": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "triple_list": [["TORADOL", "None", "TORADOL"]]}, {"text": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "triple_list": [["lithium", "None", "TORADOL"]]}, {"text": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "triple_list": [["NSAIDs", "None", "methotrexate"]]}, {"text": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "triple_list": [["NSAIDs", "None", "methotrexate"]]}, {"text": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "The effect of TORADOL on methotrexate clearance has not been studied.", "triple_list": [["TORADOL", "None", "methotrexate"]]}, {"text": "The concurrent use of TORADOL with muscle relaxants has not been formally studied.", "triple_list": [["TORADOL", "None", "muscle relaxants"]]}, {"text": "Do not mix TORADOL and morphine in the same syringe.", "triple_list": [["TORADOL", "None", "morphine"]]}, {"text": "When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.", "triple_list": [["Acarbose", "None", "sulfonylureas"]]}, {"text": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "triple_list": [["digestive enzyme preparations", "None", "Acarbose"]]}, {"text": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.", "triple_list": [["sulfonylurea", "None", "glyburide"]]}, {"text": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.", "triple_list": [["metformin", "None", "Acarbose"]]}, {"text": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "triple_list": [["metformin", "None", "metformin"]]}, {"text": "Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.", "triple_list": [["beta-blockers", "None", "anti-hypertensives"]]}, {"text": "Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.", "triple_list": [["beta-blockers", "None", "cardiac glycosides"]]}, {"text": "Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.", "triple_list": [["anti-hypertensives", "None", "cardiac glycosides"]]}, {"text": "Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.\r\n", "triple_list": [["S-ketamine", "None", "itraconazole"]]}, {"text": "This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ", "triple_list": [["S-ketamine", "None", "ticlopidine"]]}, {"text": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "triple_list": [["S-ketamine", "None", "ticlopidine"]]}, {"text": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "triple_list": [["S-ketamine", "None", "itraconazole"]]}, {"text": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "triple_list": [["ticlopidine", "None", "itraconazole"]]}, {"text": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "triple_list": [["ketamine", "None", "itraconazole"]]}, {"text": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "triple_list": [["norketamine", "None", "ketamine"]]}, {"text": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "triple_list": [["norketamine", "None", "ticlopidine"]]}, {"text": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "triple_list": [["norketamine", "None", "itraconazole"]]}, {"text": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "triple_list": [["ketamine", "None", "ticlopidine"]]}, {"text": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "triple_list": [["ketamine", "None", "itraconazole"]]}, {"text": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "triple_list": [["ticlopidine", "None", "itraconazole"]]}, {"text": "In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ", "triple_list": [["ticlopidine", "None", "itraconazole"]]}, {"text": "Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.", "triple_list": [["insulin", "None", "hypoglycemic"]]}, {"text": "Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.", "triple_list": [["insulin", "None", "hypoglycemics"]]}, {"text": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "triple_list": [["Cholestyramine", "None", "Cholestyramine"]]}, {"text": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "triple_list": [["Cholestyramine", "None", "T4"]]}, {"text": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "triple_list": [["Cholestyramine", "None", "T3"]]}, {"text": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "triple_list": [["T4", "None", "T3"]]}, {"text": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.", "triple_list": [["levothyroxine", "None", "thyroid"]]}, {"text": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.", "triple_list": [["estrogens", "None", "thyroid"]]}, {"text": "Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.", "triple_list": [["estrogens", "None", "contraceptives"]]}, {"text": "Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.", "triple_list": [["imipramine", "None", "tricyclic antidepressants"]]}, {"text": "Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.", "triple_list": [["thyroid hormone", "None", "contraceptives"]]}, {"text": "Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.", "triple_list": [["estrogens", "None", "contraceptives"]]}, {"text": "Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.", "triple_list": [["androgen", "None", "corticosteroid"]]}, {"text": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "triple_list": [["Charcoal", "None", "cholestyramine"]]}, {"text": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "triple_list": [["Charcoal", "None", "activated charcoal"]]}, {"text": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "triple_list": [["cholestyramine", "None", "activated charcoal"]]}, {"text": "NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.", "triple_list": [["diclofenac", "None", "ibuprofen"]]}, {"text": "Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.", "triple_list": [["ARAVA", "None", "ARAVA"]]}, {"text": "Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.", "triple_list": [["ARAVA", "None", "ARAVA"]]}, {"text": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "triple_list": [["quinolones", "None", "anticoagulant"]]}, {"text": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "triple_list": [["anticoagulant", "None", "warfarin"]]}, {"text": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "triple_list": [["anticoagulant", "None", "cyclosporine"]]}, {"text": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "triple_list": [["warfarin", "None", "cyclosporine"]]}, {"text": "Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.", "triple_list": [["salicylates", "None", "salicylate"]]}, {"text": "Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.", "triple_list": [["diuretics", "None", "lithium"]]}, {"text": "Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.", "triple_list": [["diuretics", "None", "lithium"]]}, {"text": "Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.", "triple_list": [["sucralfate", "None", "furosemide"]]}, {"text": "Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.", "triple_list": [["furosemide", "None", "furosemide"]]}, {"text": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.", "triple_list": [["indomethacin", "None", "furosemide"]]}, {"text": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.", "triple_list": [["furosemide", "None", "furosemide"]]}, {"text": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "triple_list": [["ibuprofen", "None", "nonsteroidal anti-inflammatory agents"]]}, {"text": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "triple_list": [["ibuprofen", "None", "ibuprofen"]]}, {"text": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "triple_list": [["nonsteroidal anti-inflammatory agents", "None", "ibuprofen"]]}, {"text": "Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.", "triple_list": [["aspirin", "None", "ibuprofen"]]}, {"text": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "triple_list": [["cimetidine", "None", "ranitidine"]]}, {"text": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "triple_list": [["cimetidine", "None", "ibuprofen"]]}, {"text": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "triple_list": [["cimetidine", "None", "ibuprofen"]]}, {"text": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "triple_list": [["ranitidine", "None", "ibuprofen"]]}, {"text": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "triple_list": [["ranitidine", "None", "ibuprofen"]]}, {"text": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "triple_list": [["ibuprofen", "None", "ibuprofen"]]}, {"text": "Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["furosemide", "None", "thiazides"]]}, {"text": "Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.", "triple_list": [["Ibuprofen", "None", "lithium"]]}, {"text": "Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["ibuprofen", "None", "lithium"]]}, {"text": "Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["resin", "None", "thiazide diuretics"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["resin", "None", "propranolol"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["resin", "None", "tetracycline"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["resin", "None", "thyroxine"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["resin", "None", "estrogens"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["thiazide diuretics", "None", "propranolol"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["thiazide diuretics", "None", "tetracycline"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["thiazide diuretics", "None", "thyroxine"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["thiazide diuretics", "None", "estrogens"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["propranolol", "None", "tetracycline"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["propranolol", "None", "thyroxine"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["propranolol", "None", "estrogens"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["tetracycline", "None", "thyroxine"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["tetracycline", "None", "estrogens"]]}, {"text": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "triple_list": [["thyroxine", "None", "estrogens"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "cholestyramine"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "resin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "digitalis"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "cholestyramine"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "resin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["cholestyramine", "None", "resin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["cholestyramine", "None", "cholestyramine"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["cholestyramine", "None", "resin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "digitalis"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "cholestyramine"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["resin", "None", "resin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["digitalis", "None", "cholestyramine"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["digitalis", "None", "resin"]]}, {"text": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "triple_list": [["cholestyramine", "None", "resin"]]}, {"text": "Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.", "triple_list": [["cholestyramine", "None", "cholestyramine"]]}, {"text": "Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.", "triple_list": [["cholestyramine", "None", "resin"]]}, {"text": "Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.", "triple_list": [["cholestyramine", "None", "fat soluble vitamins"]]}, {"text": "Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.", "triple_list": [["cholestyramine", "None", "resin"]]}, {"text": "Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.", "triple_list": [["cholestyramine", "None", "fat soluble vitamins"]]}, {"text": "Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.", "triple_list": [["resin", "None", "fat soluble vitamins"]]}, {"text": "When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.", "triple_list": [["cholestyramine", "None", "resin"]]}, {"text": "When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.", "triple_list": [["cholestyramine", "None", "fat-soluble vitamins"]]}, {"text": "When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.", "triple_list": [["resin", "None", "fat-soluble vitamins"]]}, {"text": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "triple_list": [["CHOLESTYRAMINE", "None", "RESIN"]]}, {"text": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "triple_list": [["CHOLESTYRAMINE", "None", "CHOLESTYRAMINE"]]}, {"text": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "triple_list": [["CHOLESTYRAMINE", "None", "RESIN"]]}, {"text": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "triple_list": [["RESIN", "None", "CHOLESTYRAMINE"]]}, {"text": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "triple_list": [["RESIN", "None", "RESIN"]]}, {"text": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "triple_list": [["CHOLESTYRAMINE", "None", "RESIN"]]}, {"text": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "triple_list": [["photosensitizing agents", "None", "sulfonamides"]]}, {"text": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "triple_list": [["photosensitizing agents", "None", "tetracyclines"]]}, {"text": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "triple_list": [["sulfonamides", "None", "tetracyclines"]]}, {"text": "Also, the potential for hepatic injury should be considered when Rebif  is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif .", "triple_list": [["Rebif", "None", "Rebif"]]}, {"text": "The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "triple_list": [["NUROMAX", "None", "succinylcholine"]]}, {"text": "The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "triple_list": [["NUROMAX", "None", "succinylcholine"]]}, {"text": "The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "triple_list": [["succinylcholine", "None", "succinylcholine"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["antibiotics", "None", "magnesium"]]}, {"text": "Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "triple_list": [["antidepressants", "None", "Type 1C antiarrhythmics"]]}, {"text": "Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. ", "triple_list": [["folic acid", "None", "digoxin"]]}, {"text": "When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. ", "triple_list": [["sulfasalazine", "None", "methotrexate"]]}, {"text": "Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. ", "triple_list": [["sulfasalazine", "None", "methotrexate"]]}, {"text": "HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.", "triple_list": [["amprenavir", "None", "HIV protease inhibitors"]]}, {"text": "Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.", "triple_list": [["amprenavir", "None", "methadone"]]}, {"text": "Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.", "triple_list": [["methadone", "None", "methadone"]]}, {"text": "Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.", "triple_list": [["amprenavir", "None", "amprenavir"]]}, {"text": "Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.", "triple_list": [["methadone", "None", "amprenavir"]]}, {"text": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "triple_list": [["spironolactone", "None", "digitalis"]]}, {"text": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "triple_list": [["digoxin", "None", "digitalis"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["clarithromycin", "None", "tetracycline"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["clarithromycin", "None", "digoxin"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["clarithromycin", "None", "digitalis"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["tetracycline", "None", "digoxin"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["tetracycline", "None", "digitalis"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["digoxin", "None", "digitalis"]]}, {"text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "triple_list": [["digoxin", "None", "digitalis"]]}, {"text": "Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.", "triple_list": [["beta-adrenergic blockers", "None", "calcium channel blockers"]]}, {"text": "Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["XENICAL", "None", "alcohol"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["XENICAL", "None", "alcohol"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["XENICAL", "None", "orlistat"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["XENICAL", "None", "orlistat"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["alcohol", "None", "alcohol"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["alcohol", "None", "orlistat"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["alcohol", "None", "orlistat"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["alcohol", "None", "orlistat"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["alcohol", "None", "orlistat"]]}, {"text": "Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ", "triple_list": [["orlistat", "None", "orlistat"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["XENICAL", "None", "cyclosporine"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["XENICAL", "None", "cyclosporine"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["XENICAL", "None", "cyclosporine"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["cyclosporine", "None", "XENICAL"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["cyclosporine", "None", "XENICAL"]]}, {"text": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ", "triple_list": [["orlistat", "None", "vitamin K"]]}, {"text": "Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ", "triple_list": [["orlistat", "None", "orlistat"]]}, {"text": "Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ", "triple_list": [["XENICAL", "None", "nifedipine"]]}, {"text": "Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ", "triple_list": [["XENICAL", "None", "nifedipine"]]}, {"text": "Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ", "triple_list": [["XENICAL", "None", "warfarin"]]}, {"text": "Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL. ", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "triple_list": [["vitamin K", "None", "warfarin"]]}, {"text": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "triple_list": [["vitamin K", "None", "XENICAL"]]}, {"text": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "triple_list": [["XENICAL", "None", "warfarin"]]}, {"text": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "triple_list": [["XENICAL", "None", "XENICAL"]]}, {"text": "For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.", "triple_list": [["Gemzar", "None", "cisplatin"]]}, {"text": "With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).", "triple_list": [["ceftibuten", "None", "theophylline"]]}, {"text": "The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.", "triple_list": [["ceftibuten", "None", "theophylline"]]}, {"text": "however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.", "triple_list": [["ceftibuten", "None", "ceftibuten"]]}, {"text": "The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40  g/mL.", "triple_list": [["ceftibuten", "None", "ceftibuten"]]}, {"text": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ", "triple_list": [["METH", "None", "atypical neuroleptic"]]}, {"text": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ", "triple_list": [["SCH-23390", "None", "atypical neuroleptic"]]}, {"text": "The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.", "triple_list": [["aspirin", "None", "hydroxylated fenoprofen"]]}, {"text": "The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.", "triple_list": [["fenoprofen", "None", "hydroxylated fenoprofen"]]}, {"text": "Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.", "triple_list": [["fenoprofen", "None", "fenoprofen"]]}, {"text": "Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.", "triple_list": [["aspirin", "None", "fenoprofen"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "aspirin"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "aspirin"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "salicylates"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "None", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "None", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "None", "salicylates"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "None", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["aspirin", "None", "salicylates"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "Nalfon"]]}, {"text": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "triple_list": [["Nalfon", "None", "salicylates"]]}, {"text": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "triple_list": [["Nalfon", "None", "steroid"]]}, {"text": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "triple_list": [["Nalfon", "None", "steroid"]]}, {"text": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "triple_list": [["steroid", "None", "steroid"]]}, {"text": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "triple_list": [["steroid", "None", "steroid"]]}, {"text": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "triple_list": [["steroid", "None", "steroid"]]}, {"text": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "triple_list": [["lansoprazole", "None", "terfenadine"]]}, {"text": "When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.", "triple_list": [["lansoprazole", "None", "theophylline"]]}, {"text": "When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["lansoprazole", "None", "omeprazole"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["lansoprazole", "None", "sucralfate"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["lansoprazole", "None", "proton pump inhibitors"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["lansoprazole", "None", "sucralfate"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["omeprazole", "None", "sucralfate"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["omeprazole", "None", "proton pump inhibitors"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["omeprazole", "None", "sucralfate"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["sucralfate", "None", "proton pump inhibitors"]]}, {"text": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "triple_list": [["sucralfate", "None", "sucralfate"]]}, {"text": "In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;", "triple_list": [["antacids", "None", "lansoprazole"]]}, {"text": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "triple_list": [["ampicillin", "None", "iron"]]}, {"text": "Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and theophylline.", "triple_list": [["nicotine", "None", "tricyclic antidepressants"]]}, {"text": "Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.", "triple_list": [["vasoconstrictor agents", "None", "nicotine"]]}, {"text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "triple_list": [["NIZORAL", "None", "Ketoconazole"]]}, {"text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "triple_list": [["NIZORAL", "None", "terfenadine"]]}, {"text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "triple_list": [["NIZORAL", "None", "terfenadine"]]}, {"text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "triple_list": [["Ketoconazole", "None", "terfenadine"]]}, {"text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "triple_list": [["ketoconazole", "None", "astemizole"]]}, {"text": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "triple_list": [["ketoconazole", "None", "desmethylastemizole"]]}, {"text": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "triple_list": [["astemizole", "None", "astemizole"]]}, {"text": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "triple_list": [["astemizole", "None", "desmethylastemizole"]]}, {"text": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "triple_list": [["astemizole", "None", "desmethylastemizole"]]}, {"text": "Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.", "triple_list": [["ketoconazole", "None", "cisapride"]]}, {"text": "Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL  Tablets.", "triple_list": [["methylprednisolone", "None", "NIZORAL"]]}, {"text": "Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "triple_list": [["midazolam", "None", "triazolam"]]}, {"text": "When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.", "triple_list": [["imidazole compounds", "None", "ketoconazole"]]}, {"text": "Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.", "triple_list": [["miconazole", "None", "ketoconazole"]]}, {"text": "After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.", "triple_list": [["ketoconazole", "None", "loratadine"]]}, {"text": "After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.", "triple_list": [["loratadine", "None", "loratadine"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "telithromycin"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "telithromycin"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["paricalcitol", "None", "telithromycin"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "paricalcitol"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "telithromycin"]]}, {"text": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "triple_list": [["ketoconazole", "None", "telithromycin"]]}, {"text": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "triple_list": [["pantoprazole", "None", "diazepam"]]}, {"text": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "triple_list": [["pantoprazole", "None", "contraceptive"]]}, {"text": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "triple_list": [["diazepam", "None", "contraceptive"]]}, {"text": "Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary. ", "triple_list": [["pantoprazole", "None", "pantoprazole"]]}, {"text": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ", "triple_list": [["ampicillin", "None", "iron"]]}, {"text": "and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ", "triple_list": [["opioids", "None", "sedatives"]]}, {"text": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ", "triple_list": [["analgesic agents", "None", "nitrous oxide"]]}, {"text": "DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ", "triple_list": [["neuromuscular blocking agents", "None", "succinylcholine"]]}, {"text": "Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.", "triple_list": [["LODOSYN", "None", "levodopa"]]}, {"text": "Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.", "triple_list": [["LODOSYN", "None", "levodopa"]]}, {"text": "Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.", "triple_list": [["levodopa", "None", "levodopa"]]}, {"text": "Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.", "triple_list": [["LODOSYN", "None", "levodopa"]]}, {"text": "Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.", "triple_list": [["LODOSYN", "None", "levodopa"]]}, {"text": "Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.", "triple_list": [["levodopa", "None", "levodopa"]]}, {"text": "Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.", "triple_list": [["metoclopramide", "None", "metoclopramide"]]}, {"text": "Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.", "triple_list": [["levodopa", "None", "metoclopramide"]]}, {"text": "Failure of neomycin to modify ACTH induced hypertension in sheep.", "triple_list": [["neomycin", "None", "ACTH"]]}, {"text": "Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ", "triple_list": [["neomycin", "None", "adrenocortical steroid"]]}, {"text": "Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ", "triple_list": [["adrenocortical steroid", "None", "ACTH"]]}, {"text": "The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep. ", "triple_list": [["neomycin", "None", "ACTH"]]}, {"text": "Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ", "triple_list": [["opioids", "None", "opioids"]]}, {"text": "On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts. ", "triple_list": [["amphetamine", "None", "heroin"]]}, {"text": "However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.", "triple_list": [["amphetamine", "None", "heroin"]]}, {"text": "The benzodiazepines are a family of anxiolytic and hypnotic drugs. ", "triple_list": [["benzodiazepines", "None", "anxiolytic"]]}, {"text": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "triple_list": [["apomorphine", "None", "diphenidol"]]}, {"text": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "triple_list": [["apomorphine", "None", "emetic"]]}, {"text": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "triple_list": [["apomorphine", "None", "apomorphine"]]}, {"text": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "triple_list": [["diphenidol", "None", "emetic"]]}, {"text": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "triple_list": [["emetic", "None", "apomorphine"]]}, {"text": "Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.", "triple_list": [["VIRACEPT", "None", "itraconazole"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["quinidine", "None", "terfenadine"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["quinidine", "None", "ergot derivatives"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["quinidine", "None", "rifampin"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["quinidine", "None", "Benzodiazepines"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["quinidine", "None", "triazolam"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["terfenadine", "None", "ergot derivatives"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["terfenadine", "None", "rifampin"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["terfenadine", "None", "Benzodiazepines"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["terfenadine", "None", "triazolam"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["ergot derivatives", "None", "rifampin"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["ergot derivatives", "None", "Benzodiazepines"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["ergot derivatives", "None", "triazolam"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["rifampin", "None", "Benzodiazepines"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["rifampin", "None", "triazolam"]]}, {"text": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "triple_list": [["Benzodiazepines", "None", "triazolam"]]}, {"text": "* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;", "triple_list": [["terfenadine", "None", "VIRACEPT"]]}, {"text": "Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;", "triple_list": [["VIRACEPT", "None", "terfenadine"]]}, {"text": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "triple_list": [["indinavir", "None", "nelfinavir"]]}, {"text": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "indinavir"]]}, {"text": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "triple_list": [["nelfinavir", "None", "indinavir"]]}, {"text": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "triple_list": [["ritonavir", "None", "nelfinavir"]]}, {"text": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "triple_list": [["ritonavir", "None", "ritonavir"]]}, {"text": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "ritonavir"]]}, {"text": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "triple_list": [["nelfinavir", "None", "ritonavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "None", "saquinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "None", "nelfinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "None", "saquinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "None", "VIRACEPT"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "None", "nelfinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["saquinavir", "None", "saquinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "saquinavir"]]}, {"text": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "triple_list": [["nelfinavir", "None", "saquinavir"]]}, {"text": "Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.", "triple_list": [["ketoconazole", "None", "nelfinavir"]]}, {"text": "Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.", "triple_list": [["ketoconazole", "None", "VIRACEPT"]]}, {"text": "Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine.", "triple_list": [["VIRACEPT", "None", "lamivudine"]]}, {"text": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "triple_list": [["rifabutin", "None", "nelfinavir"]]}, {"text": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "triple_list": [["rifabutin", "None", "rifabutin"]]}, {"text": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "triple_list": [["VIRACEPT", "None", "rifabutin"]]}, {"text": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "triple_list": [["nelfinavir", "None", "rifabutin"]]}, {"text": "Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.", "triple_list": [["rifampin", "None", "nelfinavir"]]}, {"text": "Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.", "triple_list": [["VIRACEPT", "None", "nelfinavir"]]}, {"text": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "triple_list": [["VIRACEPT", "None", "ethinyl estradiol"]]}, {"text": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "triple_list": [["VIRACEPT", "None", "norethindrone"]]}, {"text": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "triple_list": [["OVCON-35", "None", "ethinyl estradiol"]]}, {"text": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "triple_list": [["OVCON-35", "None", "norethindrone"]]}, {"text": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "triple_list": [["ethinyl estradiol", "None", "norethindrone"]]}, {"text": "Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.\r\n", "triple_list": [["fluoxetine", "None", "cisapride"]]}, {"text": "STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men. ", "triple_list": [["fluoxetine", "None", "cisapride"]]}, {"text": "and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). ", "triple_list": [["cisapride", "None", "fluoxetine"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["aspirin", "None", "salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["aspirin", "None", "magnesium/choline salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["aspirin", "None", "salsalate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["aspirin", "None", "choline salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["aspirin", "None", "magnesium salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["aspirin", "None", "bismuth subsalicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salicylate", "None", "magnesium/choline salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salicylate", "None", "salsalate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salicylate", "None", "choline salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salicylate", "None", "magnesium salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salicylate", "None", "bismuth subsalicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["magnesium/choline salicylate", "None", "salsalate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["magnesium/choline salicylate", "None", "choline salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["magnesium/choline salicylate", "None", "magnesium salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["magnesium/choline salicylate", "None", "bismuth subsalicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salsalate", "None", "choline salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salsalate", "None", "magnesium salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["salsalate", "None", "bismuth subsalicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["choline salicylate", "None", "magnesium salicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["choline salicylate", "None", "bismuth subsalicylate"]]}, {"text": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "triple_list": [["magnesium salicylate", "None", "bismuth subsalicylate"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "ibuprofen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "ketoprofen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "Orudis"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "diclofenac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "etodolac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "indomethacin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "ketoprofen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "Orudis"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "diclofenac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "etodolac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "indomethacin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ibuprofen", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "Orudis"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "diclofenac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "etodolac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "indomethacin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["ketoprofen", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["Orudis", "None", "diclofenac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["Orudis", "None", "etodolac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["Orudis", "None", "indomethacin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["Orudis", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["Orudis", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["Orudis", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["diclofenac", "None", "etodolac"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["diclofenac", "None", "indomethacin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["diclofenac", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["diclofenac", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["diclofenac", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["etodolac", "None", "indomethacin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["etodolac", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["etodolac", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["etodolac", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["indomethacin", "None", "nabumetone"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["indomethacin", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["indomethacin", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nabumetone", "None", "oxaprozin"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["nabumetone", "None", "naproxen"]]}, {"text": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "triple_list": [["oxaprozin", "None", "naproxen"]]}, {"text": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);", "triple_list": [["sulfisoxazole", "None", "sulfasalazine"]]}, {"text": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "triple_list": [["monoamine oxidase inhibitor", "None", "isocarboxazid"]]}, {"text": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "triple_list": [["monoamine oxidase inhibitor", "None", "tranylcypromine"]]}, {"text": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "triple_list": [["monoamine oxidase inhibitor", "None", "phenelzine"]]}, {"text": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "triple_list": [["isocarboxazid", "None", "tranylcypromine"]]}, {"text": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "triple_list": [["isocarboxazid", "None", "phenelzine"]]}, {"text": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "triple_list": [["tranylcypromine", "None", "phenelzine"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["beta-blocker", "None", "propranolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["beta-blocker", "None", "atenolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["beta-blocker", "None", "acebutolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["beta-blocker", "None", "metoprolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["propranolol", "None", "atenolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["propranolol", "None", "acebutolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["propranolol", "None", "metoprolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["atenolol", "None", "acebutolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["atenolol", "None", "metoprolol"]]}, {"text": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "triple_list": [["acebutolol", "None", "metoprolol"]]}, {"text": "- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;", "triple_list": [["diuretic", "None", "hydrochlorothiazide"]]}, {"text": "- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;", "triple_list": [["diuretic", "None", "chlorothiazide"]]}, {"text": "- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;", "triple_list": [["hydrochlorothiazide", "None", "chlorothiazide"]]}, {"text": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "triple_list": [["steroid medicine", "None", "prednisone"]]}, {"text": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "triple_list": [["steroid medicine", "None", "methylprednisolone"]]}, {"text": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "triple_list": [["steroid medicine", "None", "prednisolone"]]}, {"text": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "triple_list": [["prednisone", "None", "methylprednisolone"]]}, {"text": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "triple_list": [["prednisone", "None", "prednisolone"]]}, {"text": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "triple_list": [["methylprednisolone", "None", "prednisolone"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["phenothiazine", "None", "chlorpromazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["phenothiazine", "None", "fluphenazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["phenothiazine", "None", "prochlorperazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["phenothiazine", "None", "promethazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["chlorpromazine", "None", "fluphenazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["chlorpromazine", "None", "prochlorperazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["chlorpromazine", "None", "promethazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["fluphenazine", "None", "prochlorperazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["fluphenazine", "None", "promethazine"]]}, {"text": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "triple_list": [["prochlorperazine", "None", "promethazine"]]}, {"text": "Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.", "triple_list": [["Angiomax", "None", "bivalirudin"]]}, {"text": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "triple_list": [["ephedrine", "None", "dexmedetomidine"]]}, {"text": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "triple_list": [["ephedrine", "None", "ephedrine"]]}, {"text": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "triple_list": [["ephedrine", "None", "dexmedetomidine"]]}, {"text": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "triple_list": [["dexmedetomidine", "None", "ephedrine"]]}, {"text": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "triple_list": [["dexmedetomidine", "None", "dexmedetomidine"]]}, {"text": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "triple_list": [["ephedrine", "None", "dexmedetomidine"]]}, {"text": "In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "triple_list": [["dexmedetomidine", "None", "dexmedetomidine"]]}, {"text": "In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "triple_list": [["ephedrine", "None", "dexmedetomidine"]]}, {"text": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "triple_list": [["dexmedetomidine", "None", "dexmedetomidine"]]}, {"text": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "triple_list": [["dexmedetomidine", "None", "analgesic"]]}, {"text": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "triple_list": [["ephedrine", "None", "dexmedetomidine"]]}, {"text": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "triple_list": [["ephedrine", "None", "analgesic"]]}, {"text": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "triple_list": [["dexmedetomidine", "None", "analgesic"]]}, {"text": "similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.", "triple_list": [["psychotropic drugs", "None", "Clozapine"]]}, {"text": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "triple_list": [["Clozapine", "None", "benzodiazepines"]]}, {"text": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "triple_list": [["Clozapine", "None", "clozapine"]]}, {"text": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "triple_list": [["Clozapine", "None", "benzodiazepine"]]}, {"text": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "triple_list": [["benzodiazepines", "None", "clozapine"]]}, {"text": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "triple_list": [["benzodiazepines", "None", "benzodiazepine"]]}, {"text": "The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.", "triple_list": [["epinephrine", "None", "epinephrine"]]}, {"text": "Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "triple_list": [["rifampin", "None", "Clozapine"]]}, {"text": "Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "triple_list": [["Clozapine", "None", "Clozapine"]]}, {"text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "triple_list": [["Clozapine", "None", "carbamazepine"]]}, {"text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "triple_list": [["Clozapine", "None", "Clozapine"]]}, {"text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "triple_list": [["carbamazepine", "None", "carbamazepine"]]}, {"text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "triple_list": [["carbamazepine", "None", "Clozapine"]]}, {"text": "In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.", "triple_list": [["clozapine", "None", "fluvoxamine"]]}, {"text": "In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.", "triple_list": [["clozapine", "None", "paroxetine"]]}, {"text": "In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.", "triple_list": [["fluvoxamine", "None", "paroxetine"]]}, {"text": "After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.", "triple_list": [["clozapine", "None", "N-desmethylclozapine"]]}, {"text": "After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.", "triple_list": [["clozapine", "None", "fluvoxamine"]]}, {"text": "After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.", "triple_list": [["N-desmethylclozapine", "None", "fluvoxamine"]]}, {"text": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.", "triple_list": [["clozapine", "None", "clozapine"]]}, {"text": "Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.", "triple_list": [["clozapine", "None", "clozapine"]]}, {"text": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "triple_list": [["Type 1C antiarrhythmics", "None", "flecainide"]]}, {"text": "Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.", "triple_list": [["Erythromycin", "None", "Ketoconazole"]]}, {"text": "Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.", "triple_list": [["Erythromycin", "None", "Fexofenadine"]]}, {"text": "Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.", "triple_list": [["Ketoconazole", "None", "Fexofenadine"]]}, {"text": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "triple_list": [["fexofenadine hydrochloride", "None", "fexofenadine"]]}, {"text": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "triple_list": [["ketoconazole", "None", "erythromycin"]]}, {"text": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "triple_list": [["ketoconazole", "None", "fexofenadine"]]}, {"text": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "triple_list": [["erythromycin", "None", "fexofenadine"]]}, {"text": "In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).", "triple_list": [["fexofenadine hydrochloride", "None", "erythromycin"]]}, {"text": "In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).", "triple_list": [["fexofenadine hydrochloride", "None", "ketoconazole"]]}, {"text": "In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).", "triple_list": [["erythromycin", "None", "ketoconazole"]]}, {"text": "No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.", "triple_list": [["fexofenadine hydrochloride", "None", "erythromycin"]]}, {"text": "The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)", "triple_list": [["fexofenadine", "None", "fexofenadine hydrochloride"]]}, {"text": "These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.", "triple_list": [["ketoconazole", "None", "erythromycin"]]}, {"text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "triple_list": [["fexofenadine", "None", "ketoconazole"]]}, {"text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "triple_list": [["fexofenadine", "None", "fexofenadine"]]}, {"text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "triple_list": [["fexofenadine", "None", "erythromycin"]]}, {"text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "triple_list": [["ketoconazole", "None", "erythromycin"]]}, {"text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "triple_list": [["fexofenadine", "None", "erythromycin"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["Antacids", "None", "fexofenadine hydrochloride"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["Antacids", "None", "aluminum"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["Antacids", "None", "magnesium"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["Antacids", "None", "antacid"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["Antacids", "None", "fexofenadine"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["fexofenadine hydrochloride", "None", "fexofenadine"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["aluminum", "None", "magnesium"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["aluminum", "None", "antacid"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["aluminum", "None", "fexofenadine"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["magnesium", "None", "antacid"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["magnesium", "None", "fexofenadine"]]}, {"text": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "triple_list": [["antacid", "None", "fexofenadine"]]}, {"text": "ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.", "triple_list": [["aluminum", "None", "magnesium"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["Zarontin", "None", "ethosuximide"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["Zarontin", "None", "ethosuximide"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["Zarontin", "None", "phenytoin"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["Zarontin", "None", "valproic acid"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["Zarontin", "None", "ethosuximide"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "None", "ethosuximide"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "None", "phenytoin"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "None", "valproic acid"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "None", "ethosuximide"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "None", "valproic acid"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["ethosuximide", "None", "ethosuximide"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["phenytoin", "None", "valproic acid"]]}, {"text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "triple_list": [["phenytoin", "None", "ethosuximide"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "nifedipine"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "nifedipine"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "nifedipine"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["nifedipine", "None", "digoxin"]]}, {"text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["nifedipine", "None", "nifedipine"]]}, {"text": "Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.", "triple_list": [["nifedipine", "None", "digoxin"]]}, {"text": "Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.", "triple_list": [["nifedipine", "None", "digoxin"]]}, {"text": "Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "nifedipine"]]}, {"text": "Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).", "triple_list": [["quinidine", "None", "quinidine"]]}, {"text": "Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).", "triple_list": [["nifedipine", "None", "quinidine"]]}, {"text": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.", "triple_list": [["nifedipine", "None", "cimetidine"]]}, {"text": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.", "triple_list": [["nifedipine", "None", "nifedipine"]]}, {"text": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ", "triple_list": [["norethindrone", "None", "norethindrone acetate"]]}, {"text": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ", "triple_list": [["ethinyl estradiol", "None", "norethindrone acetate"]]}, {"text": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ", "triple_list": [["ethinyl estradiol", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ", "triple_list": [["norethindrone acetate", "None", "ethinyl estradiol"]]}, {"text": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "triple_list": [["TOBI", "None", "TOBI"]]}, {"text": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "triple_list": [["TOBI", "None", "dornase alfa"]]}, {"text": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "triple_list": [["TOBI", "None", "aminoglycosides"]]}, {"text": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "triple_list": [["dornase alfa", "None", "aminoglycosides"]]}, {"text": "Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ", "triple_list": [["diuretics", "None", "antibiotic"]]}, {"text": "Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ", "triple_list": [["aminoglycoside", "None", "antibiotic"]]}, {"text": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion]\r\nChronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "triple_list": [["angiotensin", "None", "angiotensin 1"]]}, {"text": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion]\r\nChronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "triple_list": [["angiotensin", "None", "angiotensin 2"]]}, {"text": "[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion]\r\nChronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. ", "triple_list": [["angiotensin 1", "None", "angiotensin 2"]]}, {"text": "Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.", "triple_list": [["angiotensins", "None", "angiotensin"]]}, {"text": "Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.", "triple_list": [["acetaminophen", "None", "acetaminophen"]]}, {"text": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "triple_list": [["cephalexin", "None", "metformin"]]}, {"text": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "triple_list": [["cephalexin", "None", "metformin"]]}, {"text": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "triple_list": [["metformin", "None", "metformin"]]}, {"text": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "triple_list": [["metformin", "None", "metformin"]]}, {"text": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "triple_list": [["metformin", "None", "metformin"]]}, {"text": "No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.", "triple_list": [["cephalexin", "None", "metformin"]]}, {"text": "Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.", "triple_list": [["metformin", "None", "cephalexin"]]}, {"text": "Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.", "triple_list": [["metformin", "None", "metformin"]]}, {"text": "Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ", "triple_list": [["antibiotics", "None", "sulfonamides"]]}, {"text": "The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.", "triple_list": [["aspirin", "None", "valdecoxib"]]}, {"text": "Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.", "triple_list": [["valdecoxib", "None", "aspirin"]]}, {"text": "In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["furosemide", "None", "thiazides"]]}, {"text": "Dextromethorphan: Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.", "triple_list": [["Dextromethorphan", "None", "Dextromethorphan"]]}, {"text": "Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.", "triple_list": [["dextromethorphan", "None", "valdecoxib"]]}, {"text": "Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.", "triple_list": [["Valdecoxib", "None", "lithium"]]}, {"text": "Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.", "triple_list": [["valdecoxib", "None", "warfarin"]]}, {"text": "Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.", "triple_list": [["valdecoxib", "None", "BEXTRA"]]}, {"text": "Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.", "triple_list": [["warfarin", "None", "BEXTRA"]]}, {"text": "Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.", "triple_list": [["R-warfarin", "None", "S-warfarin"]]}, {"text": "Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.", "triple_list": [["Ketoconazole", "None", "Ketoconazole"]]}, {"text": "Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.", "triple_list": [["Ketoconazole", "None", "fluconazole"]]}, {"text": "Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.", "triple_list": [["Ketoconazole", "None", "fluconazole"]]}, {"text": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "triple_list": [["ketoconazole", "None", "fluconazole"]]}, {"text": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "triple_list": [["ketoconazole", "None", "valdecoxib"]]}, {"text": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "triple_list": [["fluconazole", "None", "valdecoxib"]]}, {"text": "Glyburide: Glyburide is a CYP 2C9 substrate.", "triple_list": [["Glyburide", "None", "Glyburide"]]}, {"text": "Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.", "triple_list": [["valdecoxib", "None", "glyburide"]]}, {"text": "Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) have not been studied.", "triple_list": [["glyburide", "None", "valdecoxib"]]}, {"text": "Omeprazole: Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.", "triple_list": [["Omeprazole", "None", "Omeprazole"]]}, {"text": "However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.", "triple_list": [["omeprazole", "None", "omeprazole"]]}, {"text": "Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.", "triple_list": [["valdecoxib", "None", "omeprazole"]]}, {"text": "Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).", "triple_list": [["Valdecoxib", "None", "contraceptive"]]}, {"text": "Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).", "triple_list": [["Valdecoxib", "None", "Ortho-Novum"]]}, {"text": "Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).", "triple_list": [["contraceptive", "None", "Ortho-Novum"]]}, {"text": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "triple_list": [["valdecoxib", "None", "norethindrone"]]}, {"text": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "triple_list": [["valdecoxib", "None", "ethinyl estradiol"]]}, {"text": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "triple_list": [["Ortho-Novum", "None", "norethindrone"]]}, {"text": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "triple_list": [["Ortho-Novum", "None", "ethinyl estradiol"]]}, {"text": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.", "triple_list": [["norethindrone", "None", "contraceptive"]]}, {"text": "These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.", "triple_list": [["ethinyl estradiol", "None", "contraceptive"]]}, {"text": "Diazepam: Diazepam (Valium) is a CYP 3A4 and CYP 2C19 substrate.", "triple_list": [["Diazepam", "None", "Diazepam"]]}, {"text": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "triple_list": [["diazepam", "None", "valdecoxib"]]}, {"text": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "triple_list": [["diazepam", "None", "diazepam"]]}, {"text": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "triple_list": [["valdecoxib", "None", "valdecoxib"]]}, {"text": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "triple_list": [["valdecoxib", "None", "diazepam"]]}, {"text": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "triple_list": [["valdecoxib", "None", "diazepam"]]}, {"text": "Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.", "triple_list": [["diazepam", "None", "valdecoxib"]]}, {"text": "Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.", "triple_list": [["diazepam", "None", "diazepam"]]}, {"text": "Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["niacin", "None", "propranolol"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["niacin", "None", "fluvastatin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["niacin", "None", "digoxin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["niacin", "None", "digoxin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["propranolol", "None", "fluvastatin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["propranolol", "None", "digoxin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["propranolol", "None", "digoxin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["fluvastatin", "None", "digoxin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["fluvastatin", "None", "digoxin"]]}, {"text": "Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. ", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "triple_list": [["Type 1C antiarrhythmics", "None", "propafenone"]]}, {"text": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "triple_list": [["SSRI", "None", "SSRI"]]}, {"text": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["disulfiram", "None", "amitriptyline HCl"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["disulfiram", "None", "anticholinergic"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["disulfiram", "None", "sympathomimetic"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["disulfiram", "None", "epinephrine"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["amitriptyline HCl", "None", "anticholinergic"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["amitriptyline HCl", "None", "sympathomimetic"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["amitriptyline HCl", "None", "epinephrine"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["anticholinergic", "None", "sympathomimetic"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["anticholinergic", "None", "epinephrine"]]}, {"text": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "triple_list": [["sympathomimetic", "None", "epinephrine"]]}, {"text": "Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.", "triple_list": [["amitriptyline HCl", "None", "neuroleptic"]]}, {"text": "Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.", "triple_list": [["anticholinergic", "None", "neuroleptic"]]}, {"text": "Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.", "triple_list": [["cimetidine", "None", "drug"]]}, {"text": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "triple_list": [["cimetidine", "None", "tricyclic antidepressants"]]}, {"text": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "triple_list": [["cimetidine", "None", "cimetidine"]]}, {"text": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "triple_list": [["cimetidine", "None", "antidepressants"]]}, {"text": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "triple_list": [["tricyclic antidepressants", "None", "antidepressants"]]}, {"text": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "triple_list": [["cimetidine", "None", "antidepressants"]]}, {"text": "Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.", "triple_list": [["methotrexate", "None", "pyrimethamine"]]}, {"text": "Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.", "triple_list": [["methotrexate", "None", "folic acid"]]}, {"text": "Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.", "triple_list": [["methotrexate", "None", "vitamin B12"]]}, {"text": "Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.", "triple_list": [["pyrimethamine", "None", "folic acid"]]}, {"text": "Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.", "triple_list": [["pyrimethamine", "None", "vitamin B12"]]}, {"text": "Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.", "triple_list": [["folic acid", "None", "vitamin B12"]]}, {"text": "Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.", "triple_list": [["para-aminosalicylic acid", "None", "alcohol"]]}, {"text": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "triple_list": [["CENTRAL NERVOUS SYSTEM DEPRESSANTS", "None", "NON-NARCOTIC ANALGESICS"]]}, {"text": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.", "triple_list": [["iron", "None", "zinc"]]}, {"text": "ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ", "triple_list": [["peripherally restricted opioid antagonist", "None", "opioid"]]}, {"text": "Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ", "triple_list": [["morphine", "None", "ADL 8-2698"]]}, {"text": "Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ", "triple_list": [["ADL 8-2698", "None", "morphine"]]}, {"text": "Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. ", "triple_list": [["ADL 8-2698", "None", "morphine"]]}, {"text": "Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular. ", "triple_list": [["erection-supporting medication", "None", "erection-supporting medication"]]}, {"text": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "triple_list": [["benzodiazepines", "None", "diazepam"]]}, {"text": "Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.", "triple_list": [["benzodiazepines", "None", "heroin"]]}, {"text": "Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.", "triple_list": [["OXC", "None", "MHD"]]}, {"text": "Increases of 22% with MHD and 47% with oxcarbazepine were observed.", "triple_list": [["MHD", "None", "oxcarbazepine"]]}, {"text": "In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.", "triple_list": [["oxcarbazepine", "None", "MHD"]]}, {"text": "In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.", "triple_list": [["oxcarbazepine", "None", "dihydropyridine calcium antagonists"]]}, {"text": "In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.", "triple_list": [["MHD", "None", "dihydropyridine calcium antagonists"]]}, {"text": "Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.", "triple_list": [["Trileptal", "None", "AEDs"]]}, {"text": "Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)", "triple_list": [["Trileptal", "None", "AED"]]}, {"text": "Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)", "triple_list": [["AED", "None", "MHD"]]}, {"text": "1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.", "triple_list": [["Trileptal", "None", "phenytoin"]]}, {"text": "1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.", "triple_list": [["Trileptal", "None", "Trileptal"]]}, {"text": "Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).", "triple_list": [["phenytoin", "None", "MHD"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["contraceptives", "None", "Trileptal"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["contraceptives", "None", "contraceptive"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["contraceptives", "None", "ethinylestradiol"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["contraceptives", "None", "levonorgestrel"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["Trileptal", "None", "ethinylestradiol"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["Trileptal", "None", "levonorgestrel"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["contraceptive", "None", "ethinylestradiol"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["contraceptive", "None", "levonorgestrel"]]}, {"text": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "triple_list": [["ethinylestradiol", "None", "levonorgestrel"]]}, {"text": "Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.", "triple_list": [["Trileptal", "None", "contraceptives"]]}, {"text": "Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.", "triple_list": [["hormonal contraceptives", "None", "contraceptives"]]}, {"text": "Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.", "triple_list": [["erythromycin", "None", "dextropropoxyphene"]]}, {"text": "The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. ", "triple_list": [["theophylline", "None", "N6-cyclopentyladenosine"]]}, {"text": "However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. ", "triple_list": [["CGS21680", "None", "CGS 21680"]]}, {"text": "therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.", "triple_list": [["glucocorticoid", "None", "hydrocortisone"]]}, {"text": "These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.", "triple_list": [["platelet inhibitors", "None", "NSAIDs"]]}, {"text": "The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.", "triple_list": [["diazepam", "None", "diazepam"]]}, {"text": "The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.", "triple_list": [["diazepam", "None", "Cerebyx"]]}, {"text": "The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.", "triple_list": [["diazepam", "None", "Cerebyx"]]}, {"text": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "triple_list": [["valproic acid", "None", "valproate"]]}, {"text": "Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.", "triple_list": [["phenytoin", "None", "Cerebyx"]]}, {"text": "Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.", "triple_list": [["colestipol", "None", "hydrochlorothiazide"]]}, {"text": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "triple_list": [["cholestyramine", "None", "colestipol"]]}, {"text": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "triple_list": [["cholestyramine", "None", "resins"]]}, {"text": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "triple_list": [["colestipol", "None", "resins"]]}, {"text": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "triple_list": [["resins", "None", "hydrochlorothiazide"]]}, {"text": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "triple_list": [["Hydrochlorothiazide", "None", "diuretic"]]}, {"text": "Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "triple_list": [["non-steroidal anti-inflammatory agents", "None", "diuretic"]]}, {"text": "Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).", "triple_list": [["carbonic anhydrase inhibitors", "None", "salicylate"]]}, {"text": "When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ", "triple_list": [["methyldopa", "None", "lithium"]]}, {"text": "When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ", "triple_list": [["ferrous sulfate", "None", "ferrous gluconate"]]}, {"text": "Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ", "triple_list": [["VMA", "None", "VMA"]]}, {"text": "Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.", "triple_list": [["Aliskiren", "None", "aliskiren"]]}, {"text": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "triple_list": [["metformin", "None", "amlodipine"]]}, {"text": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "triple_list": [["metformin", "None", "aliskiren"]]}, {"text": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "triple_list": [["amlodipine", "None", "aliskiren"]]}, {"text": "Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.", "triple_list": [["ketoconazole", "None", "aliskiren"]]}, {"text": "Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.", "triple_list": [["aliskiren", "None", "aliskiren"]]}, {"text": "Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.", "triple_list": [["Aliskiren", "None", "Aliskiren"]]}, {"text": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.", "triple_list": [["aliskiren", "None", "ramipril"]]}, {"text": "Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.", "triple_list": [["aliskiren", "None", "warfarin"]]}, {"text": "Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.", "triple_list": [["aliskiren", "None", "furosemide"]]}, {"text": "Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.", "triple_list": [["furosemide", "None", "furosemide"]]}, {"text": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "triple_list": [["calcium", "None", "calcium"]]}, {"text": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "triple_list": [["iron", "None", "calcium"]]}, {"text": "Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ", "triple_list": [["calcium", "None", "heme iron"]]}, {"text": "We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ", "triple_list": [["calcium", "None", "nonheme iron"]]}, {"text": "We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. ", "triple_list": [["calcium", "None", "heme iron"]]}, {"text": "Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ", "triple_list": [["calcium chloride", "None", "minerals"]]}, {"text": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "triple_list": [["Sanctura", "None", "Sanctura"]]}, {"text": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "triple_list": [["Sanctura", "None", "metformin"]]}, {"text": "Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. ", "triple_list": [["Sanctura", "None", "Sanctura"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["volatile inhalation anesthetics", "None", "erythromycin"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["volatile inhalation anesthetics", "None", "ALFENTA"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["volatile inhalation anesthetics", "None", "ALFENTA"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["ALFENTA", "None", "erythromycin"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["ALFENTA", "None", "ALFENTA"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["ALFENTA", "None", "ALFENTA"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["erythromycin", "None", "ALFENTA"]]}, {"text": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "triple_list": [["ALFENTA", "None", "ALFENTA"]]}, {"text": "Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.", "triple_list": [["ALFENTA", "None", "ALFENTA"]]}, {"text": "Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.\r\n", "triple_list": [["verapamil", "None", "azoxymethane"]]}, {"text": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "triple_list": [["bombesin", "None", "verapamil hydrochloride"]]}, {"text": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "triple_list": [["bombesin", "None", "verapamil"]]}, {"text": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "triple_list": [["bombesin", "None", "azoxymethane"]]}, {"text": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "triple_list": [["verapamil hydrochloride", "None", "verapamil"]]}, {"text": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "triple_list": [["verapamil hydrochloride", "None", "azoxymethane"]]}, {"text": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ", "triple_list": [["verapamil", "None", "azoxymethane"]]}, {"text": "METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ", "triple_list": [["AOM", "None", "bombesin"]]}, {"text": "METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ", "triple_list": [["AOM", "None", "verapamil"]]}, {"text": "METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ", "triple_list": [["bombesin", "None", "verapamil"]]}, {"text": "Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. ", "triple_list": [["verapamil", "None", "bombesin"]]}, {"text": "However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.", "triple_list": [["irbesartan", "None", "warfarin"]]}, {"text": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "triple_list": [["warfarin", "None", "irbesartan"]]}, {"text": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "triple_list": [["irbesartan", "None", "warfarin"]]}, {"text": "The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide", "triple_list": [["irbesartan", "None", "nifedipine"]]}, {"text": "Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.", "triple_list": [["WELLBUTRIN", "None", "WELLBUTRIN"]]}, {"text": "In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.", "triple_list": [["bupropion", "None", "hydroxybupropion"]]}, {"text": "The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.", "triple_list": [["threohydrobupropion", "None", "bupropion"]]}, {"text": "The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.", "triple_list": [["cimetidine", "None", "bupropion"]]}, {"text": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.", "triple_list": [["bupropion", "None", "hydroxybupropion"]]}, {"text": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "triple_list": [["antidepressants", "None", "antipsychotics"]]}, {"text": "Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.", "triple_list": [["bupropion", "None", "bupropion"]]}, {"text": "Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.", "triple_list": [["bupropion", "None", "hydroxybupropion"]]}, {"text": "Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.", "triple_list": [["bupropion", "None", "hydroxybupropion"]]}, {"text": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "triple_list": [["bupropion", "None", "desipramine"]]}, {"text": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "triple_list": [["desipramine", "None", "desipramine"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["antidepressants", "None", "antipsychotics"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["antidepressants", "None", "beta-blockers"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["antidepressants", "None", "Type 1C antiarrhythmics"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["antipsychotics", "None", "beta-blockers"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["antipsychotics", "None", "Type 1C antiarrhythmics"]]}, {"text": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "triple_list": [["beta-blockers", "None", "Type 1C antiarrhythmics"]]}, {"text": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .", "triple_list": [["bupropion", "None", "MAO inhibitor"]]}, {"text": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .", "triple_list": [["MAO inhibitor", "None", "phenelzine"]]}, {"text": "Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "triple_list": [["levodopa", "None", "amantadine"]]}, {"text": "Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.", "triple_list": [["alcohol", "None", "alcohol"]]}, {"text": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "triple_list": [["vitamin D analogues", "None", "Cholestyramine"]]}, {"text": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "triple_list": [["vitamin D analogues", "None", "Cholestyramine"]]}, {"text": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "triple_list": [["Cholestyramine", "None", "Cholestyramine"]]}, {"text": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "triple_list": [["phenytoin", "None", "phenobarbital"]]}, {"text": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "triple_list": [["Thiazides", "None", "Thiazides"]]}, {"text": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "triple_list": [["Thiazides", "None", "calcium"]]}, {"text": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "triple_list": [["Thiazides", "None", "calcium"]]}, {"text": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "triple_list": [["Ketoconazole", "None", "Ketoconazole"]]}, {"text": "However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.", "triple_list": [["ketoconazole", "None", "vitamin D"]]}, {"text": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "triple_list": [["carvedilol", "None", "carvedilol"]]}, {"text": "When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.", "triple_list": [["agents with b-blocking properties", "None", "b-blocking agent"]]}, {"text": "When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.", "triple_list": [["clonidine", "None", "b-blocking agent"]]}, {"text": "In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "triple_list": [["Digoxin", "None", "Digoxin"]]}, {"text": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "triple_list": [["Digoxin", "None", "digoxin"]]}, {"text": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "triple_list": [["Digoxin", "None", "carvedilol"]]}, {"text": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "triple_list": [["Digoxin", "None", "digoxin"]]}, {"text": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "triple_list": [["Digoxin", "None", "carvedilol"]]}, {"text": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "triple_list": [["COREG", "None", "calcium channel blockers"]]}, {"text": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "triple_list": [["calcium channel blockers", "None", "verapamil"]]}, {"text": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "triple_list": [["calcium channel blockers", "None", "diltiazem"]]}, {"text": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "triple_list": [["verapamil", "None", "diltiazem"]]}, {"text": "Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).", "triple_list": [["thioridazine", "None", "tricyclic antidepressants"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "CNS depressants"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "anticholinergics"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "anticholinergics"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "anticholinergics"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["monoamine oxidase (MAO) inhibitors", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["monoamine oxidase (MAO) inhibitors", "None", "antihistamines"]]}, {"text": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "triple_list": [["aminoglycosides", "None", "non-steroidal anti-inflammatory"]]}, {"text": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "triple_list": [["aminoglycosides", "None", "polymyxins"]]}, {"text": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "triple_list": [["aminoglycosides", "None", "neomycin sulfate"]]}, {"text": "Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.", "triple_list": [["polymyxins", "None", "neomycin sulfate"]]}, {"text": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "triple_list": [["coumarin", "None", "anticoagulants"]]}, {"text": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ", "triple_list": [["atropine", "None", "tricyclic antidepressants"]]}, {"text": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.", "triple_list": [["beta-blockers", "None", "cardiac glycosides"]]}, {"text": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "triple_list": [["amphotericin B", "None", "pentamidine"]]}, {"text": "Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.", "triple_list": [["foscarnet", "None", "ganciclovir"]]}, {"text": "CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ", "triple_list": [["Macrolide antibiotics", "None", "HMG-CoA reductase inhibitors"]]}, {"text": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "triple_list": [["anticoagulants", "None", "rifampin"]]}, {"text": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "triple_list": [["anticoagulants", "None", "corticosteroids"]]}, {"text": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "triple_list": [["anticoagulants", "None", "corticosteroids"]]}, {"text": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "triple_list": [["rifampin", "None", "corticosteroids"]]}, {"text": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "triple_list": [["rifampin", "None", "corticosteroids"]]}, {"text": "May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).", "triple_list": [["corticosteroids", "None", "corticosteroids"]]}, {"text": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ", "triple_list": [["Macrolide Antibiotics", "None", "ergot alkaloid drugs"]]}, {"text": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ", "triple_list": [["Macrolide Antibiotics", "None", "dihydroergotamine"]]}, {"text": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ", "triple_list": [["ergot alkaloid drugs", "None", "dihydroergotamine"]]}, {"text": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "triple_list": [["macrolide antibiotics", "None", "reverse transcriptase inhibitors"]]}, {"text": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "triple_list": [["macrolide antibiotics", "None", "azole antifungals"]]}, {"text": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "triple_list": [["reverse transcriptase inhibitors", "None", "azole antifungals"]]}, {"text": "[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports. ", "triple_list": [["neuroleptics", "None", "neuroleptics"]]}, {"text": "Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.", "triple_list": [["anticoagulant", "None", "EULEXIN"]]}, {"text": "The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.", "triple_list": [["non-nucleoside reverse transcriptase inhibitors", "None", "antiretroviral"]]}, {"text": "The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ", "triple_list": [["non-nucleoside reverse transcriptase inhibitor", "None", "antiretroviral"]]}, {"text": "The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ", "triple_list": [["non-nucleoside reverse transcriptase inhibitor", "None", "protease inhibitor"]]}, {"text": "The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ", "triple_list": [["antiretroviral", "None", "protease inhibitor"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["efavirenz", "None", "nevirapine"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["efavirenz", "None", "PI"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["efavirenz", "None", "indinavir"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["efavirenz", "None", "nevirapine"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["efavirenz", "None", "efavirenz"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["nevirapine", "None", "PI"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["nevirapine", "None", "indinavir"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["nevirapine", "None", "nevirapine"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["nevirapine", "None", "efavirenz"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["PI", "None", "indinavir"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["PI", "None", "nevirapine"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["PI", "None", "efavirenz"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["indinavir", "None", "nevirapine"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["indinavir", "None", "efavirenz"]]}, {"text": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "triple_list": [["nevirapine", "None", "efavirenz"]]}, {"text": "A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. ", "triple_list": [["nevirapine", "None", "PI"]]}, {"text": "Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.", "triple_list": [["prednisone", "None", "highly active antiretroviral"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["vincristine", "None", "prednisone"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["vincristine", "None", "prednisone"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["vincristine", "None", "vincristine"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["vincristine", "None", "antiretroviral"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["prednisone", "None", "prednisone"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["prednisone", "None", "vincristine"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["prednisone", "None", "antiretroviral"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["prednisone", "None", "vincristine"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["prednisone", "None", "antiretroviral"]]}, {"text": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "triple_list": [["vincristine", "None", "antiretroviral"]]}, {"text": "Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.", "triple_list": [["alcohol", "None", "CNS depression-producing drugs"]]}, {"text": "Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; ", "triple_list": [["alcohols", "None", "acetaldehyde"]]}, {"text": "TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.", "triple_list": [["digitalis preparations", "None", "beta-adrenergic blocking agents"]]}, {"text": "During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.", "triple_list": [["TAMBOCOR", "None", "digoxin"]]}, {"text": "During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "triple_list": [["TAMBOCOR", "None", "flecainide"]]}, {"text": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "triple_list": [["TAMBOCOR", "None", "propranolol"]]}, {"text": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "triple_list": [["propranolol", "None", "flecainide"]]}, {"text": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "triple_list": [["flecainide", "None", "propranolol"]]}, {"text": "In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;", "triple_list": [["TAMBOCOR", "None", "propranolol"]]}, {"text": "In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.", "triple_list": [["TAMBOCOR", "None", "beta blockers"]]}, {"text": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "triple_list": [["amiodarone", "None", "flecainide"]]}, {"text": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "triple_list": [["amiodarone", "None", "flecainide"]]}, {"text": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "triple_list": [["flecainide", "None", "flecainide"]]}, {"text": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "triple_list": [["flecainide", "None", "flecainide"]]}, {"text": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "triple_list": [["flecainide", "None", "flecainide"]]}, {"text": "Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;", "triple_list": [["quinidine", "None", "flecainide"]]}, {"text": "Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;", "triple_list": [["flecainide", "None", "flecainide"]]}, {"text": "There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil.", "triple_list": [["TAMBOCOR", "None", "disopyramide"]]}, {"text": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "triple_list": [["TAMBOCOR", "None", "disopyramide"]]}, {"text": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "triple_list": [["TAMBOCOR", "None", "verapamil"]]}, {"text": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "triple_list": [["TAMBOCOR", "None", "TAMBOCOR"]]}, {"text": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "triple_list": [["disopyramide", "None", "verapamil"]]}, {"text": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "triple_list": [["TAMBOCOR", "None", "nifedipine"]]}, {"text": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "triple_list": [["TAMBOCOR", "None", "diltiazem"]]}, {"text": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "triple_list": [["nifedipine", "None", "diltiazem"]]}, {"text": "In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.", "triple_list": [["des-ciclesonide", "None", "warfarin"]]}, {"text": "In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.", "triple_list": [["ciclesonide", "None", "des-ciclesonide"]]}, {"text": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.", "triple_list": [["ciclesonide", "None", "des-ciclesonide"]]}, {"text": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.", "triple_list": [["ciclesonide", "None", "ciclesonide"]]}, {"text": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.", "triple_list": [["des-ciclesonide", "None", "ciclesonide"]]}, {"text": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "triple_list": [["vardenafil", "None", "vardenafil"]]}, {"text": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "triple_list": [["vardenafil", "None", "Vardenafil"]]}, {"text": "Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.", "triple_list": [["vardenafil", "None", "Vardenafil"]]}, {"text": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "triple_list": [["vardenafil", "None", "Vardenafil"]]}, {"text": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "triple_list": [["vardenafil", "None", "Vardenafil"]]}, {"text": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "triple_list": [["ketoconazole", "None", "Vardenafil"]]}, {"text": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Indinavir", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Indinavir", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Indinavir", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Vardenafil", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Vardenafil", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["Vardenafil", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["vardenafil", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["vardenafil", "None", "vardenafil"]]}, {"text": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "triple_list": [["vardenafil", "None", "vardenafil"]]}, {"text": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "triple_list": [["Vardenafil", "None", "vardenafil"]]}, {"text": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "triple_list": [["Vardenafil", "None", "vardenafil"]]}, {"text": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "triple_list": [["vardenafil", "None", "vardenafil"]]}, {"text": "In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.", "triple_list": [["warfarin", "None", "vardenafil"]]}, {"text": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "triple_list": [["nitrates", "None", "Vardenafil"]]}, {"text": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "triple_list": [["vardenafil", "None", "Vardenafil"]]}, {"text": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "triple_list": [["nitrates", "None", "Vardenafil"]]}, {"text": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "triple_list": [["nitrates", "None", "nitrates"]]}, {"text": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "triple_list": [["Vardenafil", "None", "nifedipine"]]}, {"text": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "triple_list": [["Vardenafil", "None", "nifedipine"]]}, {"text": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "triple_list": [["nifedipine", "None", "nifedipine"]]}, {"text": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "triple_list": [["Vardenafil", "None", "Vardenafil"]]}, {"text": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "triple_list": [["terazosin", "None", "Vardenafil"]]}, {"text": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "triple_list": [["tamsulosin", "None", "Vardenafil"]]}, {"text": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "triple_list": [["tamsulosin", "None", "tamsulosin"]]}, {"text": "The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.", "triple_list": [["Vardenafil", "None", "alpha-blockers"]]}, {"text": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "triple_list": [["Vardenafil", "None", "ritonavir"]]}, {"text": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "triple_list": [["ritonavir", "None", "ritonavir"]]}, {"text": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "triple_list": [["Vardenafil", "None", "indinavir"]]}, {"text": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "triple_list": [["Alcohol", "None", "Alcohol"]]}, {"text": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "triple_list": [["Alcohol", "None", "vardenafil"]]}, {"text": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "triple_list": [["Alcohol", "None", "vardenafil"]]}, {"text": "Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).", "triple_list": [["alcohol", "None", "alcohol"]]}, {"text": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "triple_list": [["Vardenafil", "None", "aspirin"]]}, {"text": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "triple_list": [["Vardenafil", "None", "glyburide"]]}, {"text": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "triple_list": [["Vardenafil", "None", "warfarin"]]}, {"text": "Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).", "triple_list": [["glyburide", "None", "warfarin"]]}, {"text": "Amphotericin B or Corticosteroids or Corticotropin (ACTH)", "triple_list": [["Corticosteroids", "None", "Corticotropin"]]}, {"text": "(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.)", "triple_list": [["thiazide diuretics", "None", "lithium"]]}, {"text": "Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)", "triple_list": [["hydroflumethiazide", "None", "diuretic"]]}, {"text": "Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)", "triple_list": [["nonsteroidal anti-inflammatory agents", "None", "diuretic"]]}, {"text": "If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted. ", "triple_list": [["glucocorticoid", "None", "glucocorticoid"]]}, {"text": "The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.", "triple_list": [["dolasetron", "None", "hydrodolasetron"]]}, {"text": "The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.", "triple_list": [["dolasetron", "None", "hydrodolasetron"]]}, {"text": "The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.", "triple_list": [["hydrodolasetron", "None", "hydrodolasetron"]]}, {"text": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "triple_list": [["hydrodolasetron", "None", "dolasetron"]]}, {"text": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "triple_list": [["hydrodolasetron", "None", "cimetidine"]]}, {"text": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "triple_list": [["hydrodolasetron", "None", "rifampin"]]}, {"text": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "triple_list": [["cimetidine", "None", "rifampin"]]}, {"text": "Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.", "triple_list": [["hydrodolasetron", "None", "dolasetron mesylate"]]}, {"text": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "triple_list": [["procaine hydrochloride", "None", "anticholinesterases"]]}, {"text": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "triple_list": [["procaine hydrochloride", "None", "procaine hydrochloride"]]}, {"text": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "triple_list": [["anticholinesterase agents", "None", "anticholinesterases"]]}, {"text": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "triple_list": [["anticholinesterase agents", "None", "procaine hydrochloride"]]}, {"text": "CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ", "triple_list": [["CNS depressant", "None", "procaine hydrochloride"]]}, {"text": "CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ", "triple_list": [["CNS depressant", "None", "CNS depressant medications"]]}, {"text": "Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ", "triple_list": [["Hyaluronidase", "None", "Hyaluronidase"]]}, {"text": "Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.", "triple_list": [["acetazolamide", "None", "procaine"]]}, {"text": "Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.", "triple_list": [["procaine hydrochloride", "None", "procaine"]]}, {"text": "Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.", "triple_list": [["anticoagulant", "None", "warfarin"]]}, {"text": "Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.", "triple_list": [["cyclosporine", "None", "quinolones"]]}, {"text": "Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.", "triple_list": [["guafacine", "None", "cardioselective beta-blocker"]]}, {"text": "In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.", "triple_list": [["guanfacine", "None", "diuretics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "sedatives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "hypnotics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "coronary vasodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "hypoglycemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "NSAIDs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "antihyperlipidemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["cardiac glycosides", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "hypnotics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "coronary vasodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "hypoglycemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "NSAIDs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "antihyperlipidemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["sedatives", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "coronary vasodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "hypoglycemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "NSAIDs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "antihyperlipidemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypnotics", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "hypoglycemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "NSAIDs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "antihyperlipidemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["coronary vasodilators", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "NSAIDs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "antihyperlipidemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["hypoglycemics", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["NSAIDs", "None", "antihyperlipidemics"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["NSAIDs", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["NSAIDs", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["NSAIDs", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["NSAIDs", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["NSAIDs", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antihyperlipidemics", "None", "antigout drugs"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antihyperlipidemics", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antihyperlipidemics", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antihyperlipidemics", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antihyperlipidemics", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antigout drugs", "None", "contraceptives"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antigout drugs", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antigout drugs", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["antigout drugs", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["contraceptives", "None", "bronchodilators"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["contraceptives", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["contraceptives", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["bronchodilators", "None", "insulin"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["bronchodilators", "None", "beta blockers"]]}, {"text": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "triple_list": [["insulin", "None", "beta blockers"]]}, {"text": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "triple_list": [["imatinib", "None", "imatinib"]]}, {"text": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "triple_list": [["imatinib", "None", "Gleevec"]]}, {"text": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "triple_list": [["imatinib", "None", "Gleevec"]]}, {"text": "There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).", "triple_list": [["imatinib", "None", "Gleevec"]]}, {"text": "There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).", "triple_list": [["imatinib", "None", "ketoconazole"]]}, {"text": "Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.", "triple_list": [["imatinib", "None", "imatinib"]]}, {"text": "Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).", "triple_list": [["rifampin", "None", "Gleevec"]]}, {"text": "Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).", "triple_list": [["Gleevec", "None", "Gleevec"]]}, {"text": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "triple_list": [["Gleevec", "None", "Gleevec"]]}, {"text": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "triple_list": [["Gleevec", "None", "simvastatin"]]}, {"text": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "triple_list": [["Gleevec", "None", "Gleevec"]]}, {"text": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "triple_list": [["Gleevec", "None", "Gleevec"]]}, {"text": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "triple_list": [["simvastatin", "None", "Gleevec"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "chloramphenicol"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "anesthetics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "benzocaine"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "para-aminobenzoic acid"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "procainamide"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "sulfonamides"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["acetaminophen", "None", "thiazide diuretics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["chloramphenicol", "None", "anesthetics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["chloramphenicol", "None", "benzocaine"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["chloramphenicol", "None", "para-aminobenzoic acid"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["chloramphenicol", "None", "procainamide"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["chloramphenicol", "None", "sulfonamides"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["chloramphenicol", "None", "thiazide diuretics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["anesthetics", "None", "benzocaine"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["anesthetics", "None", "para-aminobenzoic acid"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["anesthetics", "None", "procainamide"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["anesthetics", "None", "sulfonamides"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["anesthetics", "None", "thiazide diuretics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["benzocaine", "None", "para-aminobenzoic acid"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["benzocaine", "None", "procainamide"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["benzocaine", "None", "sulfonamides"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["benzocaine", "None", "thiazide diuretics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["para-aminobenzoic acid", "None", "procainamide"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["para-aminobenzoic acid", "None", "sulfonamides"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["para-aminobenzoic acid", "None", "thiazide diuretics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["procainamide", "None", "sulfonamides"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["procainamide", "None", "thiazide diuretics"]]}, {"text": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "triple_list": [["sulfonamides", "None", "thiazide diuretics"]]}, {"text": "Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied;", "triple_list": [["central nervous system depressants", "None", "benzodiazepines"]]}, {"text": "however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "triple_list": [["ROMAZICON", "None", "muscle relaxants"]]}, {"text": "Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.", "triple_list": [["ROMAZICON", "None", "benzodiazepine"]]}, {"text": "The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.", "triple_list": [["benzodiazepines", "None", "flumazenil"]]}, {"text": "Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.", "triple_list": [["ROMAZICON", "None", "long-acting benzodiazepine"]]}, {"text": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.", "triple_list": [["long-acting benzodiazepines", "None", "short-acting benzodiazepines"]]}, {"text": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "triple_list": [["benzodiazepines", "None", "alcohol"]]}, {"text": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "triple_list": [["benzodiazepines", "None", "sedative"]]}, {"text": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "triple_list": [["benzodiazepines", "None", "ROMAZICON"]]}, {"text": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "triple_list": [["alcohol", "None", "sedative"]]}, {"text": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "triple_list": [["alcohol", "None", "ROMAZICON"]]}, {"text": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "triple_list": [["sedative", "None", "ROMAZICON"]]}, {"text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "triple_list": [["PHENYTOIN", "None", "DISULFIRAM"]]}, {"text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "triple_list": [["PHENYTOIN", "None", "PHENYTOIN"]]}, {"text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "triple_list": [["PHENYTOIN", "None", "PHENYTOIN"]]}, {"text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "triple_list": [["DISULFIRAM", "None", "PHENYTOIN"]]}, {"text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "triple_list": [["PHENYTOIN", "None", "PHENYTOIN"]]}, {"text": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "triple_list": [["anticoagulants", "None", "disulfiram"]]}, {"text": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "triple_list": [["disulfiram", "None", "disulfiram"]]}, {"text": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "triple_list": [["disulfiram", "None", "disulfiram"]]}, {"text": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "triple_list": [["disulfiram", "None", "nitrites"]]}, {"text": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "triple_list": [["nitrite", "None", "disulfiram"]]}, {"text": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "triple_list": [["nitrite", "None", "nitrites"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "None", "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "triple_list": [["3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "triple_list": [["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "None", "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"]]}, {"text": "May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;", "triple_list": [["colestipol", "None", "diuretic"]]}, {"text": "May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;", "triple_list": [["thiazide diuretics", "None", "diuretic"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["macrolide antibiotics", "None", "HIV protease inhibitors"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["macrolide antibiotics", "None", "indinavir"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["macrolide antibiotics", "None", "SUBUTEX"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["macrolide antibiotics", "None", "SUBOXONE"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["HIV protease inhibitors", "None", "indinavir"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["HIV protease inhibitors", "None", "SUBUTEX"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["HIV protease inhibitors", "None", "SUBOXONE"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["indinavir", "None", "SUBUTEX"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["indinavir", "None", "SUBOXONE"]]}, {"text": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "triple_list": [["SUBUTEX", "None", "SUBOXONE"]]}, {"text": "In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.", "triple_list": [["buprenorphine", "None", "SUBUTEX"]]}, {"text": "An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ", "triple_list": [["rosiglitazone", "None", "rosiglitazone"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["buspirone hydrochloride", "None", "buspirone HCl"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["buspirone hydrochloride", "None", "psychotropic drugs"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["buspirone hydrochloride", "None", "buspirone HCl"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["MAO inhibitors", "None", "buspirone HCl"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["MAO inhibitors", "None", "psychotropic drugs"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["MAO inhibitors", "None", "buspirone HCl"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["buspirone HCl", "None", "psychotropic drugs"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["buspirone HCl", "None", "buspirone HCl"]]}, {"text": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "triple_list": [["psychotropic drugs", "None", "buspirone HCl"]]}, {"text": "In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.", "triple_list": [["buspirone HCl", "None", "haloperidol"]]}, {"text": "In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.", "triple_list": [["haloperidol", "None", "haloperidol"]]}, {"text": "In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.", "triple_list": [["buspirone", "None", "warfarin"]]}, {"text": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "triple_list": [["amphotericin B", "None", "imidazoles"]]}, {"text": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "triple_list": [["amphotericin B", "None", "imidazoles"]]}, {"text": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "triple_list": [["amphotericin B", "None", "amphotericin B"]]}, {"text": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "triple_list": [["imidazoles", "None", "imidazoles"]]}, {"text": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "triple_list": [["imidazoles", "None", "amphotericin B"]]}, {"text": "Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.", "triple_list": [["desflurane", "None", "epinephrine"]]}, {"text": "Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.\r\n", "triple_list": [["ketamine", "None", "propofol"]]}, {"text": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ", "triple_list": [["ketamine", "None", "propofol"]]}, {"text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ", "triple_list": [["propofol", "None", "ketamine"]]}, {"text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ", "triple_list": [["propofol", "None", "propofol"]]}, {"text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ", "triple_list": [["ketamine", "None", "propofol"]]}, {"text": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "triple_list": [["ketamine", "None", "propofol"]]}, {"text": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "triple_list": [["propofol", "None", "propofol"]]}, {"text": "Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.", "triple_list": [["TNF blocking agents", "None", "abatacept"]]}, {"text": "Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.", "triple_list": [["TNF antagonist", "None", "TNF antagonists"]]}, {"text": "Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.", "triple_list": [["ORENCIA", "None", "TNF antagonists"]]}, {"text": "Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.", "triple_list": [["aminoglycoside", "None", "aminoglycoside"]]}, {"text": "Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.", "triple_list": [["ritonavir", "None", "ritonavir"]]}, {"text": "Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.", "triple_list": [["INVIRASE", "None", "ritonavir"]]}, {"text": "Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.", "triple_list": [["methylergonovine", "None", "ergot"]]}, {"text": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "triple_list": [["rifampin", "None", "saquinavir"]]}, {"text": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "triple_list": [["rifampin", "None", "antiretroviral"]]}, {"text": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "triple_list": [["rifampin", "None", "saquinavir"]]}, {"text": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "triple_list": [["saquinavir", "None", "antiretroviral"]]}, {"text": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "triple_list": [["saquinavir", "None", "saquinavir"]]}, {"text": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.", "triple_list": [["antiretroviral", "None", "saquinavir"]]}, {"text": "Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.", "triple_list": [["saquinavir", "None", "protease inhibitor"]]}, {"text": "Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.", "triple_list": [["saquinavir", "None", "saquinavir"]]}, {"text": "Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.", "triple_list": [["protease inhibitor", "None", "saquinavir"]]}, {"text": "Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.", "triple_list": [["INVIRASE", "None", "ritonavir"]]}, {"text": "Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.", "triple_list": [["ritonavir", "None", "ritonavir"]]}, {"text": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "triple_list": [["oxyphenbutazone", "None", "oxyphenbutazone"]]}, {"text": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "triple_list": [["androgens", "None", "oxyphenbutazone"]]}, {"text": "By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM. ", "triple_list": [["arsenate", "None", "As(V)"]]}, {"text": "At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines. ", "triple_list": [["As(V)", "None", "As(V)"]]}, {"text": "However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V). ", "triple_list": [["As(V)", "None", "As(V)"]]}, {"text": "Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. ", "triple_list": [["arsenate", "None", "phosphate"]]}, {"text": "Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "triple_list": [["vaccine", "None", "vaccine"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["antacid", "None", "fosinoprilat"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["antacid", "None", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["antacid", "None", "antacids"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["antacid", "None", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinopril", "None", "fosinoprilat"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinopril", "None", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinopril", "None", "antacids"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinopril", "None", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinoprilat", "None", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinoprilat", "None", "antacids"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinoprilat", "None", "fosinopril"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinopril", "None", "antacids"]]}, {"text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "triple_list": [["fosinopril", "None", "fosinopril"]]}, {"text": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "triple_list": [["fosinoprilat", "None", "fosinopril"]]}, {"text": "In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.", "triple_list": [["aspirin", "None", "fosinoprilat"]]}, {"text": "In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for Digoxin.", "triple_list": [["Fosinopril", "None", "digoxin"]]}, {"text": "Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.\n", "triple_list": [["moxifloxacin", "None", "lomefloxacin"]]}, {"text": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ", "triple_list": [["lomefloxacin", "None", "fluoroquinolone antibiotics"]]}, {"text": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "triple_list": [["moxifloxacin", "None", "fluoroquinolones"]]}, {"text": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "triple_list": [["moxifloxacin", "None", "erythromycin"]]}, {"text": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "triple_list": [["fluoroquinolones", "None", "erythromycin"]]}, {"text": "The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ", "triple_list": [["moxifloxacin", "None", "lomefloxacin"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["sucralfate", "None", "gelusil"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["sucralfate", "None", "erythromycin"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["sucralfate", "None", "multi-minerals"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["gelusil", "None", "erythromycin"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["gelusil", "None", "multi-minerals"]]}, {"text": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "triple_list": [["erythromycin", "None", "multi-minerals"]]}, {"text": "When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ", "triple_list": [["DIFLUCAN", "None", "sulfonylurea"]]}, {"text": "Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ", "triple_list": [["phenytoin", "None", "DIFLUCAN"]]}, {"text": "Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ", "triple_list": [["cyclosporine", "None", "DIFLUCAN"]]}, {"text": "Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. ", "triple_list": [["Rifampin", "None", "Rifampin"]]}, {"text": "Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ", "triple_list": [["theophylline", "None", "DIFLUCAN"]]}, {"text": "Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ", "triple_list": [["fluconazole", "None", "DIFLUCAN"]]}, {"text": "Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ", "triple_list": [["fluconazole", "None", "terfenadine"]]}, {"text": "A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.", "triple_list": [["fluconazole", "None", "cisapride"]]}, {"text": "A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ", "triple_list": [["midazolam", "None", "midazolam"]]}, {"text": "Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ", "triple_list": [["fluconazole", "None", "midazolam"]]}, {"text": "This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ", "triple_list": [["midazolam", "None", "fluconazole"]]}, {"text": "This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ", "triple_list": [["fluconazole", "None", "fluconazole"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["ethinyl estradiol", "None", "contraceptives"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["ethinyl estradiol", "None", "ethinyl estradiol"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["levonorgestrel", "None", "contraceptives"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["levonorgestrel", "None", "ethinyl estradiol"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["levonorgestrel", "None", "levonorgestrel"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["contraceptives", "None", "ethinyl estradiol"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["contraceptives", "None", "levonorgestrel"]]}, {"text": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels. ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. ", "triple_list": [["ethinyl estradiol", "None", "fluconazole"]]}, {"text": "The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. ", "triple_list": [["levonorgestrel", "None", "fluconazole"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "None", "fluconazole"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "None", "ethinyl estradiol"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "None", "levonorgestrel"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["ethinyl estradiol", "None", "fluconazole"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["ethinyl estradiol", "None", "ethinyl estradiol"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["levonorgestrel", "None", "fluconazole"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["levonorgestrel", "None", "ethinyl estradiol"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["levonorgestrel", "None", "levonorgestrel"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "None", "ethinyl estradiol"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["fluconazole", "None", "levonorgestrel"]]}, {"text": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "triple_list": [["ethinyl estradiol", "None", "levonorgestrel"]]}, {"text": "The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.", "triple_list": [["PRINIVIL", "None", "diuretic"]]}, {"text": "The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.", "triple_list": [["PRINIVIL", "None", "PRINIVIL"]]}, {"text": "Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.", "triple_list": [["ACE inhibitors", "None", "diuretics"]]}, {"text": "Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.", "triple_list": [["ACE inhibitors", "None", "ACE inhibitor"]]}, {"text": "Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.", "triple_list": [["diuretics", "None", "ACE inhibitor"]]}, {"text": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "triple_list": [["PRINIVIL", "None", "PRINIVIL"]]}, {"text": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "triple_list": [["PRINIVIL", "None", "indomethacin"]]}, {"text": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "triple_list": [["PRINIVIL", "None", "indomethacin"]]}, {"text": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "triple_list": [["PRINIVIL", "None", "indomethacin"]]}, {"text": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "triple_list": [["PRINIVIL", "None", "indomethacin"]]}, {"text": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "triple_list": [["indomethacin", "None", "indomethacin"]]}, {"text": "Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["PRINIVIL", "None", "nitrates"]]}, {"text": "Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["PRINIVIL", "None", "digoxin"]]}, {"text": "Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["nitrates", "None", "digoxin"]]}, {"text": "No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide.", "triple_list": [["PRINIVIL", "None", "propranolol"]]}, {"text": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "triple_list": [["potassium-sparing diuretics", "None", "potassium"]]}, {"text": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "triple_list": [["Lithium", "None", "Lithium"]]}, {"text": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "triple_list": [["Lithium", "None", "lithium"]]}, {"text": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "triple_list": [["Lithium", "None", "lithium"]]}, {"text": "It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.", "triple_list": [["lithium", "None", "PRINIVIL"]]}, {"text": "It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ", "triple_list": [["TNKase", "None", "heparin"]]}, {"text": "Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ", "triple_list": [["ketoconazole", "None", "retapamulin"]]}, {"text": "Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ", "triple_list": [["retapamulin", "None", "retapamulin"]]}, {"text": "Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ", "triple_list": [["retapamulin", "None", "retapamulin"]]}, {"text": "Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.", "triple_list": [["amphotericin B", "None", "filipin"]]}, {"text": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "triple_list": [["filipin", "None", "amphotericin B"]]}, {"text": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "triple_list": [["filipin", "None", "polyene antibiotics"]]}, {"text": "Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; ", "triple_list": [["amphotericin B", "None", "polyene antibiotics"]]}, {"text": "and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. ", "triple_list": [["filipin", "None", "amphotericin B"]]}, {"text": "Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.", "triple_list": [["calcium", "None", "multivalent cations"]]}, {"text": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "triple_list": [["theophylline", "None", "erythromycin"]]}, {"text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "triple_list": [["theophylline", "None", "erythromycin"]]}, {"text": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "triple_list": [["erythromycin", "None", "digoxin"]]}, {"text": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "triple_list": [["ergotamine", "None", "dihydroergotamine"]]}, {"text": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "triple_list": [["triazolam", "None", "midazolam"]]}, {"text": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "triple_list": [["antihistamines", "None", "terfenadine"]]}, {"text": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "triple_list": [["antihistamines", "None", "astemizole"]]}, {"text": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "triple_list": [["terfenadine", "None", "astemizole"]]}, {"text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "triple_list": [["erythromycin", "None", "cisapride"]]}, {"text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "triple_list": [["erythromycin", "None", "erythromycin"]]}, {"text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "triple_list": [["cisapride", "None", "erythromycin"]]}, {"text": "This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.", "triple_list": [["sunitinib", "None", "sunitinib"]]}, {"text": "This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.", "triple_list": [["sunitinib", "None", "docetaxel"]]}, {"text": "This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.", "triple_list": [["sunitinib", "None", "docetaxel"]]}, {"text": "NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. ", "triple_list": [["sunitinib", "None", "docetaxel"]]}, {"text": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "triple_list": [["docetaxel", "None", "sunitinib"]]}, {"text": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "triple_list": [["docetaxel", "None", "docetaxel"]]}, {"text": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "triple_list": [["sunitinib", "None", "sunitinib"]]}, {"text": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "triple_list": [["sunitinib", "None", "docetaxel"]]}, {"text": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "triple_list": [["sunitinib", "None", "docetaxel"]]}, {"text": "For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. ", "triple_list": [["calcium-entry blocking agents", "None", "nifedipine"]]}, {"text": "by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; ", "triple_list": [["verapamil", "None", "diltiazem"]]}, {"text": "Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.\n", "triple_list": [["amprenavir", "None", "rifabutin"]]}, {"text": "Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.\n", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.\n", "triple_list": [["rifabutin", "None", "rifampin"]]}, {"text": "The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ", "triple_list": [["amprenavir", "None", "rifabutin"]]}, {"text": "The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ", "triple_list": [["rifabutin", "None", "rifampin"]]}, {"text": "All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ", "triple_list": [["amprenavir", "None", "rifabutin"]]}, {"text": "All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ", "triple_list": [["rifabutin", "None", "rifampin"]]}, {"text": "Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ", "triple_list": [["amprenavir", "None", "rifabutin"]]}, {"text": "Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ", "triple_list": [["amprenavir", "None", "amprenavir"]]}, {"text": "Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ", "triple_list": [["rifabutin", "None", "amprenavir"]]}, {"text": "Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ", "triple_list": [["rifabutin", "None", "rifampin"]]}, {"text": "Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ", "triple_list": [["rifabutin", "None", "25-O-desacetylrifabutin"]]}, {"text": "Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ", "triple_list": [["amprenavir", "None", "amprenavir"]]}, {"text": "Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ", "triple_list": [["amprenavir", "None", "rifampin"]]}, {"text": "The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. ", "triple_list": [["rifabutin", "None", "rifampin"]]}, {"text": "Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.", "triple_list": [["rifampin", "None", "rifabutin"]]}, {"text": "Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.", "triple_list": [["TIKOSYN", "None", "dofetilide"]]}, {"text": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "triple_list": [["TIKOSYN", "None", "anti-ulcer"]]}, {"text": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "triple_list": [["TIKOSYN", "None", "antacids"]]}, {"text": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "triple_list": [["TIKOSYN", "None", "TIKOSYN"]]}, {"text": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "triple_list": [["anti-ulcer", "None", "antacids"]]}, {"text": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "triple_list": [["anti-ulcer", "None", "TIKOSYN"]]}, {"text": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "triple_list": [["antacids", "None", "TIKOSYN"]]}, {"text": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "triple_list": [["TIKOSYN", "None", "dofetilide"]]}, {"text": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "triple_list": [["TIKOSYN", "None", "dofetilide"]]}, {"text": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "triple_list": [["verapamil", "None", "dofetilide"]]}, {"text": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "triple_list": [["verapamil", "None", "dofetilide"]]}, {"text": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "triple_list": [["dofetilide", "None", "dofetilide"]]}, {"text": "Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.", "triple_list": [["TIKOSYN", "None", "dofetilide"]]}, {"text": "Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.", "triple_list": [["trimethoprim", "None", "sulfamethoxazole"]]}, {"text": "Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.", "triple_list": [["HCTZ", "None", "HCTZ"]]}, {"text": "Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.", "triple_list": [["HCTZ", "None", "triamterene"]]}, {"text": "Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.", "triple_list": [["HCTZ", "None", "triamterene"]]}, {"text": "HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).", "triple_list": [["TIKOSYN", "None", "diuretic"]]}, {"text": "In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.", "triple_list": [["TIKOSYN", "None", "diuretics"]]}, {"text": "In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.", "triple_list": [["TIKOSYN", "None", "diuretics"]]}, {"text": "In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.", "triple_list": [["diuretics", "None", "diuretics"]]}, {"text": "Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).", "triple_list": [["potassium depleting diuretics", "None", "TIKOSYN"]]}, {"text": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "triple_list": [["TIKOSYN", "None", "dofetilide"]]}, {"text": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "triple_list": [["estrogens", "None", "antacid"]]}, {"text": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "triple_list": [["estrogens", "None", "theophylline"]]}, {"text": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "triple_list": [["antacid", "None", "theophylline"]]}, {"text": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.", "triple_list": [["TIKOSYN", "None", "propranolol"]]}, {"text": "decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;", "triple_list": [["antithrombin III", "None", "antithrombin III"]]}, {"text": "increased levels of fibrinogen and fibrinogen activity;", "triple_list": [["fibrinogen", "None", "fibrinogen"]]}, {"text": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.", "triple_list": [["anesthetics", "None", "anesthetics"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["ibogaine", "None", "morphine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["ibogaine", "None", "cocaine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["ibogaine", "None", "ethanol"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["ibogaine", "None", "nicotine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["18-MC", "None", "morphine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["18-MC", "None", "cocaine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["18-MC", "None", "ethanol"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["18-MC", "None", "nicotine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["morphine", "None", "cocaine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["morphine", "None", "ethanol"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["morphine", "None", "nicotine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["cocaine", "None", "ethanol"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["cocaine", "None", "nicotine"]]}, {"text": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "triple_list": [["ethanol", "None", "nicotine"]]}, {"text": "Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ", "triple_list": [["ibogaine", "None", "opioid"]]}, {"text": "Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ", "triple_list": [["18-MC", "None", "opioid"]]}, {"text": "Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ", "triple_list": [["ibogaine", "None", "ibogaine"]]}, {"text": "Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ", "triple_list": [["18-MC", "None", "ibogaine"]]}, {"text": "Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants. ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ", "triple_list": [["18-MC", "None", "ibogaine"]]}, {"text": "While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ", "triple_list": [["18-MC", "None", "18-MC"]]}, {"text": "While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ", "triple_list": [["18-MC", "None", "ibogaine"]]}, {"text": "While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ", "triple_list": [["ibogaine", "None", "ibogaine"]]}, {"text": "While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ", "triple_list": [["18-MC", "None", "ibogaine"]]}, {"text": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "triple_list": [["18-MC", "None", "ibogaine"]]}, {"text": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "triple_list": [["18-MC", "None", "ibogaine"]]}, {"text": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "triple_list": [["18-MC", "None", "18-MC"]]}, {"text": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "triple_list": [["ibogaine", "None", "ibogaine"]]}, {"text": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "triple_list": [["ibogaine", "None", "18-MC"]]}, {"text": "Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.", "triple_list": [["Sumatriptan", "None", "Sumatriptan"]]}, {"text": "Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.", "triple_list": [["Sumatriptan", "None", "D.H.E. 45"]]}, {"text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "triple_list": [["D.H.E. 45", "None", "propranolol"]]}, {"text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "triple_list": [["D.H.E. 45", "None", "propranolol"]]}, {"text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "triple_list": [["D.H.E. 45", "None", "ergotamine"]]}, {"text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "triple_list": [["propranolol", "None", "ergotamine"]]}, {"text": "Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.", "triple_list": [["Nicotine", "None", "Nicotine"]]}, {"text": "Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.", "triple_list": [["Nicotine", "None", "ergot"]]}, {"text": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "triple_list": [["erythromycin", "None", "D.H.E. 45"]]}, {"text": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "triple_list": [["erythromycin", "None", "antibiotics"]]}, {"text": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "triple_list": [["D.H.E. 45", "None", "antibiotics"]]}, {"text": "SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.", "triple_list": [["SSRIs", "None", "5-HT1 agonists"]]}, {"text": "SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.", "triple_list": [["SSRIs", "None", "SSRIs"]]}, {"text": "There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.", "triple_list": [["SSRIs", "None", "D.H.E. 45"]]}, {"text": "Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.", "triple_list": [["contraceptives", "None", "D.H.E. 45"]]}, {"text": "Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.", "triple_list": [["ELSPAR", "None", "methotrexate"]]}, {"text": "Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.", "triple_list": [["methotrexate", "None", "ELSPAR"]]}, {"text": "These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.", "triple_list": [["ELSPAR", "None", "ELSPAR"]]}, {"text": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.", "triple_list": [["metformin", "None", "metformin"]]}, {"text": "Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.\r\n", "triple_list": [["avian influenza vaccines", "None", "ginseng stem-and-leaf saponins"]]}, {"text": "In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. ", "triple_list": [["GSLS", "None", "inactivated ND vaccine"]]}, {"text": "Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.", "triple_list": [["GSLS", "None", "GSLS"]]}, {"text": "Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC  is given concurrently with agents that affect CYP3A4 activity.", "triple_list": [["Fentanyl", "None", "DURAGESIC"]]}, {"text": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "triple_list": [["fentanyl", "None", "fentanyl"]]}, {"text": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "triple_list": [["ritonavir", "None", "fentanyl"]]}, {"text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "triple_list": [["diltiazem", "None", "erythromycin"]]}, {"text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "triple_list": [["diltiazem", "None", "fentanyl"]]}, {"text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "triple_list": [["erythromycin", "None", "fentanyl"]]}, {"text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "triple_list": [["fentanyl", "None", "fentanyl"]]}, {"text": "MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics", "triple_list": [["DURAGESIC", "None", "MAO inhibitors"]]}, {"text": "MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics", "triple_list": [["MAOI", "None", "MAO inhibitors"]]}, {"text": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "triple_list": [["PLETAL", "None", "PLETAL"]]}, {"text": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "triple_list": [["PLETAL", "None", "ketoconazole"]]}, {"text": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "triple_list": [["PLETAL", "None", "erythromycin"]]}, {"text": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "triple_list": [["ketoconazole", "None", "erythromycin"]]}, {"text": "Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.", "triple_list": [["omeprazole", "None", "erythromycin"]]}, {"text": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "triple_list": [["tetracyclines", "None", "anticoagulant"]]}, {"text": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "triple_list": [["anticoagulant", "None", "anticoagulant"]]}, {"text": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.", "triple_list": [["tetracyclines", "None", "antacids"]]}, {"text": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "triple_list": [["nitrosourea", "None", "CCNU"]]}, {"text": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "triple_list": [["nitrosourea", "None", "CCNU"]]}, {"text": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "triple_list": [["CCNU", "None", "CCNU"]]}, {"text": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "triple_list": [["Lithium", "None", "Lithium"]]}, {"text": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "triple_list": [["Lithium", "None", "diuretics"]]}, {"text": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "triple_list": [["Lithium", "None", "lithium"]]}, {"text": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "triple_list": [["Lithium", "None", "lithium"]]}, {"text": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "triple_list": [["diuretics", "None", "lithium"]]}, {"text": "This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.", "triple_list": [["probenecid", "None", "bumetanide"]]}, {"text": "This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.", "triple_list": [["bumetanide", "None", "bumetanide"]]}, {"text": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "triple_list": [["Indomethacin", "None", "Indomethacin"]]}, {"text": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "triple_list": [["Indomethacin", "None", "bumetanide"]]}, {"text": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "triple_list": [["Indomethacin", "None", "bumetanide"]]}, {"text": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "triple_list": [["bumetanide", "None", "bumetanide"]]}, {"text": "- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.", "triple_list": [["bumetanide", "None", "warfarin"]]}, {"text": "Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ", "triple_list": [["precocene I", "None", "tranylcypromine"]]}, {"text": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "triple_list": [["sulfaphenazole", "None", "quinidine"]]}, {"text": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "triple_list": [["sulfaphenazole", "None", "precocene I"]]}, {"text": "These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. ", "triple_list": [["precocene I", "None", "precocene I"]]}, {"text": "The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.", "triple_list": [["methylxanthines", "None", "caffeine"]]}, {"text": "In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.", "triple_list": [["adenosine", "None", "adenosine"]]}, {"text": "In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.", "triple_list": [["VIOXX", "None", "ACE inhibitor"]]}, {"text": "In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.", "triple_list": [["VIOXX", "None", "ACE inhibitor"]]}, {"text": "In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.", "triple_list": [["ACE inhibitor", "None", "ACE inhibitor"]]}, {"text": "Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.", "triple_list": [["aspirin", "None", "VIOXX"]]}, {"text": "Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.", "triple_list": [["VIOXX", "None", "VIOXX"]]}, {"text": "In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.", "triple_list": [["aspirin", "None", "VIOXX"]]}, {"text": "In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.", "triple_list": [["aspirin", "None", "ibuprofen"]]}, {"text": "In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.", "triple_list": [["VIOXX", "None", "ibuprofen"]]}, {"text": "Patients taking low-dose aspirin plus ibuprofen were not studied.", "triple_list": [["aspirin", "None", "ibuprofen"]]}, {"text": "Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.", "triple_list": [["VIOXX", "None", "aspirin"]]}, {"text": "Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.", "triple_list": [["VIOXX", "None", "aspirin"]]}, {"text": "Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.", "triple_list": [["Rofecoxib", "None", "digoxin"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["furosemide", "None", "thiazides"]]}, {"text": "Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.", "triple_list": [["Ketoconazole", "None", "Ketoconazole"]]}, {"text": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "triple_list": [["NSAIDs", "None", "lithium"]]}, {"text": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["VIOXX", "None", "lithium"]]}, {"text": "Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.", "triple_list": [["VIOXX", "None", "methotrexate"]]}, {"text": "Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.", "triple_list": [["VIOXX", "None", "methotrexate"]]}, {"text": "Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "triple_list": [["methotrexate", "None", "rofecoxib"]]}, {"text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "triple_list": [["rofecoxib", "None", "methotrexate"]]}, {"text": "Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.", "triple_list": [["methotrexate", "None", "VIOXX"]]}, {"text": "Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.", "triple_list": [["Contraceptives", "None", "Rofecoxib"]]}, {"text": "Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.", "triple_list": [["Contraceptives", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.", "triple_list": [["Rofecoxib", "None", "ethinyl estradiol"]]}, {"text": "Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.", "triple_list": [["prednisolone", "None", "Rofecoxib"]]}, {"text": "Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.", "triple_list": [["prednisolone", "None", "prednisolone"]]}, {"text": "Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.", "triple_list": [["Rofecoxib", "None", "prednisolone"]]}, {"text": "Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.", "triple_list": [["VIOXX", "None", "rofecoxib"]]}, {"text": "Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.", "triple_list": [["rifampin", "None", "rofecoxib"]]}, {"text": "Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.", "triple_list": [["VIOXX", "None", "VIOXX"]]}, {"text": "Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.", "triple_list": [["VIOXX", "None", "theophylline"]]}, {"text": "Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.", "triple_list": [["theophylline", "None", "VIOXX"]]}, {"text": "Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ", "triple_list": [["fluvoxamine", "None", "tolbutamide"]]}, {"text": "OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ", "triple_list": [["fluvoxamine", "None", "fluvoxamine"]]}, {"text": "OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ", "triple_list": [["tolbutamide", "None", "fluvoxamine"]]}, {"text": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ", "triple_list": [["tolbutamide", "None", "tolbutamide"]]}, {"text": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ", "triple_list": [["tolbutamide", "None", "4-hydroxytolbutamide"]]}, {"text": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ", "triple_list": [["tolbutamide", "None", "carboxytolbutamide"]]}, {"text": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ", "triple_list": [["tolbutamide", "None", "4-hydroxytolbutamide"]]}, {"text": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ", "triple_list": [["tolbutamide", "None", "carboxytolbutamide"]]}, {"text": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ", "triple_list": [["4-hydroxytolbutamide", "None", "carboxytolbutamide"]]}, {"text": "The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "triple_list": [["4-hydroxytolbutamide", "None", "carboxytolbutamide"]]}, {"text": "The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "triple_list": [["4-hydroxytolbutamide", "None", "tolbutamide"]]}, {"text": "The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "triple_list": [["4-hydroxytolbutamide", "None", "tolbutamide"]]}, {"text": "The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "triple_list": [["carboxytolbutamide", "None", "tolbutamide"]]}, {"text": "The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "triple_list": [["carboxytolbutamide", "None", "tolbutamide"]]}, {"text": "The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ", "triple_list": [["tolbutamide", "None", "tolbutamide"]]}, {"text": "Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ", "triple_list": [["zidovudine", "None", "rifabutin"]]}, {"text": "Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ", "triple_list": [["zidovudine", "None", "megestrol acetate"]]}, {"text": "Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ", "triple_list": [["rifabutin", "None", "megestrol acetate"]]}, {"text": "A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ", "triple_list": [["megestrol acetate", "None", "indinavir"]]}, {"text": "A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.", "triple_list": [["zidovudine", "None", "rifabutin"]]}, {"text": "The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.", "triple_list": [["zidovudine", "None", "megestrol acetate"]]}, {"text": "The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.", "triple_list": [["rifabutin", "None", "megestrol acetate"]]}, {"text": "Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.", "triple_list": [["azithromycin", "None", "zidovudine"]]}, {"text": "Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.", "triple_list": [["azithromycin", "None", "dideoxyinosine"]]}, {"text": "Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.", "triple_list": [["zidovudine", "None", "dideoxyinosine"]]}, {"text": "Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. ", "triple_list": [["azithromycin", "None", "zidovudine"]]}, {"text": "The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. ", "triple_list": [["zidovudine", "None", "azithromycin"]]}, {"text": "The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. ", "triple_list": [["zidovudine", "None", "zidovudine"]]}, {"text": "The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. ", "triple_list": [["azithromycin", "None", "zidovudine"]]}, {"text": "Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21. ", "triple_list": [["dideoxyinosine", "None", "azithromycin"]]}, {"text": "Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ", "triple_list": [["zidovudine", "None", "zidovudine"]]}, {"text": "Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ", "triple_list": [["zidovudine", "None", "zidovudine"]]}, {"text": "Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ", "triple_list": [["zidovudine", "None", "zidovudine"]]}, {"text": "Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.", "triple_list": [["azithromycin", "None", "zidovudine"]]}, {"text": "The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ", "triple_list": [["UNIVASC", "None", "UNIVASC"]]}, {"text": "The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ", "triple_list": [["UNIVASC", "None", "moexpril"]]}, {"text": "The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ", "triple_list": [["UNIVASC", "None", "moexpril"]]}, {"text": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "triple_list": [["potassium-sparing diuretics", "None", "potassium"]]}, {"text": "Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ", "triple_list": [["warfarin", "None", "anticoagulant"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "triple_list": [["lithium", "None", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "triple_list": [["lithium", "None", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.", "triple_list": [["conivaptan", "None", "digoxin"]]}, {"text": "Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "triple_list": [["androgens", "None", "estrogens"]]}, {"text": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "triple_list": [["androgens", "None", "dopamine"]]}, {"text": "Amiodarone: Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.", "triple_list": [["Amiodarone", "None", "Amiodarone"]]}, {"text": "Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.", "triple_list": [["insulin", "None", "antidiabetic agents"]]}, {"text": "Cytokines (interferon, interleukin): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.", "triple_list": [["Cytokines", "None", "Cytokines"]]}, {"text": "Theophylline: Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.", "triple_list": [["Theophylline", "None", "Theophylline"]]}, {"text": "Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.", "triple_list": [["barbiturates", "None", "narcotics"]]}, {"text": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "triple_list": [["diclofenac", "None", "diclofenac"]]}, {"text": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "triple_list": [["diclofenac", "None", "aspirin"]]}, {"text": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "triple_list": [["aspirin", "None", "diclofenac"]]}, {"text": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "triple_list": [["NSAIDs", "None", "NSAIDs"]]}, {"text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "triple_list": [["NSAIDs", "None", "warfarin"]]}, {"text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "triple_list": [["NSAIDs", "None", "anticoagulant"]]}, {"text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "triple_list": [["NSAIDs", "None", "anticoagulant"]]}, {"text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "triple_list": [["warfarin", "None", "anticoagulant"]]}, {"text": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "triple_list": [["digoxin", "None", "methotrexate"]]}, {"text": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "triple_list": [["digoxin", "None", "cyclosporine"]]}, {"text": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "triple_list": [["methotrexate", "None", "cyclosporine"]]}, {"text": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "triple_list": [["diclofenac", "None", "diclofenac"]]}, {"text": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "triple_list": [["diclofenac", "None", "NSAID"]]}, {"text": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "triple_list": [["diclofenac", "None", "NSAID"]]}, {"text": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "triple_list": [["diclofenac", "None", "cyclosporine"]]}, {"text": "Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.", "triple_list": [["diclofenac", "None", "lithium"]]}, {"text": "In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.", "triple_list": [["insulin", "None", "hypoglycemic agents"]]}, {"text": "Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.", "triple_list": [["Diclofenac", "None", "NSAIDs"]]}, {"text": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "triple_list": [["salicylic acid", "None", "prednisolone"]]}, {"text": "Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.", "triple_list": [["sulfamethoxazole", "None", "diclofenac"]]}, {"text": "In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.", "triple_list": [["WelChol", "None", "simvastatin"]]}, {"text": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "triple_list": [["lapatinib", "None", "lapatinib"]]}, {"text": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "triple_list": [["lapatinib", "None", "Herceptin"]]}, {"text": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "triple_list": [["Herceptin", "None", "lapatinib"]]}, {"text": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "triple_list": [["Herceptin", "None", "Herceptin"]]}, {"text": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "triple_list": [["lapatinib", "None", "Herceptin"]]}, {"text": "We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ", "triple_list": [["lapatinib", "None", "Herceptin"]]}, {"text": "We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ", "triple_list": [["lapatinib", "None", "Herceptin"]]}, {"text": "We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ", "triple_list": [["Herceptin", "None", "Herceptin"]]}, {"text": "The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.", "triple_list": [["Lotensin", "None", "diuretic"]]}, {"text": "The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.", "triple_list": [["Lotensin", "None", "Lotensin"]]}, {"text": "Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.", "triple_list": [["Anticoagulants", "None", "warfarin"]]}, {"text": "Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.", "triple_list": [["Anticoagulants", "None", "acenocoumarol"]]}, {"text": "Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.", "triple_list": [["warfarin", "None", "acenocoumarol"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "ACE inhibitors"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "triple_list": [["Accutane", "None", "vitamin supplements"]]}, {"text": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "triple_list": [["Accutane", "None", "vitamin A"]]}, {"text": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "triple_list": [["vitamin A", "None", "vitamin supplements"]]}, {"text": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "triple_list": [["vitamin A", "None", "vitamin A"]]}, {"text": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "triple_list": [["vitamin supplements", "None", "vitamin A"]]}, {"text": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "triple_list": [["Accutane", "None", "Accutane"]]}, {"text": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "triple_list": [["Accutane", "None", "tetracyclines"]]}, {"text": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "triple_list": [["tetracyclines", "None", "Accutane"]]}, {"text": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "triple_list": [["tetracyclines", "None", "tetracyclines"]]}, {"text": "Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.", "triple_list": [["Progesterone", "None", "progesterone"]]}, {"text": "Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.", "triple_list": [["Progesterone", "None", "Accutane"]]}, {"text": "Phenytoin: Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.", "triple_list": [["Accutane", "None", "phenytoin"]]}, {"text": "Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. ", "triple_list": [["allopurinol", "None", "Vitamin E"]]}, {"text": "(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. ", "triple_list": [["penicillins", "None", "cephaloridine"]]}, {"text": "To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ", "triple_list": [["probenecid", "None", "cloxacillin"]]}, {"text": "To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ", "triple_list": [["probenecid", "None", "cloxacillin"]]}, {"text": "To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ", "triple_list": [["probenecid", "None", "probenecid"]]}, {"text": "To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ", "triple_list": [["cloxacillin", "None", "cloxacillin"]]}, {"text": "To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ", "triple_list": [["cloxacillin", "None", "probenecid"]]}, {"text": "To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. ", "triple_list": [["cloxacillin", "None", "probenecid"]]}, {"text": "No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively). ", "triple_list": [["cloxacillin", "None", "probenecid"]]}, {"text": "Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.", "triple_list": [["Clonazepam", "None", "Clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "None", "anticholinergic agent"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "None", "propantheline"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["propantheline", "None", "anticholinergic agent"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["propantheline", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["propantheline", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["propantheline", "None", "propantheline"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["anticholinergic agent", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["anticholinergic agent", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["anticholinergic agent", "None", "propantheline"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "None", "clonazepam"]]}, {"text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "triple_list": [["clonazepam", "None", "propantheline"]]}, {"text": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "triple_list": [["carbamazepine", "None", "clonazepam"]]}, {"text": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "triple_list": [["clonazepam", "None", "clonazepam"]]}, {"text": "Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.", "triple_list": [["clonazepam", "None", "clonazepam"]]}, {"text": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "triple_list": [["LEXAPRO", "None", "alcohol"]]}, {"text": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "triple_list": [["LEXAPRO", "None", "alcohol"]]}, {"text": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "triple_list": [["LEXAPRO", "None", "LEXAPRO"]]}, {"text": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "triple_list": [["alcohol", "None", "alcohol"]]}, {"text": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "triple_list": [["alcohol", "None", "LEXAPRO"]]}, {"text": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.", "triple_list": [["NSAID", "None", "aspirin"]]}, {"text": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.", "triple_list": [["cimetidine", "None", "citalopram"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "digoxin"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "digoxin"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "digoxin"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "digoxin"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["digoxin", "None", "citalopram"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "triple_list": [["citalopram", "None", "digoxin"]]}, {"text": "Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "triple_list": [["citalopram", "None", "lithium"]]}, {"text": "Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "triple_list": [["citalopram", "None", "lithium"]]}, {"text": "Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "triple_list": [["lithium", "None", "citalopram"]]}, {"text": "Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.", "triple_list": [["citalopram", "None", "lithium"]]}, {"text": "Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.", "triple_list": [["lithium", "None", "LEXAPRO"]]}, {"text": "Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "triple_list": [["Celexa", "None", "pimozide"]]}, {"text": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "triple_list": [["Celexa", "None", "citalopram"]]}, {"text": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "triple_list": [["Celexa", "None", "pimozide"]]}, {"text": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "triple_list": [["pimozide", "None", "pimozide"]]}, {"text": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "triple_list": [["citalopram", "None", "pimozide"]]}, {"text": "Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.", "triple_list": [["citalopram", "None", "theophylline"]]}, {"text": "Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.", "triple_list": [["citalopram", "None", "theophylline"]]}, {"text": "Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.", "triple_list": [["theophylline", "None", "citalopram"]]}, {"text": "Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.", "triple_list": [["citalopram", "None", "carbamazepine"]]}, {"text": "Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.", "triple_list": [["citalopram", "None", "carbamazepine"]]}, {"text": "Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.", "triple_list": [["carbamazepine", "None", "carbamazepine"]]}, {"text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "triple_list": [["citalopram", "None", "carbamazepine"]]}, {"text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "triple_list": [["citalopram", "None", "carbamazepine"]]}, {"text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "triple_list": [["citalopram", "None", "escitalopram"]]}, {"text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "triple_list": [["carbamazepine", "None", "carbamazepine"]]}, {"text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "triple_list": [["carbamazepine", "None", "escitalopram"]]}, {"text": "Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.", "triple_list": [["citalopram", "None", "triazolam"]]}, {"text": "Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.", "triple_list": [["citalopram", "None", "triazolam"]]}, {"text": "Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.", "triple_list": [["triazolam", "None", "citalopram"]]}, {"text": "Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.", "triple_list": [["triazolam", "None", "triazolam"]]}, {"text": "Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.", "triple_list": [["citalopram", "None", "triazolam"]]}, {"text": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "triple_list": [["citalopram", "None", "ketoconazole"]]}, {"text": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "triple_list": [["ketoconazole", "None", "citalopram"]]}, {"text": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "triple_list": [["ketoconazole", "None", "citalopram"]]}, {"text": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.", "triple_list": [["ritonavir", "None", "escitalopram"]]}, {"text": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.", "triple_list": [["ritonavir", "None", "ritonavir"]]}, {"text": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.", "triple_list": [["ritonavir", "None", "escitalopram"]]}, {"text": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.", "triple_list": [["escitalopram", "None", "ritonavir"]]}, {"text": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.", "triple_list": [["escitalopram", "None", "escitalopram"]]}, {"text": "Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.", "triple_list": [["ritonavir", "None", "escitalopram"]]}, {"text": "However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.", "triple_list": [["escitalopram", "None", "ritonavir"]]}, {"text": "However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.", "triple_list": [["escitalopram", "None", "escitalopram"]]}, {"text": "However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.", "triple_list": [["ritonavir", "None", "escitalopram"]]}, {"text": "Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.", "triple_list": [["escitalopram", "None", "escitalopram"]]}, {"text": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "triple_list": [["citalopram", "None", "citalopram"]]}, {"text": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "triple_list": [["citalopram", "None", "escitalopram"]]}, {"text": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "triple_list": [["citalopram", "None", "escitalopram"]]}, {"text": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "triple_list": [["citalopram", "None", "escitalopram"]]}, {"text": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "triple_list": [["citalopram", "None", "escitalopram"]]}, {"text": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "triple_list": [["escitalopram", "None", "escitalopram"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "None", "escitalopram"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "None", "tricyclic antidepressant"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "None", "desipramine"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "None", "desipramine"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "None", "tricyclic antidepressant"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["escitalopram", "None", "desipramine"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["tricyclic antidepressant", "None", "desipramine"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["tricyclic antidepressant", "None", "desipramine"]]}, {"text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "triple_list": [["desipramine", "None", "desipramine"]]}, {"text": "Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).", "triple_list": [["LEXAPRO", "None", "beta-adrenergic blocker"]]}, {"text": "Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).", "triple_list": [["beta-adrenergic blocker", "None", "metoprolol"]]}, {"text": "Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.", "triple_list": [["LEXAPRO", "None", "metoprolol"]]}, {"text": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "triple_list": [["Citalopram", "None", "Citalopram"]]}, {"text": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "triple_list": [["Citalopram", "None", "escitalopram"]]}, {"text": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "triple_list": [["Citalopram", "None", "citalopram"]]}, {"text": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "triple_list": [["Citalopram", "None", "escitalopram"]]}, {"text": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "triple_list": [["Citalopram", "None", "citalopram"]]}, {"text": "Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.", "triple_list": [["Anticoagulants", "None", "COUMARIN ANTICOAGULANTS"]]}, {"text": "HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.", "triple_list": [["HMG-CoA reductase inhibitors", "None", "TRICOR"]]}, {"text": "HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.", "triple_list": [["HMG-CoA reductase inhibitors", "None", "HMG-CoA reductase inhibitors"]]}, {"text": "Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.", "triple_list": [["bile acid sequestrants", "None", "TRICOR"]]}, {"text": "Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.", "triple_list": [["bile acid sequestrants", "None", "bile acid binding resin"]]}, {"text": "Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.", "triple_list": [["fenofibrate", "None", "fenofibric acid"]]}, {"text": "Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.", "triple_list": [["fenofibrate", "None", "pravastatin"]]}, {"text": "Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.", "triple_list": [["pravastatin", "None", "pravastatin"]]}, {"text": "Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.", "triple_list": [["fenofibrate", "None", "atorvastatin"]]}, {"text": "Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.", "triple_list": [["atorvastatin", "None", "atorvastatin"]]}, {"text": "Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.\r\n", "triple_list": [["miconazole", "None", "miconazole"]]}, {"text": "Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ", "triple_list": [["Theophylline", "None", "Theophylline"]]}, {"text": "Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ", "triple_list": [["Theophylline", "None", "theophylline"]]}, {"text": "Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ", "triple_list": [["Theophylline", "None", "theophylline"]]}, {"text": "In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. ", "triple_list": [["etofibrate", "None", "etofibrate"]]}, {"text": "However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.", "triple_list": [["phenobarbital", "None", "diazepam"]]}, {"text": "However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.", "triple_list": [["phenobarbital", "None", "Dantrium"]]}, {"text": "However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.", "triple_list": [["diazepam", "None", "Dantrium"]]}, {"text": "The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.", "triple_list": [["dantrolene sodium", "None", "verapamil"]]}, {"text": "The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.", "triple_list": [["dantrolene sodium", "None", "halothane"]]}, {"text": "The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.", "triple_list": [["verapamil", "None", "halothane"]]}, {"text": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ", "triple_list": [["ALKERAN", "None", "live organism vaccines"]]}, {"text": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ", "triple_list": [["ALKERAN", "None", "Nalidixic acid"]]}, {"text": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ", "triple_list": [["ALKERAN", "None", "melphalan"]]}, {"text": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ", "triple_list": [["live organism vaccines", "None", "Nalidixic acid"]]}, {"text": "DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ", "triple_list": [["live organism vaccines", "None", "melphalan"]]}, {"text": "Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.", "triple_list": [["Cromolyn sodium", "None", "isoproterenol"]]}, {"text": "Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.", "triple_list": [["piperazine", "None", "piperazine"]]}, {"text": "Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.", "triple_list": [["pyrantel", "None", "piperazine"]]}, {"text": "Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.\r\n", "triple_list": [["cinacalcet", "None", "darbepoetin"]]}, {"text": "Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. ", "triple_list": [["cinacalcet", "None", "darbepoetin"]]}, {"text": "The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. ", "triple_list": [["darbepoetin", "None", "cinacalcet"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "triple_list": [["phenytoin", "None", "rifampin"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "triple_list": [["corticosteroids", "None", "corticosteroid"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ", "triple_list": [["troleandomycin", "None", "ketoconazole"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ", "triple_list": [["salicylate", "None", "salicylate"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ", "triple_list": [["salicylate", "None", "corticosteroid"]]}, {"text": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "triple_list": [["doxorubicin", "None", "etoposide"]]}, {"text": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "triple_list": [["doxorubicin", "None", "celecoxib"]]}, {"text": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "triple_list": [["etoposide", "None", "celecoxib"]]}, {"text": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "triple_list": [["celecoxib", "None", "celecoxib"]]}, {"text": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "triple_list": [["celecoxib", "None", "doxorubicin"]]}, {"text": "These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. ", "triple_list": [["celecoxib", "None", "doxorubicin"]]}, {"text": "Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation", "triple_list": [["thrombolytics", "None", "REFLUDAN"]]}, {"text": "DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.", "triple_list": [["primidone", "None", "DIAMOX"]]}, {"text": "By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.", "triple_list": [["primidone", "None", "primidone"]]}, {"text": "Acetazolamide increases lithium excretion and the lithium may be decreased.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["CANCIDAS", "None", "tacrolimus"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["CANCIDAS", "None", "CANCIDAS"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["CANCIDAS", "None", "tacrolimus"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["tacrolimus", "None", "tacrolimus"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["tacrolimus", "None", "CANCIDAS"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["tacrolimus", "None", "tacrolimus"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["tacrolimus", "None", "CANCIDAS"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["tacrolimus", "None", "tacrolimus"]]}, {"text": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "triple_list": [["CANCIDAS", "None", "tacrolimus"]]}, {"text": "For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.", "triple_list": [["tacrolimus", "None", "tacrolimus"]]}, {"text": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "triple_list": [["CANCIDAS", "None", "caspofungin"]]}, {"text": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "triple_list": [["CANCIDAS", "None", "CANCIDAS"]]}, {"text": "When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. ", "triple_list": [["ouabain", "None", "PTX"]]}, {"text": "The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain. ", "triple_list": [["ouabain", "None", "ouabain"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "epinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "norepinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "monoamine oxidase inhibitors"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["epinephrine", "None", "norepinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["monoamine oxidase inhibitors", "None", "tricyclic antidepressants"]]}, {"text": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "triple_list": [["vasopressor drugs", "None", "ergot-type oxytocic drugs"]]}, {"text": "Talk to your doctor if you are taking certain antibiotics such as erythromycin, clarithromycin or azithromycin.", "triple_list": [["antibiotics", "None", "clarithromycin"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "metoprolol"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "antihistamines"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "carbamazepine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "cimetidine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "estrogens"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "fluoxetine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antidepressants", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "antihistamines"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "carbamazepine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "cimetidine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "estrogens"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "fluoxetine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["metoprolol", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "carbamazepine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "cimetidine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "estrogens"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "fluoxetine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["antihistamines", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "cimetidine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "estrogens"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "fluoxetine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["carbamazepine", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["cimetidine", "None", "estrogens"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["cimetidine", "None", "fluoxetine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["cimetidine", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["cimetidine", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["cimetidine", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["cimetidine", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["estrogens", "None", "fluoxetine"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["estrogens", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["estrogens", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["estrogens", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["estrogens", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["fluoxetine", "None", "ketoconazole"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["fluoxetine", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["fluoxetine", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["fluoxetine", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["ketoconazole", "None", "levodopa"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["ketoconazole", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["ketoconazole", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["levodopa", "None", "lithium"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["levodopa", "None", "muscle relaxants"]]}, {"text": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "triple_list": [["lithium", "None", "muscle relaxants"]]}, {"text": "Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.", "triple_list": [["SN38", "None", "irinotecan"]]}, {"text": "Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.", "triple_list": [["SN38", "None", "AVASTIN"]]}, {"text": "Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.", "triple_list": [["irinotecan", "None", "AVASTIN"]]}, {"text": "Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.", "triple_list": [["Contraceptives", "None", "cefditoren pivoxil"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.", "triple_list": [["probenecid", "None", "cefditoren"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.", "triple_list": [["cefditoren pivoxil", "None", "cefditoren"]]}, {"text": "The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.", "triple_list": [["nevirapine", "None", "antithrombotic agent"]]}, {"text": "The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.", "triple_list": [["antithrombotic agent", "None", "warfarin"]]}, {"text": "Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["Methadone", "None", "opiate"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["Methadone", "None", "Methadone"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["Methadone", "None", "nevirapine"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["Methadone", "None", "methadone"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["opiate", "None", "Methadone"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["opiate", "None", "nevirapine"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["opiate", "None", "methadone"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["Methadone", "None", "methadone"]]}, {"text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "triple_list": [["nevirapine", "None", "methadone"]]}, {"text": "Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.", "triple_list": [["rifampin", "None", "nevirapine"]]}, {"text": "Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.", "triple_list": [["nevirapine", "None", "rifabutin"]]}, {"text": "aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.", "triple_list": [["nevirapine", "None", "methadone"]]}, {"text": "aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.", "triple_list": [["methadone", "None", "methadone"]]}, {"text": "In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.", "triple_list": [["theophylline", "None", "lomefloxacin"]]}, {"text": "In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.", "triple_list": [["lomefloxacin", "None", "theophylline"]]}, {"text": "In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.", "triple_list": [["lomefloxacin", "None", "theophylline"]]}, {"text": "In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["Sucralfate", "None", "antacids"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["Sucralfate", "None", "magnesium"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["Sucralfate", "None", "Videx"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["antacids", "None", "magnesium"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["antacids", "None", "Videx"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["antacids", "None", "lomefloxacin"]]}, {"text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "triple_list": [["magnesium", "None", "Videx"]]}, {"text": "therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.", "triple_list": [["lomefloxacin", "None", "lomefloxacin"]]}, {"text": "Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.", "triple_list": [["caffeine", "None", "lomefloxacin"]]}, {"text": "Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.", "triple_list": [["Cimetidine", "None", "Cimetidine"]]}, {"text": "The interaction between lomefloxacin and cimetidine has not been studied.", "triple_list": [["lomefloxacin", "None", "cimetidine"]]}, {"text": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Interaction between lomefloxacin and cyclosporine has not been studied.", "triple_list": [["lomefloxacin", "None", "cyclosporine"]]}, {"text": "Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.", "triple_list": [["lomefloxacin", "None", "lomefloxacin"]]}, {"text": "Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.", "triple_list": [["lomefloxacin", "None", "omeprazole"]]}, {"text": "Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.", "triple_list": [["lomefloxacin", "None", "omeprazole"]]}, {"text": "Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.", "triple_list": [["phenytoin", "None", "phenytoin sodium"]]}, {"text": "Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.", "triple_list": [["phenytoin", "None", "lomefloxacin"]]}, {"text": "Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.", "triple_list": [["phenytoin sodium", "None", "lomefloxacin"]]}, {"text": "Probenecid: Probenecid slows the renal elimination of lome-floxacin.", "triple_list": [["Probenecid", "None", "Probenecid"]]}, {"text": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "triple_list": [["terfenadine", "None", "lomefloxacin"]]}, {"text": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "triple_list": [["terfenadine", "None", "lomefloxacin"]]}, {"text": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "triple_list": [["lomefloxacin", "None", "lomefloxacin"]]}, {"text": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "triple_list": [["lomefloxacin", "None", "terfenadine"]]}, {"text": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "triple_list": [["lomefloxacin", "None", "terfenadine"]]}, {"text": "However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.", "triple_list": [["warfarin", "None", "lomefloxacin"]]}, {"text": "However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.", "triple_list": [["warfarin", "None", "lomefloxacin"]]}, {"text": "The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro. ", "triple_list": [["prostaglandin F2alpha", "None", "oxytocin"]]}, {"text": "In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. ", "triple_list": [["norepinephrine", "None", "oxytocin"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "CNS depressants"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "anticholinergics"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "anticholinergics"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "anticholinergics"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["monoamine oxidase (MAO) inhibitors", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["monoamine oxidase (MAO) inhibitors", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.\r\n", "triple_list": [["hydrocortisone", "None", "d-amphetamine"]]}, {"text": "However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans. ", "triple_list": [["glucocorticoids", "None", "psychostimulants"]]}, {"text": "METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. ", "triple_list": [["Hydrocortisone", "None", "d-amphetamine"]]}, {"text": "CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.", "triple_list": [["glucocorticoids", "None", "d-amphetamine"]]}, {"text": "Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ", "triple_list": [["ezetimibe", "None", "fibrates"]]}, {"text": "Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ", "triple_list": [["gemfibrozil", "None", "ezetimibe"]]}, {"text": "Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ", "triple_list": [["ezetimibe", "None", "ezetimibe"]]}, {"text": "A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ", "triple_list": [["ezetimibe", "None", "ezetimibe"]]}, {"text": "In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ", "triple_list": [["ezetimibe", "None", "ezetimibe"]]}, {"text": "Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ", "triple_list": [["ezetimibe", "None", "HMG-CoA reductase inhibitors"]]}, {"text": "Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ", "triple_list": [["ezetimibe", "None", "ezetimibe"]]}, {"text": "Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ", "triple_list": [["HMG-CoA reductase inhibitors", "None", "ezetimibe"]]}, {"text": "When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ", "triple_list": [["ZETIA", "None", "HMG-CoA reductase inhibitor"]]}, {"text": "When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ", "triple_list": [["ZETIA", "None", "HMG-CoA reductase inhibitor"]]}, {"text": "When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ", "triple_list": [["HMG-CoA reductase inhibitor", "None", "HMG-CoA reductase inhibitor"]]}, {"text": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "triple_list": [["alcohol", "None", "CNS depressants"]]}, {"text": "The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. ", "triple_list": [["sodium bicarbonate", "None", "calcium"]]}, {"text": "Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).", "triple_list": [["Ibandronate", "None", "H2 blockers"]]}, {"text": "Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.", "triple_list": [["Ibandronate", "None", "Ibandronate"]]}, {"text": "In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.", "triple_list": [["aspirin", "None", "nonsteroidal anti-inflammatory drugs"]]}, {"text": "Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).", "triple_list": [["aspirin", "None", "NSAID"]]}, {"text": "Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).", "triple_list": [["aspirin", "None", "ibandronate"]]}, {"text": "Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).", "triple_list": [["NSAID", "None", "ibandronate"]]}, {"text": "Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.", "triple_list": [["aspirin", "None", "nonsteroidal anti-inflammatory drugs"]]}, {"text": "The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).", "triple_list": [["aspirin", "None", "NSAIDs"]]}, {"text": "The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).", "triple_list": [["aspirin", "None", "ibandronate"]]}, {"text": "The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).", "triple_list": [["NSAIDs", "None", "ibandronate"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["aspirin", "None", "NSAIDs"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["aspirin", "None", "bisphosphonates"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["aspirin", "None", "NSAIDs"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["NSAIDs", "None", "bisphosphonates"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["NSAIDs", "None", "aspirin"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["NSAIDs", "None", "NSAIDs"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["bisphosphonates", "None", "aspirin"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["bisphosphonates", "None", "NSAIDs"]]}, {"text": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "triple_list": [["aspirin", "None", "NSAIDs"]]}, {"text": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "triple_list": [["Bezalip", "None", "Bezalip retard"]]}, {"text": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "triple_list": [["Bezalip", "None", "Bezalip"]]}, {"text": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "triple_list": [["Bezalip", "None", "Bezalip retard"]]}, {"text": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "triple_list": [["Bezalip retard", "None", "Bezalip"]]}, {"text": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "triple_list": [["Bezalip retard", "None", "Bezalip retard"]]}, {"text": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "triple_list": [["Bezalip", "None", "Bezalip retard"]]}, {"text": "For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters", "triple_list": [["Bezalip", "None", "Bezalip"]]}, {"text": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "triple_list": [["sulphonylureas", "None", "insulin"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip", "None", "Bezalip retard"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip", "None", "Bezalip"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip", "None", "Bezalip retard"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip retard", "None", "Bezalip"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip retard", "None", "Bezalip retard"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["anion-exchange resins", "None", "Bezalip"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["anion-exchange resins", "None", "Bezalip retard"]]}, {"text": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "triple_list": [["Bezalip", "None", "Bezalip retard"]]}, {"text": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "triple_list": [["Perhexiline hydrogen maleate", "None", "MAO-inhibitors"]]}, {"text": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "triple_list": [["NIMBEX", "None", "succinylcholine"]]}, {"text": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "triple_list": [["NIMBEX", "None", "NIMBEX"]]}, {"text": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "triple_list": [["NIMBEX", "None", "succinylcholine"]]}, {"text": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "triple_list": [["succinylcholine", "None", "succinylcholine"]]}, {"text": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "triple_list": [["NIMBEX", "None", "succinylcholine"]]}, {"text": "The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "triple_list": [["NIMBEX", "None", "succinylcholine"]]}, {"text": "The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "triple_list": [["NIMBEX", "None", "succinylcholine"]]}, {"text": "The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.", "triple_list": [["succinylcholine", "None", "succinylcholine"]]}, {"text": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "triple_list": [["NIMBEX", "None", "NIMBEX"]]}, {"text": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "triple_list": [["isoflurane", "None", "enflurane"]]}, {"text": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "triple_list": [["isoflurane", "None", "NIMBEX"]]}, {"text": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "triple_list": [["isoflurane", "None", "NIMBEX"]]}, {"text": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "triple_list": [["enflurane", "None", "NIMBEX"]]}, {"text": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "triple_list": [["enflurane", "None", "NIMBEX"]]}, {"text": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "triple_list": [["NIMBEX", "None", "NIMBEX"]]}, {"text": "In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.", "triple_list": [["enflurane", "None", "isoflurane"]]}, {"text": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "triple_list": [["antibiotics", "None", "magnesium"]]}, {"text": "While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.", "triple_list": [["phenytoin", "None", "carbamazepine"]]}, {"text": "[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]\r\nThe effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ", "triple_list": [["radiopertechnetate", "None", "sodium perchlorate"]]}, {"text": "[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]\r\nThe effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ", "triple_list": [["radiopertechnetate", "None", "sodium perchlorate"]]}, {"text": "[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]\r\nThe effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ", "triple_list": [["radiopertechnetate", "None", "radiopertechnetate"]]}, {"text": "[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]\r\nThe effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ", "triple_list": [["sodium perchlorate", "None", "sodium perchlorate"]]}, {"text": "[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]\r\nThe effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ", "triple_list": [["sodium perchlorate", "None", "radiopertechnetate"]]}, {"text": "[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]\r\nThe effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. ", "triple_list": [["sodium perchlorate", "None", "radiopertechnetate"]]}, {"text": "An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. ", "triple_list": [["perchlorate", "None", "pertechnetate"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antidepressants", "None", "MAO inhibitors"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antidepressants", "None", "antihistamines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antidepressants", "None", "potassium chloride"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antidepressants", "None", "absorbent-type anti-diarrhea medicines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antidepressants", "None", "phenothiazines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["MAO inhibitors", "None", "antihistamines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["MAO inhibitors", "None", "potassium chloride"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["MAO inhibitors", "None", "absorbent-type anti-diarrhea medicines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["MAO inhibitors", "None", "phenothiazines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antihistamines", "None", "potassium chloride"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antihistamines", "None", "absorbent-type anti-diarrhea medicines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["antihistamines", "None", "phenothiazines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["potassium chloride", "None", "absorbent-type anti-diarrhea medicines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["potassium chloride", "None", "phenothiazines"]]}, {"text": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "triple_list": [["absorbent-type anti-diarrhea medicines", "None", "phenothiazines"]]}, {"text": "The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.", "triple_list": [["NovoSeven", "None", "coagulation factor"]]}, {"text": "Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.", "triple_list": [["activated prothrombin complex concentrates", "None", "prothrombin complex concentrates"]]}, {"text": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "triple_list": [["acetaminophen", "None", "caffeine"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["anticholinergic", "None", "AKINETON"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["narcotic analgesics", "None", "phenothiazines"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["narcotic analgesics", "None", "antiarrhythmics"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["narcotic analgesics", "None", "quinidine"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["phenothiazines", "None", "antiarrhythmics"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["phenothiazines", "None", "quinidine"]]}, {"text": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "triple_list": [["antiarrhythmics", "None", "quinidine"]]}, {"text": "For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.", "triple_list": [["vitamin K antagonists", "None", "vitamin K antagonists"]]}, {"text": "The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.", "triple_list": [["imipramine", "None", "desipramine"]]}, {"text": "Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).", "triple_list": [["Alprazolam", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["Alprazolam", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["Alprazolam", "None", "fluoxetine"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["Alprazolam", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["Alprazolam", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["alprazolam", "None", "fluoxetine"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["fluoxetine", "None", "alprazolam"]]}, {"text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "benzodiazepines"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["benzodiazepines", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "macrolide antibiotics"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["alprazolam", "None", "erythromycin"]]}, {"text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "triple_list": [["macrolide antibiotics", "None", "erythromycin"]]}, {"text": "Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.", "triple_list": [["alprazolam", "None", "sertraline"]]}, {"text": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "triple_list": [["benzodiazepines", "None", "alprazolam"]]}, {"text": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ", "triple_list": [["noradrenaline", "None", "KCl"]]}, {"text": "However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. ", "triple_list": [["L-NAME", "None", "reseveratrol"]]}, {"text": "This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.", "triple_list": [["resveratrol", "None", "resveratrol"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["monoamine oxidase inhibitor", "None", "isocarboxazid"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["monoamine oxidase inhibitor", "None", "tranylcypromine"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["monoamine oxidase inhibitor", "None", "phenelzine"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["isocarboxazid", "None", "tranylcypromine"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["isocarboxazid", "None", "phenelzine"]]}, {"text": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "triple_list": [["tranylcypromine", "None", "phenelzine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "amitriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "amoxapine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "doxepin"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "nortriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "imipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "clomipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["tricyclic antidepressant", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "amoxapine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "doxepin"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "nortriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "imipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "clomipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amitriptyline", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amoxapine", "None", "doxepin"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amoxapine", "None", "nortriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amoxapine", "None", "imipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amoxapine", "None", "clomipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amoxapine", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["amoxapine", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["doxepin", "None", "nortriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["doxepin", "None", "imipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["doxepin", "None", "clomipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["doxepin", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["doxepin", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["nortriptyline", "None", "imipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["nortriptyline", "None", "clomipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["nortriptyline", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["nortriptyline", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["imipramine", "None", "clomipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["imipramine", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["imipramine", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["clomipramine", "None", "protriptyline"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["clomipramine", "None", "desipramine"]]}, {"text": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "triple_list": [["protriptyline", "None", "desipramine"]]}, {"text": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "triple_list": [["BOTOX", "None", "toxin"]]}, {"text": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "triple_list": [["aminoglycosides", "None", "toxin"]]}, {"text": "Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.", "triple_list": [["Multivitamins", "None", "Quinolones"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["quinolones", "None", "antacids"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["quinolones", "None", "quinolones"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["antacids", "None", "iron"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["antacids", "None", "multivitamins"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["antacids", "None", "iron"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["antacids", "None", "VIDEX"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["antacids", "None", "quinolones"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["iron", "None", "multivitamins"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["iron", "None", "iron"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["iron", "None", "VIDEX"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["iron", "None", "quinolones"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["multivitamins", "None", "iron"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["multivitamins", "None", "VIDEX"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["multivitamins", "None", "quinolones"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["iron", "None", "VIDEX"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["iron", "None", "quinolones"]]}, {"text": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "triple_list": [["VIDEX", "None", "quinolones"]]}, {"text": "Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.", "triple_list": [["Theobromine", "None", "caffeine"]]}, {"text": "Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.", "triple_list": [["theophylline", "None", "grepafloxacin"]]}, {"text": "Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["grepafloxacin", "None", "grepafloxacin"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["theophylline", "None", "grepafloxacin"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "triple_list": [["quinolones", "None", "quinolone antimicrobial"]]}, {"text": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "triple_list": [["quinolones", "None", "warfarin"]]}, {"text": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "triple_list": [["warfarin", "None", "quinolone antimicrobial"]]}, {"text": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "triple_list": [["grepafloxacin", "None", "grepafloxacin"]]}, {"text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "triple_list": [["theophylline", "None", "grepafloxacin"]]}, {"text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.", "triple_list": [["grepafloxacin", "None", "theophylline"]]}, {"text": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "triple_list": [["vitamin D analogues", "None", "Cholestyramine"]]}, {"text": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "triple_list": [["vitamin D analogues", "None", "Cholestyramine"]]}, {"text": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "triple_list": [["Cholestyramine", "None", "Cholestyramine"]]}, {"text": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "triple_list": [["phenytoin", "None", "phenobarbital"]]}, {"text": "Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.", "triple_list": [["Thiazides", "None", "Thiazides"]]}, {"text": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "triple_list": [["Ketoconazole", "None", "Ketoconazole"]]}, {"text": "However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.", "triple_list": [["ketoconazole", "None", "vitamin D"]]}, {"text": "Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. ", "triple_list": [["panobinostat", "None", "panobinostat"]]}, {"text": "Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.", "triple_list": [["panobinostat", "None", "panobinostat"]]}, {"text": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ", "triple_list": [["sodium salicylate", "None", "sulfamethizole"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["Neurontin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["Neurontin", "None", "gabapentin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["Neurontin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["Neurontin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["Neurontin", "None", "gabapentin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "gabapentin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "gabapentin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["gabapentin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["gabapentin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["gabapentin", "None", "gabapentin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "gabapentin"]]}, {"text": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "triple_list": [["phenytoin", "None", "gabapentin"]]}, {"text": "Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;", "triple_list": [["carbamazepine", "None", "carbamazepine 10, 11 epoxide"]]}, {"text": "Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;", "triple_list": [["carbamazepine", "None", "gabapentin"]]}, {"text": "Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;", "triple_list": [["carbamazepine 10, 11 epoxide", "None", "gabapentin"]]}, {"text": "Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.", "triple_list": [["gabapentin", "None", "carbamazepine"]]}, {"text": "Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;", "triple_list": [["valproic acid", "None", "gabapentin"]]}, {"text": "Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;", "triple_list": [["phenobarbital", "None", "gabapentin"]]}, {"text": "Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.", "triple_list": [["naproxen sodium", "None", "gabapentin"]]}, {"text": "Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.", "triple_list": [["Neurontin", "None", "gabapentin"]]}, {"text": "Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg Neurontin  and 21% to 22% lower, respectively, after administration of 500 mg Neurontin .", "triple_list": [["Neurontin", "None", "Neurontin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["morphine", "None", "gabapentin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["morphine", "None", "gabapentin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["Neurontin", "None", "gabapentin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["Neurontin", "None", "gabapentin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["Neurontin", "None", "morphine"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["gabapentin", "None", "gabapentin"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["gabapentin", "None", "morphine"]]}, {"text": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "triple_list": [["gabapentin", "None", "morphine"]]}, {"text": "The effect of gabapentin on cimetidine was not evaluated.", "triple_list": [["gabapentin", "None", "cimetidine"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["norethindrone", "None", "norethindrone acetate"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["norethindrone", "None", "gabapentin"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["ethinyl estradiol", "None", "norethindrone acetate"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["ethinyl estradiol", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["ethinyl estradiol", "None", "gabapentin"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["norethindrone acetate", "None", "ethinyl estradiol"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["norethindrone acetate", "None", "gabapentin"]]}, {"text": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "triple_list": [["ethinyl estradiol", "None", "gabapentin"]]}, {"text": "Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.", "triple_list": [["Maalox", "None", "Maalox"]]}, {"text": "Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.", "triple_list": [["Maalox", "None", "gabapentin"]]}, {"text": "Effect of Probenecid: Probenecid is a blocker of renal tubular secretion.", "triple_list": [["Probenecid", "None", "Probenecid"]]}, {"text": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "triple_list": [["acetylcholine chloride", "None", "carbachol"]]}, {"text": "[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes]\r\nThe effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. ", "triple_list": [["sandimmune", "None", "sandimmune"]]}, {"text": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "triple_list": [["Lorazepam", "None", "scopolamine"]]}, {"text": "The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.", "triple_list": [["Exjade", "None", "antacid preparations"]]}, {"text": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "triple_list": [["deferasirox", "None", "aluminum"]]}, {"text": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "triple_list": [["deferasirox", "None", "Exjade"]]}, {"text": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "triple_list": [["deferasirox", "None", "aluminum"]]}, {"text": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "triple_list": [["aluminum", "None", "Exjade"]]}, {"text": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "triple_list": [["aluminum", "None", "aluminum"]]}, {"text": "The effect of digoxin on Exjade pharmacokinetics has not been studied.", "triple_list": [["digoxin", "None", "Exjade"]]}, {"text": "The concomitant administration of Exjade and vitamin C has not been formally studied.", "triple_list": [["Exjade", "None", "vitamin C"]]}, {"text": "The interaction of Exjade with hydroxyurea has not been formally studied.", "triple_list": [["Exjade", "None", "hydroxyurea"]]}, {"text": "No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.", "triple_list": [["deferasirox", "None", "hydroxyurea"]]}, {"text": "In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.", "triple_list": [["efavirenz", "None", "efavirenz"]]}, {"text": "Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal", "triple_list": [["Benzodiazepines", "None", "Anti-Migraine"]]}, {"text": "astemizole midazolam, triazolam cisapride ergot derivatives voriconazole", "triple_list": [["triazolam", "None", "cisapride"]]}, {"text": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "triple_list": [["SUSTIVA", "None", "atazanavir"]]}, {"text": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "triple_list": [["SUSTIVA", "None", "ritonavir"]]}, {"text": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "triple_list": [["SUSTIVA", "None", "SUSTIVA"]]}, {"text": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "triple_list": [["atazanavir", "None", "ritonavir"]]}, {"text": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "triple_list": [["atazanavir", "None", "SUSTIVA"]]}, {"text": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).", "triple_list": [["ritonavir", "None", "SUSTIVA"]]}, {"text": "Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.", "triple_list": [["SUSTIVA", "None", "atazanavir"]]}, {"text": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "triple_list": [["SUSTIVA", "None", "indinavir"]]}, {"text": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "triple_list": [["SUSTIVA", "None", "indinavir"]]}, {"text": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.", "triple_list": [["methadone", "None", "opiate"]]}, {"text": "Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.", "triple_list": [["efavirenz", "None", "contraceptives"]]}, {"text": "Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.", "triple_list": [["contraceptives", "None", "contraceptives"]]}, {"text": "Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.", "triple_list": [["rifabutin", "None", "rifabutin"]]}, {"text": "Anticonvulsants: Phenytoin Phenobarbital Carbamazepine", "triple_list": [["Phenytoin", "None", "Phenobarbital"]]}, {"text": "Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.", "triple_list": [["SUSTIVA", "None", "triazole antifungals"]]}, {"text": "Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.", "triple_list": [["SUSTIVA", "None", "NRTIs"]]}, {"text": "Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.", "triple_list": [["SUSTIVA", "None", "lamivudine"]]}, {"text": "Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.", "triple_list": [["NRTIs", "None", "lamivudine"]]}, {"text": "Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.", "triple_list": [["NRTIs", "None", "efavirenz"]]}, {"text": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.", "triple_list": [["Levosimendan", "None", "ethanol"]]}, {"text": "The net effect of these interactions is summarized in the following table: AED AED Felbatol", "triple_list": [["AED", "None", "AED"]]}, {"text": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "triple_list": [["Felbatol", "None", "Antiepileptic Drugs"]]}, {"text": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "triple_list": [["Felbatol", "None", "phenytoin"]]}, {"text": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "triple_list": [["Antiepileptic Drugs", "None", "Felbatol"]]}, {"text": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "triple_list": [["Antiepileptic Drugs", "None", "phenytoin"]]}, {"text": "In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.", "triple_list": [["phenytoin", "None", "felbamate"]]}, {"text": "In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.", "triple_list": [["phenytoin", "None", "Felbatol"]]}, {"text": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.", "triple_list": [["phenytoin", "None", "Felbatol"]]}, {"text": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.", "triple_list": [["Felbatol", "None", "phenytoin"]]}, {"text": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.", "triple_list": [["phenytoin", "None", "Felbatol"]]}, {"text": "Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.", "triple_list": [["Felbatol", "None", "carbamazepine epoxide"]]}, {"text": "Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.", "triple_list": [["carbamazepine", "None", "carbamazepine epoxide"]]}, {"text": "In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8 2 micrograms/mL.", "triple_list": [["carbamazepine", "None", "carbamazepine"]]}, {"text": "In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.", "triple_list": [["carbamazepine", "None", "carbamazepine epoxide"]]}, {"text": "In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63 16 micrograms/mL.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "Corresponding values for free valproate Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol , respectively.", "triple_list": [["valproate", "None", "Felbatol"]]}, {"text": "The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.", "triple_list": [["valproate", "None", "Felbatol"]]}, {"text": "The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.", "triple_list": [["valproate", "None", "Felbatol"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["felbamate", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["felbamate", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["felbamate", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "Phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "Phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Antiepileptic Drugs", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "Phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Phenytoin", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "phenytoin"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["phenytoin", "None", "Felbatol"]]}, {"text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "Carbamazepine"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Carbamazepine", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["carbamazepine", "None", "Felbatol"]]}, {"text": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "triple_list": [["valproate", "None", "Felbatol"]]}, {"text": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "triple_list": [["valproate", "None", "Felbatol"]]}, {"text": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "triple_list": [["Felbatol", "None", "valproate"]]}, {"text": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "triple_list": [["valproate", "None", "Felbatol"]]}, {"text": "Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.", "triple_list": [["felbamate", "None", "felbamate"]]}, {"text": "Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.", "triple_list": [["Antacids", "None", "Felbatol"]]}, {"text": "Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.", "triple_list": [["Antacids", "None", "Felbatol"]]}, {"text": "Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.", "triple_list": [["Felbatol", "None", "Felbatol"]]}, {"text": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "triple_list": [["Erythromycin", "None", "Felbatol"]]}, {"text": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "triple_list": [["Erythromycin", "None", "erythromycin"]]}, {"text": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "triple_list": [["Erythromycin", "None", "felbamate"]]}, {"text": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "triple_list": [["Felbatol", "None", "erythromycin"]]}, {"text": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "triple_list": [["Felbatol", "None", "felbamate"]]}, {"text": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "triple_list": [["erythromycin", "None", "felbamate"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Felbatol", "None", "Combination Oral Contraceptives"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Felbatol", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Felbatol", "None", "ethinyl estradiol"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Felbatol", "None", "gestodene"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Felbatol", "None", "felbamate"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Felbatol", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Combination Oral Contraceptives", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Combination Oral Contraceptives", "None", "ethinyl estradiol"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Combination Oral Contraceptives", "None", "gestodene"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Combination Oral Contraceptives", "None", "felbamate"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["Combination Oral Contraceptives", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["contraceptive", "None", "ethinyl estradiol"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["contraceptive", "None", "gestodene"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["contraceptive", "None", "felbamate"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["contraceptive", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["ethinyl estradiol", "None", "gestodene"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["ethinyl estradiol", "None", "felbamate"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["ethinyl estradiol", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["gestodene", "None", "felbamate"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["gestodene", "None", "contraceptive"]]}, {"text": "Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.", "triple_list": [["felbamate", "None", "contraceptive"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["BREVIBLOC", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["BREVIBLOC", "None", "BREVIBLOC"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["BREVIBLOC", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["BREVIBLOC", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["warfarin", "None", "BREVIBLOC"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["BREVIBLOC", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["BREVIBLOC", "None", "warfarin"]]}, {"text": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.", "triple_list": [["BREVIBLOC", "None", "digoxin"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["morphine", "None", "BREVIBLOC"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["morphine", "None", "BREVIBLOC"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["BREVIBLOC", "None", "morphine"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["BREVIBLOC", "None", "BREVIBLOC"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["BREVIBLOC", "None", "morphine"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["morphine", "None", "BREVIBLOC"]]}, {"text": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "triple_list": [["anticoagulant", "None", "chloral hydrate"]]}, {"text": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "triple_list": [["anticoagulant", "None", "methaqualone"]]}, {"text": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "triple_list": [["anticoagulant", "None", "coumarin"]]}, {"text": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "triple_list": [["chloral hydrate", "None", "methaqualone"]]}, {"text": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "triple_list": [["chloral hydrate", "None", "coumarin"]]}, {"text": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "triple_list": [["methaqualone", "None", "coumarin"]]}, {"text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.", "triple_list": [["chloral hydrate", "None", "methaqualone"]]}, {"text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.", "triple_list": [["chloral hydrate", "None", "anticoagulant"]]}, {"text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.", "triple_list": [["methaqualone", "None", "anticoagulant"]]}, {"text": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "triple_list": [["gefitinib", "None", "gefitinib"]]}, {"text": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "triple_list": [["IRESSA", "None", "vinorelbine"]]}, {"text": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "triple_list": [["IRESSA", "None", "IRESSA"]]}, {"text": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "triple_list": [["IRESSA", "None", "vinorelbine"]]}, {"text": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "triple_list": [["vinorelbine", "None", "IRESSA"]]}, {"text": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "triple_list": [["vinorelbine", "None", "vinorelbine"]]}, {"text": "Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.", "triple_list": [["dasatinib", "None", "Dasatinib"]]}, {"text": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "triple_list": [["SPRYCEL", "None", "dasatinib"]]}, {"text": "In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.", "triple_list": [["SPRYCEL", "None", "SPRYCEL"]]}, {"text": "Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.", "triple_list": [["dasatinib", "None", "dasatinib"]]}, {"text": "If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.", "triple_list": [["SPRYCEL", "None", "SPRYCEL"]]}, {"text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "triple_list": [["H2 blockers", "None", "proton pump inhibitors"]]}, {"text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "triple_list": [["H2 blockers", "None", "famotidine"]]}, {"text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "triple_list": [["proton pump inhibitors", "None", "famotidine"]]}, {"text": "The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.", "triple_list": [["H2 blockers", "None", "proton pump inhibitors"]]}, {"text": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "triple_list": [["antacids", "None", "H2 blockers"]]}, {"text": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "triple_list": [["antacids", "None", "proton pump inhibitors"]]}, {"text": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "triple_list": [["antacids", "None", "SPRYCEL"]]}, {"text": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "triple_list": [["H2 blockers", "None", "proton pump inhibitors"]]}, {"text": "Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.", "triple_list": [["dasatinib", "None", "Dasatinib"]]}, {"text": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "triple_list": [["lenalidomide", "None", "CCI-779"]]}, {"text": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "triple_list": [["lenalidomide", "None", "lenalidomide"]]}, {"text": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "triple_list": [["lenalidomide", "None", "CCI-779"]]}, {"text": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "triple_list": [["CCI-779", "None", "lenalidomide"]]}, {"text": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "triple_list": [["CCI-779", "None", "CCI-779"]]}, {"text": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "triple_list": [["lenalidomide", "None", "CCI-779"]]}, {"text": "Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.", "triple_list": [["phenylpropanolamine", "None", "pseudoephedrine"]]}, {"text": "Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.", "triple_list": [["linezolid", "None", "serotonergic agents"]]}, {"text": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "triple_list": [["antidepressants", "None", "selective serotonin reuptake inhibitors"]]}, {"text": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "triple_list": [["Anticoagulants", "None", "Antiplatelet Agents"]]}, {"text": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "triple_list": [["Anticoagulants", "None", "antiplatelet agents"]]}, {"text": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "triple_list": [["Antiplatelet Agents", "None", "antiplatelet agents"]]}, {"text": "Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke. ", "triple_list": [["Antiplatelets", "None", "aspirin"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "triple_list": [["antiarrhythmic agents of class I", "None", "antipsychotic agents"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "triple_list": [["antiarrhythmic agents of class I", "None", "narcotic analgesics"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "triple_list": [["antiarrhythmic agents of class I", "None", "nitrates"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "triple_list": [["antipsychotic agents", "None", "narcotic analgesics"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "triple_list": [["antipsychotic agents", "None", "nitrates"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "triple_list": [["narcotic analgesics", "None", "nitrates"]]}, {"text": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "triple_list": [["losartan", "None", "losartan"]]}, {"text": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "triple_list": [["losartan", "None", "erythromycin"]]}, {"text": "Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.", "triple_list": [["losartan", "None", "erythromycin"]]}, {"text": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "triple_list": [["potassium-sparing diuretics", "None", "potassium"]]}, {"text": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "triple_list": [["losartan", "None", "non-steroidal anti-inflammatory drug"]]}, {"text": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "triple_list": [["diazepam", "None", "midazolam"]]}, {"text": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "triple_list": [["diazepam", "None", "metamizol"]]}, {"text": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "triple_list": [["diazepam", "None", "indomethacin"]]}, {"text": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "triple_list": [["midazolam", "None", "metamizol"]]}, {"text": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "triple_list": [["midazolam", "None", "indomethacin"]]}, {"text": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "triple_list": [["metamizol", "None", "indomethacin"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["midazolam", "None", "diazepam"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["midazolam", "None", "morphine"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["midazolam", "None", "metamizol"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["midazolam", "None", "indomethacin"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["diazepam", "None", "morphine"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["diazepam", "None", "metamizol"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["diazepam", "None", "indomethacin"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["morphine", "None", "metamizol"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["morphine", "None", "indomethacin"]]}, {"text": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "triple_list": [["metamizol", "None", "indomethacin"]]}, {"text": "Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. ", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Ketoconazole", "None", "Erythromycin"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Ketoconazole", "None", "Clarithromycin"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Ketoconazole", "None", "Telithromycin"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Ketoconazole", "None", "HIV protease inhibitors"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Ketoconazole", "None", "Nefazodone"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Ketoconazole", "None", "Cyclosporine"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Erythromycin", "None", "Clarithromycin"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Erythromycin", "None", "Telithromycin"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Erythromycin", "None", "HIV protease inhibitors"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Erythromycin", "None", "Nefazodone"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Erythromycin", "None", "Cyclosporine"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Clarithromycin", "None", "Telithromycin"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Clarithromycin", "None", "HIV protease inhibitors"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Clarithromycin", "None", "Nefazodone"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Clarithromycin", "None", "Cyclosporine"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Telithromycin", "None", "HIV protease inhibitors"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Telithromycin", "None", "Nefazodone"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Telithromycin", "None", "Cyclosporine"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["HIV protease inhibitors", "None", "Nefazodone"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["HIV protease inhibitors", "None", "Cyclosporine"]]}, {"text": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "triple_list": [["Nefazodone", "None", "Cyclosporine"]]}, {"text": "Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)", "triple_list": [["fibrates", "None", "Niacin"]]}, {"text": "Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).", "triple_list": [["amiodarone", "None", "verapamil"]]}, {"text": "Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.", "triple_list": [["lovastatin", "None", "warfarin"]]}, {"text": "Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.", "triple_list": [["lovastatin", "None", "digoxin"]]}, {"text": "Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.", "triple_list": [["lovastatin", "None", "digoxin"]]}, {"text": "Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide", "triple_list": [["MEVACOR", "None", "glipizide"]]}, {"text": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "triple_list": [["phenytoin", "None", "fluvoxamine"]]}, {"text": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "triple_list": [["phenytoin", "None", "drugs"]]}, {"text": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "triple_list": [["fluvoxamine", "None", "phenytoin"]]}, {"text": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "triple_list": [["fluvoxamine", "None", "drugs"]]}, {"text": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "triple_list": [["phenytoin", "None", "drugs"]]}, {"text": "During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. ", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1). ", "triple_list": [["CYP2C9", "None", "CYP2C9"]]}, {"text": "In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. ", "triple_list": [["atypical antipsychotic", "None", "clozapine"]]}, {"text": "In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. ", "triple_list": [["atypical antipsychotic", "None", "PCP"]]}, {"text": "In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. ", "triple_list": [["clozapine", "None", "PCP"]]}, {"text": "PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule. ", "triple_list": [["PCP", "None", "PCP"]]}, {"text": "Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone. ", "triple_list": [["clozapine", "None", "PCP"]]}, {"text": "These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication. ", "triple_list": [["clozapine", "None", "PCP"]]}, {"text": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "triple_list": [["Myfortic", "None", "antacids"]]}, {"text": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "triple_list": [["Myfortic", "None", "Myfortic"]]}, {"text": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "triple_list": [["antacids", "None", "Myfortic"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["azathioprine", "None", "mycophenolate mofetil"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["azathioprine", "None", "Myfortic"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["azathioprine", "None", "azathioprine"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["azathioprine", "None", "mycophenolate mofetil"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["mycophenolate mofetil", "None", "Myfortic"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["mycophenolate mofetil", "None", "azathioprine"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["mycophenolate mofetil", "None", "mycophenolate mofetil"]]}, {"text": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "triple_list": [["azathioprine", "None", "mycophenolate mofetil"]]}, {"text": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ", "triple_list": [["Myfortic", "None", "Myfortic"]]}, {"text": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ", "triple_list": [["cholestyramine", "None", "Myfortic"]]}, {"text": "Interference of MPAG hydrolysis may lead to less MPA available for absorption.", "triple_list": [["MPAG", "None", "MPA"]]}, {"text": "Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ", "triple_list": [["ketoconazole", "None", "terfenadine"]]}, {"text": "Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "triple_list": [["terfenadine", "None", "itraconazole"]]}, {"text": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "triple_list": [["terfenadine", "None", "itraconazole"]]}, {"text": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "triple_list": [["terfenadine", "None", "itraconazole"]]}, {"text": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "triple_list": [["itraconazole", "None", "itraconazole"]]}, {"text": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ", "triple_list": [["erythromycin", "None", "clarithromycin"]]}, {"text": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "triple_list": [["troleandomycin", "None", "terfenadine"]]}, {"text": "Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.", "triple_list": [["terfenadine", "None", "azithromycin"]]}, {"text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "triple_list": [["ergot-type medications", "None", "dihydroergotamine"]]}, {"text": "The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.", "triple_list": [["naratriptan", "None", "5-HT1 agonists"]]}, {"text": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "triple_list": [["oxyphenbutazone", "None", "oxyphenbutazone"]]}, {"text": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "triple_list": [["androgens", "None", "oxyphenbutazone"]]}, {"text": "Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. ", "triple_list": [["galangin", "None", "vancomycin"]]}, {"text": "A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;", "triple_list": [["lithium", "None", "HALDOL"]]}, {"text": "In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.", "triple_list": [["haloperidol", "None", "haloperidol"]]}, {"text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "triple_list": [["haloperidol", "None", "rifampin"]]}, {"text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "triple_list": [["haloperidol", "None", "rifampin"]]}, {"text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "triple_list": [["haloperidol", "None", "haloperidol"]]}, {"text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "triple_list": [["rifampin", "None", "rifampin"]]}, {"text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "triple_list": [["rifampin", "None", "haloperidol"]]}, {"text": "A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.", "triple_list": [["ampicillin", "None", "tetracyclines"]]}, {"text": "A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort.", "triple_list": [["hormonal contraceptives", "None", "contraceptive"]]}, {"text": "By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone. ", "triple_list": [["spermidine", "None", "putrescine"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["ginsenosides", "None", "selective Ca(2+) channel blockers"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["ginsenosides", "None", "nimodipine"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["ginsenosides", "None", "omega-conotoxin GVIA"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["ginsenosides", "None", "omega-agatoxin IVA"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["selective Ca(2+) channel blockers", "None", "nimodipine"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["selective Ca(2+) channel blockers", "None", "omega-conotoxin GVIA"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["selective Ca(2+) channel blockers", "None", "omega-agatoxin IVA"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["nimodipine", "None", "omega-conotoxin GVIA"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["nimodipine", "None", "omega-agatoxin IVA"]]}, {"text": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ", "triple_list": [["omega-conotoxin GVIA", "None", "omega-agatoxin IVA"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["ketoconazole", "None", "azole antifungals"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["ketoconazole", "None", "macrolide antibiotics"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["ketoconazole", "None", "cyclosporine"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["azole antifungals", "None", "macrolide antibiotics"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["azole antifungals", "None", "cyclosporine"]]}, {"text": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "triple_list": [["macrolide antibiotics", "None", "cyclosporine"]]}, {"text": "Phenytoin, phenobarbital and carbamazepine are ge nerally classified as enzyme inducers;", "triple_list": [["phenobarbital", "None", "carbamazepine"]]}, {"text": "Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.", "triple_list": [["GABITRIL", "None", "Tiagabine"]]}, {"text": "Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.", "triple_list": [["GABITRIL", "None", "phenytoin"]]}, {"text": "Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.", "triple_list": [["Tiagabine", "None", "phenytoin"]]}, {"text": "Carbamazepine: Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.", "triple_list": [["Tiagabine", "None", "carbamazepine"]]}, {"text": "Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.", "triple_list": [["Primidone", "None", "tiagabine"]]}, {"text": "Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.", "triple_list": [["Primidone", "None", "phenobarbital"]]}, {"text": "Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.", "triple_list": [["tiagabine", "None", "phenobarbital"]]}, {"text": "The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.", "triple_list": [["tiagabine", "None", "phenobarbital"]]}, {"text": "The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.", "triple_list": [["tiagabine", "None", "primidone"]]}, {"text": "The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.", "triple_list": [["phenobarbital", "None", "primidone"]]}, {"text": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "triple_list": [["GABITRIL", "None", "tiagabine"]]}, {"text": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "triple_list": [["GABITRIL", "None", "carbamazepine"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["tiagabine", "None", "valproate"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["tiagabine", "None", "tiagabine"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["tiagabine", "None", "valproate"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["tiagabine", "None", "tiagabine"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["valproate", "None", "tiagabine"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["valproate", "None", "tiagabine"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["tiagabine", "None", "valproate"]]}, {"text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "triple_list": [["tiagabine", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["GABITRIL", "None", "Cimetidine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["GABITRIL", "None", "cimetidine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["GABITRIL", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["GABITRIL", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["Cimetidine", "None", "cimetidine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["Cimetidine", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["Cimetidine", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["cimetidine", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["cimetidine", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "triple_list": [["tiagabine", "None", "tiagabine"]]}, {"text": "Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.", "triple_list": [["tiagabine", "None", "theophylline"]]}, {"text": "Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.", "triple_list": [["R-warfarin", "None", "S-warfarin"]]}, {"text": "Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.", "triple_list": [["R-warfarin", "None", "tiagabine"]]}, {"text": "Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.", "triple_list": [["S-warfarin", "None", "tiagabine"]]}, {"text": "Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.", "triple_list": [["tiagabine", "None", "digoxin"]]}, {"text": "Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.", "triple_list": [["tiagabine", "None", "digoxin"]]}, {"text": "Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.", "triple_list": [["triazolam", "None", "tiagabine"]]}, {"text": "Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.", "triple_list": [["ethanol", "None", "triazolam"]]}, {"text": "Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.", "triple_list": [["tiagabine", "None", "contraceptives"]]}, {"text": "Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.", "triple_list": [["Antipyrine", "None", "Antipyrine"]]}, {"text": "Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.", "triple_list": [["Antipyrine", "None", "tiagabine"]]}, {"text": "Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.", "triple_list": [["Antipyrine", "None", "tiagabine"]]}, {"text": "Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.", "triple_list": [["GABITRIL", "None", "tiagabine"]]}, {"text": "No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.", "triple_list": [["antibiotics", "None", "mesalamine"]]}, {"text": "Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.", "triple_list": [["antacids", "None", "lactulose"]]}, {"text": "Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.", "triple_list": [["lactulose", "None", "lactulose"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["isocarboxazid", "None", "phenelzine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["isocarboxazid", "None", "procarbazine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["isocarboxazid", "None", "selegiline"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["isocarboxazid", "None", "tranylcypromine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["isocarboxazid", "None", "L-tryptophan"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["phenelzine", "None", "procarbazine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["phenelzine", "None", "selegiline"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["phenelzine", "None", "tranylcypromine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["phenelzine", "None", "L-tryptophan"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["procarbazine", "None", "selegiline"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["procarbazine", "None", "tranylcypromine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["procarbazine", "None", "L-tryptophan"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["selegiline", "None", "tranylcypromine"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["selegiline", "None", "L-tryptophan"]]}, {"text": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "triple_list": [["tranylcypromine", "None", "L-tryptophan"]]}, {"text": "Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.", "triple_list": [["coumarin", "None", "coumarin anticoagulants"]]}, {"text": "Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.", "triple_list": [["ethotoin", "None", "coumarin anticoagulants"]]}, {"text": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "triple_list": [["CRM197", "None", "CRM197"]]}, {"text": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "triple_list": [["CRM197", "None", "doxorubicin"]]}, {"text": "In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n", "triple_list": [["minocycline", "None", "fosfomycin"]]}, {"text": "This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ", "triple_list": [["minocycline", "None", "fosfomycin"]]}, {"text": "The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. ", "triple_list": [["minocycline", "None", "fosfomycin"]]}, {"text": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "triple_list": [["myocardial depressants", "None", "calcium antagonists"]]}, {"text": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "triple_list": [["myocardial depressants", "None", "phenylalkylamine"]]}, {"text": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "triple_list": [["myocardial depressants", "None", "benzothiazepine"]]}, {"text": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "triple_list": [["calcium antagonists", "None", "phenylalkylamine"]]}, {"text": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "triple_list": [["calcium antagonists", "None", "benzothiazepine"]]}, {"text": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "triple_list": [["phenylalkylamine", "None", "benzothiazepine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "antibiotics"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "ampicillin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "anticonvulsants"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "antifungals"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "atorvastatin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "clofibrate"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["acetaminophen", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "ampicillin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "anticonvulsants"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "antifungals"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "atorvastatin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "clofibrate"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antibiotics", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "anticonvulsants"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "antifungals"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "atorvastatin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "clofibrate"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["ampicillin", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "antifungals"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "atorvastatin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "clofibrate"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["anticonvulsants", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "atorvastatin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "clofibrate"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["antifungals", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "clofibrate"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["atorvastatin", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["clofibrate", "None", "cyclosporine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["clofibrate", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["clofibrate", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["clofibrate", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["clofibrate", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["clofibrate", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["cyclosporine", "None", "protease inhibitors"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["cyclosporine", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["cyclosporine", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["cyclosporine", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["cyclosporine", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["protease inhibitors", "None", "morphine"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["protease inhibitors", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["protease inhibitors", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["protease inhibitors", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["morphine", "None", "prednisolone"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["morphine", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["morphine", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["prednisolone", "None", "rifadin"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["prednisolone", "None", "theophylline"]]}, {"text": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "triple_list": [["rifadin", "None", "theophylline"]]}, {"text": "No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. ", "triple_list": [["ELOXATIN", "None", "5-FU"]]}, {"text": "Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.", "triple_list": [["dopamine", "None", "dopamine"]]}, {"text": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "triple_list": [["MAO inhibitors", "None", "dopamine HCl"]]}, {"text": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "triple_list": [["dopamine HCl", "None", "dopamine HCl"]]}, {"text": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "triple_list": [["phenytoin", "None", "anticonvulsant"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "MAOI"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "Arecoline"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "MAOI"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "MAOI"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "Arecoline"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Monoamine oxidase inhibitors", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "MAOI"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Arecoline"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Arecoline"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["MAOI", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["flupenthixol", "None", "Arecoline"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["flupenthixol", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["flupenthixol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["flupenthixol", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["flupenthixol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Arecoline", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Arecoline", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Arecoline", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Arecoline", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Ethanol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Ethanol", "None", "Ethanol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Ethanol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Flupenthixol", "None", "Flupenthixol"]]}, {"text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "triple_list": [["Ethanol", "None", "Flupenthixol"]]}, {"text": "Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.", "triple_list": [["levamisole", "None", "warfarin sodium"]]}, {"text": "Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.", "triple_list": [["warfarin sodium", "None", "warfarin sodium"]]}, {"text": "The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.", "triple_list": [["bromocriptine mesylate", "None", "alcohol"]]}, {"text": "The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.", "triple_list": [["bromocriptine mesylate", "None", "bromocriptine mesylate"]]}, {"text": "Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants: Heparin sodium may prolong the one-stage prothrombin time.", "triple_list": [["Heparin", "None", "Heparin sodium"]]}, {"text": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.", "triple_list": [["Heparin", "None", "antihistamines"]]}, {"text": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "triple_list": [["aspirin", "None", "non-steroidal anti-inflammatory drugs"]]}, {"text": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "triple_list": [["aspirin", "None", "ginkgo"]]}, {"text": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "triple_list": [["non-steroidal anti-inflammatory drugs", "None", "ginkgo"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.", "triple_list": [["loracarbef", "None", "loracarbef"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.", "triple_list": [["probenecid", "None", "loracarbef"]]}, {"text": "In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ", "triple_list": [["methadone", "None", "methadone"]]}, {"text": "In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ", "triple_list": [["PEG-Intron", "None", "methadone"]]}, {"text": "In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["troleandomycin", "None", "cisapride"]]}, {"text": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["nefazodone", "None", "cisapride"]]}, {"text": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["ketoconazole", "None", "cisapride"]]}, {"text": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "triple_list": [["Cimetidine", "None", "cisapride"]]}, {"text": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "triple_list": [["cimetidine", "None", "ranitidine"]]}, {"text": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["indinavir", "None", "ritonavir"]]}, {"text": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["indinavir", "None", "cisapride"]]}, {"text": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["ritonavir", "None", "cisapride"]]}, {"text": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.", "triple_list": [["cisapride", "None", "cisapride"]]}, {"text": "The concomitant use of alcohol or other central nervous system depressants may have an additive effect.", "triple_list": [["alcohol", "None", "central nervous system depressants"]]}, {"text": "The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.", "triple_list": [["AMEVIVE", "None", "immunosuppressive"]]}, {"text": "Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).", "triple_list": [["AMEVIVE", "None", "AMEVIVE"]]}, {"text": "Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).", "triple_list": [["AMEVIVE", "None", "AMEVIVE"]]}, {"text": "Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).", "triple_list": [["AMEVIVE", "None", "AMEVIVE"]]}, {"text": "The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.\r\n", "triple_list": [["ketamine", "None", "Innovar"]]}, {"text": "The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.\r\n", "triple_list": [["ketamine", "None", "digitalis"]]}, {"text": "The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.\r\n", "triple_list": [["Innovar", "None", "digitalis"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["digitalis", "None", "ketamine"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["digitalis", "None", "ouabain"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["digitalis", "None", "ouabain"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["digitalis", "None", "ketamine"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["digitalis", "None", "Innovar"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ketamine", "None", "ouabain"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ketamine", "None", "ketamine"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ketamine", "None", "Innovar"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ouabain", "None", "ouabain"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ouabain", "None", "ketamine"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ouabain", "None", "Innovar"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ouabain", "None", "ketamine"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ouabain", "None", "Innovar"]]}, {"text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "triple_list": [["ketamine", "None", "Innovar"]]}, {"text": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "triple_list": [["ouabain", "None", "fentayl"]]}, {"text": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "triple_list": [["droperidol", "None", "fentayl"]]}, {"text": "May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).", "triple_list": [["beta-adrenergic blocking agents", "None", "adrenergic bronchodilators"]]}, {"text": "May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).", "triple_list": [["beta-adrenergic blocking agents", "None", "procainamide"]]}, {"text": "May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).", "triple_list": [["adrenergic bronchodilators", "None", "procainamide"]]}, {"text": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "triple_list": [["ketoconazole", "None", "troleandomycin"]]}, {"text": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "triple_list": [["ketoconazole", "None", "voriconazole"]]}, {"text": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "triple_list": [["troleandomycin", "None", "voriconazole"]]}, {"text": "Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR", "triple_list": [["warfarin", "None", "coumarin-derivative anticoagulants"]]}, {"text": "Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.", "triple_list": [["calcium", "None", "calcium"]]}, {"text": "Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.", "triple_list": [["calcium acetate", "None", "calcium"]]}, {"text": "Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.", "triple_list": [["digitalis glycosides", "None", "calcium"]]}, {"text": "Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.", "triple_list": [["cimetidine", "None", "mebendazole"]]}, {"text": "Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.", "triple_list": [["mebendazole", "None", "mebendazole"]]}, {"text": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "triple_list": [["decongestants", "None", "anesthetics"]]}, {"text": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "triple_list": [["decongestants", "None", "sympathomimetic amine"]]}, {"text": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "triple_list": [["anesthetics", "None", "sympathomimetic amine"]]}, {"text": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "triple_list": [["imipramine", "None", "imipramine"]]}, {"text": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "triple_list": [["Type 1C antiarrhythmics", "None", "propafenone"]]}, {"text": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.", "triple_list": [["SSRI", "None", "SSRI"]]}, {"text": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.", "triple_list": [["nitrates", "None", "L-arginine"]]}, {"text": "Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.", "triple_list": [["nitrates", "None", "nitrates"]]}, {"text": "Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.", "triple_list": [["Adrenergic blockers", "None", "Adrenergic blockers"]]}, {"text": "Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;", "triple_list": [["tricyclic", "None", "Amphetamines"]]}, {"text": "Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;", "triple_list": [["tricyclic", "None", "tricyclic"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "None", "d-amphetamine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["desipramine", "None", "protriptyline"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["desipramine", "None", "tricyclics"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["desipramine", "None", "d-amphetamine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["protriptyline", "None", "tricyclics"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["protriptyline", "None", "d-amphetamine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["tricyclics", "None", "d-amphetamine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "Chlorpromazine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "amphetamine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "amphetamine"]]}, {"text": "Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.", "triple_list": [["Haloperidol", "None", "Haloperidol"]]}, {"text": "Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.", "triple_list": [["amphetamines", "None", "methenamine"]]}, {"text": "Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.", "triple_list": [["acidifying agents", "None", "methenamine"]]}, {"text": "Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.", "triple_list": [["doxylamine", "None", "doxylamine"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["cyclosporin A", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["cyclosporin A", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["cyclosporin A", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["etoposide", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["etoposide", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["etoposide", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["etoposide", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["etoposide", "None", "etoposide"]]}, {"text": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "triple_list": [["etoposide", "None", "etoposide"]]}, {"text": "Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.", "triple_list": [["Aprepitant", "None", "digoxin"]]}, {"text": "Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.", "triple_list": [["Aprepitant", "None", "digoxin"]]}, {"text": "5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.", "triple_list": [["aprepitant", "None", "ondansetron"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["Aprepitant", "None", "dexamethasone"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["Aprepitant", "None", "dexamethasone"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["dexamethasone", "None", "Aprepitant"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["dexamethasone", "None", "dexamethasone"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["dexamethasone", "None", "dexamethasone"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["Aprepitant", "None", "dexamethasone"]]}, {"text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "triple_list": [["dexamethasone", "None", "dexamethasone"]]}, {"text": "The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.", "triple_list": [["dexamethasone", "None", "dexamethasone"]]}, {"text": "The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.", "triple_list": [["dexamethasone", "None", "dexamethasone"]]}, {"text": "The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.", "triple_list": [["Aprepitant", "None", "dexamethasone"]]}, {"text": "Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.", "triple_list": [["methylprednisolone", "None", "methylprednisolone"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "None", "methylprednisolone"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "None", "methylprednisolone"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "None", "Aprepitant"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "None", "methylprednisolone"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "None", "Aprepitant"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["Aprepitant", "None", "methylprednisolone"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "triple_list": [["methylprednisolone", "None", "Aprepitant"]]}, {"text": "Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.", "triple_list": [["Aprepitant", "None", "warfarin"]]}, {"text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "triple_list": [["Aprepitant", "None", "S(-) warfarin"]]}, {"text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "triple_list": [["Aprepitant", "None", "S(-)warfarin"]]}, {"text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "triple_list": [["S(-) warfarin", "None", "S(-)warfarin"]]}, {"text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "triple_list": [["S(-) warfarin", "None", "Aprepitant"]]}, {"text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "triple_list": [["Aprepitant", "None", "tolbutamide"]]}, {"text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "triple_list": [["Aprepitant", "None", "tolbutamide"]]}, {"text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "triple_list": [["tolbutamide", "None", "tolbutamide"]]}, {"text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "triple_list": [["tolbutamide", "None", "Aprepitant"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["contraceptive", "None", "ethinyl estradiol"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["contraceptive", "None", "norethindrone"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["contraceptive", "None", "ethinyl estradiol"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["contraceptive", "None", "norethindrone"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["ethinyl estradiol", "None", "norethindrone"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["ethinyl estradiol", "None", "ethinyl estradiol"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["ethinyl estradiol", "None", "norethindrone"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["norethindrone", "None", "ethinyl estradiol"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["norethindrone", "None", "norethindrone"]]}, {"text": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "triple_list": [["ethinyl estradiol", "None", "norethindrone"]]}, {"text": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "triple_list": [["Aprepitant", "None", "midazolam"]]}, {"text": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "triple_list": [["midazolam", "None", "midazolam"]]}, {"text": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.", "triple_list": [["midazolam", "None", "benzodiazepines"]]}, {"text": "In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "triple_list": [["midazolam", "None", "midazolam"]]}, {"text": "In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "triple_list": [["Aprepitant", "None", "midazolam"]]}, {"text": "In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "triple_list": [["midazolam", "None", "midazolam"]]}, {"text": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "triple_list": [["midazolam", "None", "Aprepitant"]]}, {"text": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "triple_list": [["aprepitant", "None", "Aprepitant"]]}, {"text": "Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.", "triple_list": [["Aprepitant", "None", "aprepitant"]]}, {"text": "Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.", "triple_list": [["Aprepitant", "None", "aprepitant"]]}, {"text": "Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.", "triple_list": [["aprepitant", "None", "aprepitant"]]}, {"text": "Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.", "triple_list": [["Aprepitant", "None", "aprepitant"]]}, {"text": "Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant.", "triple_list": [["Aprepitant", "None", "Aprepitant"]]}, {"text": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "triple_list": [["aprepitant", "None", "aprepitant"]]}, {"text": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "triple_list": [["aprepitant", "None", "diltiazem"]]}, {"text": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "triple_list": [["diltiazem", "None", "aprepitant"]]}, {"text": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "triple_list": [["diltiazem", "None", "diltiazem"]]}, {"text": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "triple_list": [["aprepitant", "None", "diltiazem"]]}, {"text": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "triple_list": [["aprepitant", "None", "aprepitant"]]}, {"text": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "triple_list": [["aprepitant", "None", "paroxetine"]]}, {"text": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "triple_list": [["paroxetine", "None", "aprepitant"]]}, {"text": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "triple_list": [["paroxetine", "None", "paroxetine"]]}, {"text": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "triple_list": [["aprepitant", "None", "paroxetine"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "triple_list": [["phenytoin", "None", "rifampin"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "triple_list": [["corticosteroids", "None", "corticosteroid"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "triple_list": [["troleandomycin", "None", "ketoconazole"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.", "triple_list": [["salicylate", "None", "salicylate"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.", "triple_list": [["salicylate", "None", "corticosteroid"]]}, {"text": "We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. ", "triple_list": [["estradiol", "None", "endotoxin"]]}, {"text": "We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. ", "triple_list": [["estradiol", "None", "endotoxin"]]}, {"text": "We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. ", "triple_list": [["endotoxin", "None", "endotoxin"]]}, {"text": "Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. ", "triple_list": [["estradiol", "None", "endotoxin"]]}, {"text": "Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. ", "triple_list": [["endotoxin", "None", "endotoxin"]]}, {"text": "These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.", "triple_list": [["estrogen", "None", "estrogens"]]}, {"text": "Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.", "triple_list": [["methotrexate", "None", "Kineret"]]}, {"text": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).", "triple_list": [["Kineret", "None", "etanercept"]]}, {"text": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).", "triple_list": [["etanercept", "None", "etanercept"]]}, {"text": "In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.", "triple_list": [["doxazosin mesylate", "None", "phenytoin"]]}, {"text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "triple_list": [["doxazosin", "None", "doxazosin"]]}, {"text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "triple_list": [["doxazosin", "None", "doxazosin"]]}, {"text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "triple_list": [["cimetidine", "None", "doxazosin"]]}, {"text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "triple_list": [["cimetidine", "None", "doxazosin"]]}, {"text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "triple_list": [["doxazosin", "None", "doxazosin"]]}, {"text": "Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).", "triple_list": [["codeine", "None", "codeine"]]}, {"text": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "triple_list": [["felodipine", "None", "felodipine"]]}, {"text": "These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).", "triple_list": [["itraconazole", "None", "CYP3A4"]]}, {"text": "The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.", "triple_list": [["felodipine", "None", "itraconazole"]]}, {"text": "The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.", "triple_list": [["felodipine", "None", "felodipine"]]}, {"text": "The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.", "triple_list": [["itraconazole", "None", "felodipine"]]}, {"text": "Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.", "triple_list": [["felodipine", "None", "erythromycin"]]}, {"text": "Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.", "triple_list": [["felodipine", "None", "felodipine"]]}, {"text": "Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.", "triple_list": [["erythromycin", "None", "felodipine"]]}, {"text": "Grapefruit juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.", "triple_list": [["felodipine", "None", "felodipine"]]}, {"text": "Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.", "triple_list": [["felodipine", "None", "cimetidine"]]}, {"text": "Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.", "triple_list": [["felodipine", "None", "felodipine"]]}, {"text": "Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.", "triple_list": [["cimetidine", "None", "felodipine"]]}, {"text": "Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.", "triple_list": [["felodipine", "None", "metoprolol"]]}, {"text": "Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.", "triple_list": [["felodipine", "None", "felodipine"]]}, {"text": "Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.", "triple_list": [["metoprolol", "None", "felodipine"]]}, {"text": "In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.", "triple_list": [["beta blockers", "None", "metoprolol"]]}, {"text": "In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.", "triple_list": [["beta blockers", "None", "felodipine"]]}, {"text": "In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.", "triple_list": [["metoprolol", "None", "felodipine"]]}, {"text": "Digoxin  When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.", "triple_list": [["PLENDIL", "None", "digoxin"]]}, {"text": "Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.", "triple_list": [["felodipine", "None", "indomethacin"]]}, {"text": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "triple_list": [["neuroleptics", "None", "thioxanthines"]]}, {"text": "Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.", "triple_list": [["pergolide mesylate", "None", "pergolide mesylate"]]}, {"text": "Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.", "triple_list": [["mercaptopurine", "None", "azathioprine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["mercaptopurine", "None", "azathioprine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["mercaptopurine", "None", "allopurinol"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["mercaptopurine", "None", "mercaptopurine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["mercaptopurine", "None", "azathioprine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["azathioprine", "None", "allopurinol"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["azathioprine", "None", "mercaptopurine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["azathioprine", "None", "azathioprine"]]}, {"text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "triple_list": [["mercaptopurine", "None", "azathioprine"]]}, {"text": "Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.", "triple_list": [["mercaptopurine", "None", "azathioprine"]]}, {"text": "The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.", "triple_list": [["allopurinol", "None", "dicumarol"]]}, {"text": "Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.", "triple_list": [["oxipurinol", "None", "oxipurinol"]]}, {"text": "The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.", "triple_list": [["uricosuric agents", "None", "allopurinol"]]}, {"text": "The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.", "triple_list": [["allopurinol", "None", "allopurinol"]]}, {"text": "Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "triple_list": [["allopurinol", "None", "allopurinol"]]}, {"text": "Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "triple_list": [["thiazide diuretics", "None", "allopurinol"]]}, {"text": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.", "triple_list": [["ampicillin", "None", "amoxicillin"]]}, {"text": "Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.", "triple_list": [["cyclophosphamide", "None", "cytotoxic agents"]]}, {"text": "However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.", "triple_list": [["allopurinol", "None", "procarbazine"]]}, {"text": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.", "triple_list": [["allopurinol", "None", "allopurinol"]]}, {"text": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.", "triple_list": [["allopurinol", "None", "chlorpropamide"]]}, {"text": "Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.", "triple_list": [["KEMSTROTM", "None", "baclofen"]]}, {"text": "Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. ", "triple_list": [["gentamicin", "None", "99mTc-MDP"]]}, {"text": "Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. ", "triple_list": [["gentamicin", "None", "radiopharmaceutical"]]}, {"text": "Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. ", "triple_list": [["99mTc-MDP", "None", "radiopharmaceutical"]]}, {"text": "The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.", "triple_list": [["gentamicin", "None", "gentamicin"]]}, {"text": "Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. ", "triple_list": [["INVEGA", "None", "Paliperidone"]]}, {"text": "Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ", "triple_list": [["INVEGA", "None", "Paliperidone"]]}, {"text": "We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.", "triple_list": [["antidepressant", "None", "warfarin"]]}, {"text": "In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "triple_list": [["citalopram", "None", "fluoxetine"]]}, {"text": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "triple_list": [["citalopram", "None", "paroxetine"]]}, {"text": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "triple_list": [["citalopram", "None", "amitriptyline"]]}, {"text": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "triple_list": [["fluoxetine", "None", "paroxetine"]]}, {"text": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "triple_list": [["fluoxetine", "None", "amitriptyline"]]}, {"text": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "triple_list": [["paroxetine", "None", "amitriptyline"]]}, {"text": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "triple_list": [["Natrecor", "None", "vasodilators"]]}, {"text": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "triple_list": [["Natrecor", "None", "ACE inhibitors"]]}, {"text": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "triple_list": [["Natrecor", "None", "Natrecor"]]}, {"text": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "triple_list": [["vasodilators", "None", "ACE inhibitors"]]}, {"text": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "triple_list": [["vasodilators", "None", "Natrecor"]]}, {"text": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "triple_list": [["ACE inhibitors", "None", "Natrecor"]]}, {"text": "Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).", "triple_list": [["flurbiprofen", "None", "antacid"]]}, {"text": "Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).", "triple_list": [["flurbiprofen", "None", "flurbiprofen"]]}, {"text": "Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).", "triple_list": [["antacid", "None", "flurbiprofen"]]}, {"text": "Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.", "triple_list": [["aspirin", "None", "flurbiprofen"]]}, {"text": "Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.", "triple_list": [["flurbiprofen", "None", "flurbiprofen"]]}, {"text": "This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).", "triple_list": [["aspirin", "None", "nonsteroidal anti-inflammatory drugs"]]}, {"text": "Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).", "triple_list": [["flurbiprofen", "None", "propranolol"]]}, {"text": "Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).", "triple_list": [["flurbiprofen", "None", "atenolol"]]}, {"text": "Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).", "triple_list": [["propranolol", "None", "atenolol"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["cimetidine", "None", "ranitidine"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["cimetidine", "None", "flurbiprofen"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["cimetidine", "None", "flurbiprofen"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["cimetidine", "None", "cimetidine"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["ranitidine", "None", "flurbiprofen"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["ranitidine", "None", "flurbiprofen"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["ranitidine", "None", "cimetidine"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["flurbiprofen", "None", "flurbiprofen"]]}, {"text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "triple_list": [["flurbiprofen", "None", "cimetidine"]]}, {"text": "Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.", "triple_list": [["flurbiprofen", "None", "digoxin"]]}, {"text": "Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.", "triple_list": [["furosemide", "None", "diuretics"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["flurbiprofen", "None", "glyburide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["flurbiprofen", "None", "metformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["flurbiprofen", "None", "chlorpropamide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["flurbiprofen", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["flurbiprofen", "None", "glyburide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["flurbiprofen", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["glyburide", "None", "metformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["glyburide", "None", "chlorpropamide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["glyburide", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["glyburide", "None", "glyburide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["glyburide", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["metformin", "None", "chlorpropamide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["metformin", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["metformin", "None", "glyburide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["metformin", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["chlorpropamide", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["chlorpropamide", "None", "glyburide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["chlorpropamide", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["phenformin", "None", "glyburide"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["phenformin", "None", "phenformin"]]}, {"text": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "triple_list": [["glyburide", "None", "phenformin"]]}, {"text": "Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.\r\n", "triple_list": [["rofecoxib", "None", "digoxin"]]}, {"text": "Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. ", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ", "triple_list": [["rofecoxib", "None", "digoxin"]]}, {"text": "The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ", "triple_list": [["rofecoxib", "None", "digoxin"]]}, {"text": "The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. ", "triple_list": [["digoxin", "None", "rofecoxib"]]}, {"text": "Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.", "triple_list": [["etretinate", "None", "acitretin"]]}, {"text": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.", "triple_list": [["acitretin", "None", "sulfonylurea"]]}, {"text": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.", "triple_list": [["glibenclamide", "None", "sulfonylurea"]]}, {"text": "Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.", "triple_list": [["glibenclamide", "None", "acitretin"]]}, {"text": "Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.", "triple_list": [["acitretin", "None", "phenytoin"]]}, {"text": "Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "triple_list": [["retinoids", "None", "vitamin A"]]}, {"text": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "triple_list": [["retinoids", "None", "retinoids"]]}, {"text": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "triple_list": [["retinoids", "None", "acitretin"]]}, {"text": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "triple_list": [["vitamin A", "None", "retinoids"]]}, {"text": "Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.", "triple_list": [["acitretin", "None", "anticoagulants of the coumarin type"]]}, {"text": "ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ", "triple_list": [["SALICYLATE DRUGS", "None", "SALICYLIC ACID"]]}, {"text": "ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ", "triple_list": [["DISALCID", "None", "SALICYLIC ACID"]]}, {"text": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. ", "triple_list": [["immunosuppressants", "None", "sirolimus"]]}, {"text": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. ", "triple_list": [["immunosuppressants", "None", "cyclosporine"]]}, {"text": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. ", "triple_list": [["sirolimus", "None", "cyclosporine"]]}, {"text": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "triple_list": [["cyclosporine", "None", "tacrolimus"]]}, {"text": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "triple_list": [["cyclosporine", "None", "tacrolimus"]]}, {"text": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "triple_list": [["tacrolimus", "None", "cyclosporine"]]}, {"text": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "triple_list": [["tacrolimus", "None", "tacrolimus"]]}, {"text": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "triple_list": [["cyclosporine", "None", "tacrolimus"]]}, {"text": "Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.", "triple_list": [["L-glutamine", "None", "indomethacin"]]}, {"text": "Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.", "triple_list": [["indomethacin", "None", "indomethacin"]]}, {"text": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "triple_list": [["candesartan cilexetil", "None", "contraceptives"]]}, {"text": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "triple_list": [["candesartan cilexetil", "None", "enalapril"]]}, {"text": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "triple_list": [["contraceptives", "None", "enalapril"]]}, {"text": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "cyclosporine"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "sulfonylurea agents"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "warfarin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "sulfonylurea agents"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "warfarin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "warfarin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. ", "triple_list": [["hypotensive agents", "None", "phenothiazines"]]}, {"text": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "triple_list": [["tricyclic antidepressant", "None", "tyramine"]]}, {"text": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "triple_list": [["CMI", "None", "tricyclic antidepressants"]]}, {"text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "triple_list": [["tricyclic antidepressants", "None", "CMI"]]}, {"text": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "triple_list": [["Type 1C antiarrhythmics", "None", "propafenone"]]}, {"text": "The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "triple_list": [["SSRI", "None", "SSRI"]]}, {"text": "Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.", "triple_list": [["tricyclic antidepressant class", "None", "tricyclic antidepressant agent"]]}, {"text": "It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).", "triple_list": [["tricyclic antidepressant class", "None", "Anafranil"]]}, {"text": "Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.", "triple_list": [["Anafranil", "None", "Anafranil"]]}, {"text": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. ", "triple_list": [["1,25(OH)2D3", "None", "antiestrogen"]]}, {"text": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. ", "triple_list": [["1,25(OH)2D3", "None", "4-hydroxytamoxifen"]]}, {"text": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. ", "triple_list": [["antiestrogen", "None", "4-hydroxytamoxifen"]]}, {"text": "It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.", "triple_list": [["amantadine", "None", "anticholinergic drugs"]]}, {"text": "Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.", "triple_list": [["ABILIFY", "None", "Aripiprazole"]]}, {"text": "Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.", "triple_list": [["ketoconazole", "None", "aripiprazole"]]}, {"text": "Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.", "triple_list": [["aripiprazole", "None", "aripiprazole"]]}, {"text": "When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.", "triple_list": [["ketoconazole", "None", "aripiprazole"]]}, {"text": "When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.", "triple_list": [["aripiprazole", "None", "aripiprazole"]]}, {"text": "Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.", "triple_list": [["aripiprazole", "None", "aripiprazole"]]}, {"text": "Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.", "triple_list": [["quinidine", "None", "aripiprazole"]]}, {"text": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.", "triple_list": [["carbamazepine", "None", "aripiprazole"]]}, {"text": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.", "triple_list": [["aripiprazole", "None", "aripiprazole"]]}, {"text": "When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.", "triple_list": [["carbamazepine", "None", "aripiprazole"]]}, {"text": "When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.", "triple_list": [["aripiprazole", "None", "aripiprazole"]]}, {"text": "No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).", "triple_list": [["lithium", "None", "aripiprazole"]]}, {"text": "Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.", "triple_list": [["ABILIFY", "None", "Aripiprazole"]]}, {"text": "Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.", "triple_list": [["aripiprazole", "None", "dehydroaripiprazole"]]}, {"text": "Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.", "triple_list": [["aripiprazole", "None", "ethanol"]]}, {"text": "Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.", "triple_list": [["aripiprazole", "None", "ethanol"]]}, {"text": "Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ", "triple_list": [["heparinase III", "None", "chondroitin ABC lyase"]]}, {"text": "Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. ", "triple_list": [["heparinase III", "None", "chondroitin ABC lyase"]]}, {"text": "Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.", "triple_list": [["corticosteroid", "None", "ACTH"]]}, {"text": "Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.", "triple_list": [["Betaseron", "None", "Betaseron"]]}, {"text": "Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.", "triple_list": [["antipyrine", "None", "Betaseron"]]}, {"text": "Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ", "triple_list": [["Cholestyramine", "None", "Cholestyramine"]]}, {"text": "Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ", "triple_list": [["Cholestyramine", "None", "raloxifene"]]}, {"text": "Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ", "triple_list": [["EVISTA", "None", "warfarin"]]}, {"text": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "triple_list": [["diflunisal", "None", "tolbutamide"]]}, {"text": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "triple_list": [["diflunisal", "None", "tolbutamide"]]}, {"text": "Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.", "triple_list": [["tolbutamide", "None", "tolbutamide"]]}, {"text": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "triple_list": [["diflunisal", "None", "hydrochlorothiazide"]]}, {"text": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "triple_list": [["hydrochlorothiazide", "None", "hydrochlorothiazide"]]}, {"text": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "triple_list": [["diflunisal", "None", "furosemide"]]}, {"text": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "triple_list": [["diflunisal", "None", "furosemide"]]}, {"text": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "triple_list": [["furosemide", "None", "furosemide"]]}, {"text": "This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.", "triple_list": [["antacids", "None", "antacids"]]}, {"text": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "triple_list": [["diflunisal", "None", "acetaminophen"]]}, {"text": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "triple_list": [["acetaminophen", "None", "acetaminophen"]]}, {"text": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "triple_list": [["acetaminophen", "None", "diflunisal"]]}, {"text": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "triple_list": [["acetaminophen", "None", "acetaminophen"]]}, {"text": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "triple_list": [["diflunisal", "None", "diflunisal"]]}, {"text": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "triple_list": [["diflunisal", "None", "acetaminophen"]]}, {"text": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "triple_list": [["acetaminophen", "None", "diflunisal"]]}, {"text": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "triple_list": [["acetaminophen", "None", "acetaminophen"]]}, {"text": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "triple_list": [["diflunisal", "None", "acetaminophen"]]}, {"text": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "triple_list": [["nonsteroial anti-inflammatory drugs", "None", "cyclosporine"]]}, {"text": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "triple_list": [["diflunisal", "None", "indomethacin"]]}, {"text": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "triple_list": [["indomethacin", "None", "indomethacin"]]}, {"text": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "triple_list": [["diflunisal", "None", "diflunisal"]]}, {"text": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "triple_list": [["diflunisal", "None", "aspirin"]]}, {"text": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "triple_list": [["diflunisal", "None", "naproxen"]]}, {"text": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "triple_list": [["diflunisal", "None", "naproxen"]]}, {"text": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "triple_list": [["naproxen", "None", "naproxen"]]}, {"text": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "triple_list": [["naproxen", "None", "naproxen"]]}, {"text": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "triple_list": [["naproxen", "None", "naproxen"]]}, {"text": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "triple_list": [["rifampin", "None", "warfarin"]]}, {"text": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "triple_list": [["rifampin", "None", "rifampin"]]}, {"text": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "triple_list": [["rifampin", "None", "rifampin"]]}, {"text": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "triple_list": [["warfarin", "None", "rifampin"]]}, {"text": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "triple_list": [["warfarin", "None", "rifampin"]]}, {"text": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "triple_list": [["rifampin", "None", "rifampin"]]}, {"text": "ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.", "triple_list": [["anesthetics", "None", "halothane"]]}, {"text": "Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.", "triple_list": [["colestipol hydrochloride", "None", "propranolol"]]}, {"text": "Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;", "triple_list": [["colestipol hydrochloride", "None", "propranolol"]]}, {"text": "However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;", "triple_list": [["colestipol hydrochloride", "None", "propranolol"]]}, {"text": "However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "triple_list": [["colestipol hydrochloride", "None", "nicotinic acid"]]}, {"text": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "triple_list": [["colestipol hydrochloride", "None", "phenytoin"]]}, {"text": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "triple_list": [["nicotinic acid", "None", "phenytoin"]]}, {"text": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "triple_list": [["digitalis preparations", "None", "digoxin"]]}, {"text": "Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.", "triple_list": [["colestipol hydrochloride", "None", "resin"]]}, {"text": "Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.", "triple_list": [["colestipol hydrochloride", "None", "colestipol hydrochloride"]]}, {"text": "Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.", "triple_list": [["resin", "None", "colestipol hydrochloride"]]}, {"text": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "triple_list": [["H2-antagonists", "None", "proton pump inhibitors"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["abacavir", "None", "lamivudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["abacavir", "None", "zidovudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["abacavir", "None", "lamivudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["abacavir", "None", "zidovudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["lamivudine", "None", "zidovudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["lamivudine", "None", "lamivudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["lamivudine", "None", "zidovudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["zidovudine", "None", "lamivudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["zidovudine", "None", "zidovudine"]]}, {"text": "Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ", "triple_list": [["lamivudine", "None", "zidovudine"]]}, {"text": "No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ", "triple_list": [["lamivudine", "None", "zidovudine"]]}, {"text": "Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ", "triple_list": [["abacavir", "None", "methadone"]]}, {"text": "Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ", "triple_list": [["abacavir", "None", "abacavir"]]}, {"text": "Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ", "triple_list": [["methadone", "None", "abacavir"]]}, {"text": "In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ", "triple_list": [["methadone", "None", "methadone"]]}, {"text": "In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ", "triple_list": [["ZIAGEN", "None", "methadone"]]}, {"text": "Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.", "triple_list": [["quinolones", "None", "norfloxacin"]]}, {"text": "Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.", "triple_list": [["norfloxacin", "None", "probenecid"]]}, {"text": "Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.", "triple_list": [["norfloxacin", "None", "norfloxacin"]]}, {"text": "The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.", "triple_list": [["nitrofurantoin", "None", "nitrofurantoin"]]}, {"text": "The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.", "triple_list": [["nitrofurantoin", "None", "Norfloxacin"]]}, {"text": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "triple_list": [["iron", "None", "antacids"]]}, {"text": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "triple_list": [["iron", "None", "sucralfate"]]}, {"text": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "triple_list": [["antacids", "None", "sucralfate"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalapril", "None", "enalaprilat"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalapril", "None", "enalapril"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalapril", "None", "enalaprilat"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalaprilat", "None", "enalapril"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalaprilat", "None", "enalaprilat"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["diuretic", "None", "enalapril"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["diuretic", "None", "enalaprilat"]]}, {"text": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "triple_list": [["enalapril", "None", "enalaprilat"]]}, {"text": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "triple_list": [["enalapril", "None", "enalapril"]]}, {"text": "In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.", "triple_list": [["indomethacin", "None", "sulindac"]]}, {"text": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["Enalapril", "None", "enalapril"]]}, {"text": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["Enalapril", "None", "prazosin"]]}, {"text": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["Enalapril", "None", "digoxin"]]}, {"text": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["enalapril", "None", "prazosin"]]}, {"text": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["enalapril", "None", "digoxin"]]}, {"text": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "triple_list": [["prazosin", "None", "digoxin"]]}, {"text": "Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.", "triple_list": [["Enalapril", "None", "enalapril"]]}, {"text": "Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "triple_list": [["potassium", "None", "potassium"]]}, {"text": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "triple_list": [["Lithium", "None", "Lithium"]]}, {"text": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "triple_list": [["Lithium", "None", "lithium"]]}, {"text": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "triple_list": [["Lithium", "None", "lithium"]]}, {"text": "It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.", "triple_list": [["lithium", "None", "enalapril"]]}, {"text": "It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin", "triple_list": [["Vitamin B2", "None", "Alcohol"]]}, {"text": "Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.", "triple_list": [["aminoglycoside antibiotics", "None", "diuretics"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "None", "coumarin-type anticoagulants"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "None", "FELDENE"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "None", "FELDENE"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "None", "coumarin-type anticoagulants"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "None", "FELDENE"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["coumarin-type anticoagulants", "None", "coumarin-type anticoagulants"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["FELDENE", "None", "FELDENE"]]}, {"text": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "triple_list": [["FELDENE", "None", "coumarin-type anticoagulants"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "FELDENE"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "aspirin"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "antacids"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "piroxicam"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "FELDENE"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "lithium"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["FELDENE", "None", "antacids"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["FELDENE", "None", "piroxicam"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["FELDENE", "None", "FELDENE"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["FELDENE", "None", "lithium"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["aspirin", "None", "antacids"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["aspirin", "None", "piroxicam"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["aspirin", "None", "FELDENE"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["aspirin", "None", "lithium"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["antacids", "None", "piroxicam"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["antacids", "None", "FELDENE"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["antacids", "None", "lithium"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "FELDENE"]]}, {"text": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "triple_list": [["piroxicam", "None", "lithium"]]}, {"text": "Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.", "triple_list": [["COPAXONE", "None", "corticosteroids"]]}, {"text": "However, 10 patients who switched from therapy with Interferon beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment.", "triple_list": [["Interferon beta", "None", "COPAXONE"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Keppra", "None", "Antiepileptic Drugs"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Keppra", "None", "Phenytoin"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Keppra", "None", "Keppra"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Keppra", "None", "phenytoin"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Antiepileptic Drugs", "None", "Phenytoin"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Antiepileptic Drugs", "None", "Keppra"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Antiepileptic Drugs", "None", "phenytoin"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Phenytoin", "None", "Keppra"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Phenytoin", "None", "phenytoin"]]}, {"text": "Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.", "triple_list": [["Keppra", "None", "phenytoin"]]}, {"text": "Valproate Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.", "triple_list": [["Keppra", "None", "valproate"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["Keppra", "None", "AEDs"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["Keppra", "None", "primidone"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["Keppra", "None", "levetiracetam"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["Keppra", "None", "AEDs"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["AEDs", "None", "primidone"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["AEDs", "None", "levetiracetam"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["AEDs", "None", "AEDs"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["primidone", "None", "levetiracetam"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["primidone", "None", "AEDs"]]}, {"text": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "triple_list": [["levetiracetam", "None", "AEDs"]]}, {"text": "These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.", "triple_list": [["levetiracetam", "None", "AEDs"]]}, {"text": "These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.", "triple_list": [["levetiracetam", "None", "AEDs"]]}, {"text": "These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.", "triple_list": [["levetiracetam", "None", "levetiracetam"]]}, {"text": "These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.", "triple_list": [["AEDs", "None", "AEDs"]]}, {"text": "These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.", "triple_list": [["AEDs", "None", "levetiracetam"]]}, {"text": "These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.", "triple_list": [["AEDs", "None", "levetiracetam"]]}, {"text": "Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.", "triple_list": [["AEDs", "None", "levetiracetam"]]}, {"text": "Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.", "triple_list": [["AEDs", "None", "AEDs"]]}, {"text": "Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.", "triple_list": [["Contraceptives", "None", "Keppra"]]}, {"text": "Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.", "triple_list": [["Contraceptives", "None", "contraceptive"]]}, {"text": "Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.", "triple_list": [["Contraceptives", "None", "ethinyl estradiol"]]}, {"text": "Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.", "triple_list": [["Keppra", "None", "contraceptive"]]}, {"text": "Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.", "triple_list": [["Keppra", "None", "ethinyl estradiol"]]}, {"text": "Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.", "triple_list": [["contraceptive", "None", "ethinyl estradiol"]]}, {"text": "Digoxin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.", "triple_list": [["Keppra", "None", "digoxin"]]}, {"text": "The effect of Keppra  on probenecid was not studied.", "triple_list": [["Keppra", "None", "probenecid"]]}, {"text": "Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ", "triple_list": [["disulfiram", "None", "ethanol"]]}, {"text": "The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol. ", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "triple_list": [["finasteride", "None", "prostaglandin synthetase inhibitors"]]}, {"text": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "triple_list": [["finasteride", "None", "quinolone anti-infectives"]]}, {"text": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "triple_list": [["prostaglandin synthetase inhibitors", "None", "quinolone anti-infectives"]]}, {"text": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "triple_list": [["clopidogrel", "None", "prasugrel"]]}, {"text": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.", "triple_list": [["celecoxib", "None", "warfarin"]]}, {"text": "Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["furosemide", "None", "thiazides"]]}, {"text": "However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.", "triple_list": [["aspirin", "None", "CELEBREX"]]}, {"text": "However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.", "triple_list": [["CELEBREX", "None", "CELEBREX"]]}, {"text": "Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.", "triple_list": [["CELEBREX", "None", "aspirin"]]}, {"text": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "triple_list": [["lithium", "None", "CELEBREX"]]}, {"text": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "triple_list": [["CELEBREX", "None", "lithium"]]}, {"text": "Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.", "triple_list": [["celecoxib", "None", "warfarin"]]}, {"text": "Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.", "triple_list": [["celecoxib", "None", "warfarin"]]}, {"text": "Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.", "triple_list": [["celecoxib", "None", "warfarin"]]}, {"text": "In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.", "triple_list": [["labetalol HCl", "None", "labetalol HCl"]]}, {"text": "In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.", "triple_list": [["tricyclic antidepressants", "None", "labetalol HCl"]]}, {"text": "During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.", "triple_list": [["labetalol HCl", "None", "halothane"]]}, {"text": "During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.", "triple_list": [["halothane", "None", "halothane"]]}, {"text": "Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.", "triple_list": [["labetalol", "None", "verapamil"]]}, {"text": "When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.", "triple_list": [["labetalol", "None", "amphetamine"]]}, {"text": "Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.", "triple_list": [["Lapatinib", "None", "Lapatinib"]]}, {"text": "Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.", "triple_list": [["Lapatinib", "None", "lapatinib"]]}, {"text": "If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.", "triple_list": [["TYKERB", "None", "lapatinib"]]}, {"text": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "triple_list": [["lapatinib", "None", "capecitabine"]]}, {"text": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "triple_list": [["lapatinib", "None", "capecitabine"]]}, {"text": "Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).", "triple_list": [["capecitabine", "None", "capecitabine"]]}, {"text": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "triple_list": [["SSRI antidepressants", "None", "paroxetine"]]}, {"text": "Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. ", "triple_list": [["antidepressant drug", "None", "antidepressants"]]}, {"text": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "triple_list": [["methotrexate", "None", "L-methionine"]]}, {"text": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "triple_list": [["methotrexate", "None", "acetaminophen"]]}, {"text": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "triple_list": [["acetaminophen", "None", "methotrexate"]]}, {"text": "Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.", "triple_list": [["nelfinavir", "None", "azithromycin"]]}, {"text": "Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.", "triple_list": [["azithromycin", "None", "azithromycin"]]}, {"text": "Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.", "triple_list": [["azithromycin", "None", "azithromycin"]]}, {"text": "Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.", "triple_list": [["efavirenz", "None", "fluconazole"]]}, {"text": "Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.", "triple_list": [["azithromycin", "None", "Digoxin"]]}, {"text": "Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.", "triple_list": [["azithromycin", "None", "digoxin"]]}, {"text": "Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.", "triple_list": [["Digoxin", "None", "digoxin"]]}, {"text": "Cyclosporine, hexobarbital and phenytoin concentrations.", "triple_list": [["hexobarbital", "None", "phenytoin"]]}, {"text": "Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.", "triple_list": [["piperacillin", "None", "aminoglycoside"]]}, {"text": "Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.", "triple_list": [["aminoglycoside", "None", "aminoglycoside"]]}, {"text": "Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.", "triple_list": [["probenecid", "None", "piperacillin"]]}, {"text": "Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.", "triple_list": [["PIPRACIL", "None", "piperacillin"]]}, {"text": "[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].\r\n", "triple_list": [["hemantane", "None", "doxycycline"]]}, {"text": "The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ", "triple_list": [["anti-parkinsonian drug", "None", "hemantane"]]}, {"text": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "triple_list": [["antibiotic drug", "None", "doxycycline"]]}, {"text": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "triple_list": [["antibiotic drug", "None", "1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"]]}, {"text": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "triple_list": [["doxycycline", "None", "1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"]]}, {"text": "Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.", "triple_list": [["astemizole", "None", "cisapride"]]}, {"text": "Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.", "triple_list": [["fluvoxamine", "None", "fluvoxamine"]]}, {"text": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "triple_list": [["Benzodiazepines", "None", "Benzodiazepines"]]}, {"text": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "triple_list": [["Benzodiazepines", "None", "triazolam"]]}, {"text": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "triple_list": [["Benzodiazepines", "None", "triazolam"]]}, {"text": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "triple_list": [["fluvoxamine maleate", "None", "alprazolam"]]}, {"text": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "triple_list": [["fluvoxamine maleate", "None", "alprazolam"]]}, {"text": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "fluvoxamine"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "Fluvoxamine"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "Fluvoxamine"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["fluvoxamine", "None", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["alprazolam", "None", "alprazolam"]]}, {"text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "triple_list": [["Fluvoxamine", "None", "alprazolam"]]}, {"text": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "triple_list": [["fluvoxamine", "None", "fluvoxamine"]]}, {"text": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "triple_list": [["fluvoxamine", "None", "diazepam"]]}, {"text": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "triple_list": [["diazepam", "None", "fluvoxamine"]]}, {"text": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "triple_list": [["diazepam", "None", "diazepam"]]}, {"text": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "triple_list": [["fluvoxamine", "None", "diazepam"]]}, {"text": "In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.", "triple_list": [["diazepam", "None", "N-desmethyldiazepam"]]}, {"text": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "triple_list": [["Theophylline", "None", "fluvoxamine"]]}, {"text": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "triple_list": [["Theophylline", "None", "Theophylline"]]}, {"text": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "triple_list": [["Theophylline", "None", "aminophylline"]]}, {"text": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "triple_list": [["fluvoxamine", "None", "Theophylline"]]}, {"text": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "triple_list": [["fluvoxamine", "None", "aminophylline"]]}, {"text": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "triple_list": [["Theophylline", "None", "aminophylline"]]}, {"text": "Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.", "triple_list": [["fluvoxamine maleate", "None", "warfarin"]]}, {"text": "Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.", "triple_list": [["anticoagulants", "None", "anticoagulant"]]}, {"text": "Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.", "triple_list": [["Fluvoxamine", "None", "anticoagulant"]]}, {"text": "Thus, if a patient has been titrated to a stable dosage of EQUETROTM, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.", "triple_list": [["EQUETROTM", "None", "EQUETROTM"]]}, {"text": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "triple_list": [["EQUETROTM", "None", "EQUETROTM"]]}, {"text": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "triple_list": [["EQUETROTM", "None", "EQUETROTM"]]}, {"text": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "triple_list": [["theophylline", "None", "EQUETROTM"]]}, {"text": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "triple_list": [["theophylline", "None", "EQUETROTM"]]}, {"text": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "triple_list": [["EQUETROTM", "None", "EQUETROTM"]]}, {"text": "Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4.", "triple_list": [["Carbamazepine", "None", "Carbamazepine"]]}, {"text": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "triple_list": [["EQUETROTM", "None", "EQUETROTM"]]}, {"text": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "triple_list": [["primidone", "None", "EQUETROTM"]]}, {"text": "Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.", "triple_list": [["Carbamazepine", "None", "carbamazepine"]]}, {"text": "Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.", "triple_list": [["Carbamazepine", "None", "lithium"]]}, {"text": "In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.", "triple_list": [["desloratadine", "None", "erythromycin"]]}, {"text": "In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.", "triple_list": [["desloratadine", "None", "ketoconazole"]]}, {"text": "In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.", "triple_list": [["erythromycin", "None", "ketoconazole"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["desloratadine", "None", "azithromycin"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["desloratadine", "None", "fluoxetine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["desloratadine", "None", "fluoxetine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["desloratadine", "None", "cimetidine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["azithromycin", "None", "fluoxetine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["azithromycin", "None", "fluoxetine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["azithromycin", "None", "cimetidine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["fluoxetine", "None", "fluoxetine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["fluoxetine", "None", "cimetidine"]]}, {"text": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "triple_list": [["fluoxetine", "None", "cimetidine"]]}, {"text": "Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.", "triple_list": [["desloratadine", "None", "3-hydroxydesloratadine"]]}, {"text": "Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.", "triple_list": [["desloratadine", "None", "desloratadine"]]}, {"text": "Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.", "triple_list": [["3-hydroxydesloratadine", "None", "desloratadine"]]}, {"text": "Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers", "triple_list": [["Desloratadine", "None", "3-Hydroxydesloratadine"]]}, {"text": "Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products). ", "triple_list": [["alcohol", "None", "nicotine"]]}, {"text": "The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. ", "triple_list": [["alcohol", "None", "nicotine"]]}, {"text": "Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.", "triple_list": [["Desmopressin", "None", "Desmopressin"]]}, {"text": "Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.", "triple_list": [["Sensipar", "None", "Sensipar"]]}, {"text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "triple_list": [["cinacalcet", "None", "amitriptyline"]]}, {"text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "triple_list": [["cinacalcet", "None", "nortriptyline"]]}, {"text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "triple_list": [["amitriptyline", "None", "amitriptyline"]]}, {"text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "triple_list": [["amitriptyline", "None", "nortriptyline"]]}, {"text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "triple_list": [["amitriptyline", "None", "nortriptyline"]]}, {"text": "Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.", "triple_list": [["Sensipar", "None", "Sensipar"]]}, {"text": "Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.", "triple_list": [["cinacalcet", "None", "Sensipar"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "CNS depressants"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "anticholinergics"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["alcohol", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "anticholinergics"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["CNS depressants", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "anticholinergics"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["anticholinergics", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "monoamine oxidase (MAO) inhibitors"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["monoamine oxidase (MAO) inhibitors", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["monoamine oxidase (MAO) inhibitors", "None", "antihistamines"]]}, {"text": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "triple_list": [["antihistamines", "None", "antihistamines"]]}, {"text": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "triple_list": [["Probenecid", "None", "Probenecid"]]}, {"text": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "triple_list": [["Probenecid", "None", "nonsteroidal anti-inflammatory"]]}, {"text": "Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.", "triple_list": [["probenecid", "None", "VISTIDE"]]}, {"text": "Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). ", "triple_list": [["atracurium", "None", "atracurium"]]}, {"text": "Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). ", "triple_list": [["atracurium", "None", "gentamycin"]]}, {"text": "Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. ", "triple_list": [["atracurium", "None", "atracurium"]]}, {"text": "At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. ", "triple_list": [["atracurium", "None", "atracurium"]]}, {"text": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "triple_list": [["central nervous system depressants", "None", "skeletal muscle relaxants"]]}, {"text": "Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.", "triple_list": [["MAO inhibitors", "None", "Levo-Dromoran"]]}, {"text": "Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.", "triple_list": [["MAO inhibitors", "None", "MAO inhibitors"]]}, {"text": "Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.", "triple_list": [["Levo-Dromoran", "None", "levorphanol"]]}, {"text": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "triple_list": [["Agonist/antagonist analgesics", "None", "dezocine"]]}, {"text": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "triple_list": [["Agonist/antagonist analgesics", "None", "pure agonist opioid analgesic"]]}, {"text": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "triple_list": [["dezocine", "None", "pure agonist opioid analgesic"]]}, {"text": "Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.", "triple_list": [["Diuretic", "None", "diuretics"]]}, {"text": "Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.", "triple_list": [["Diuretic", "None", "diuretic"]]}, {"text": "Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.", "triple_list": [["diuretics", "None", "diuretic"]]}, {"text": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "triple_list": [["captopril", "None", "captopril"]]}, {"text": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "triple_list": [["captopril", "None", "captopril"]]}, {"text": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "triple_list": [["diuretic", "None", "captopril"]]}, {"text": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "triple_list": [["diuretic", "None", "captopril"]]}, {"text": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "triple_list": [["captopril", "None", "captopril"]]}, {"text": "Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;", "triple_list": [["vasodilators", "None", "captopril"]]}, {"text": "therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.", "triple_list": [["nitroglycerin", "None", "nitrates"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "triple_list": [["lithium", "None", "ACE inhibitor"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "triple_list": [["lithium", "None", "ACE inhibitor"]]}, {"text": "Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.", "triple_list": [["Furosemide", "None", "captopril"]]}, {"text": "Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.", "triple_list": [["Furosemide", "None", "captopril"]]}, {"text": "Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.", "triple_list": [["captopril", "None", "captopril"]]}, {"text": "Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.", "triple_list": [["captopril", "None", "allopurinol"]]}, {"text": "Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.", "triple_list": [["REVLIMID", "None", "lenalidomide"]]}, {"text": "Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.", "triple_list": [["REVLIMID", "None", "lenalidomide"]]}, {"text": "Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.", "triple_list": [["lenalidomide", "None", "lenalidomide"]]}, {"text": "Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.", "triple_list": [["warfarin", "None", "lenalidomide"]]}, {"text": "Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ", "triple_list": [["HDAC Inhibitors", "None", "ZOLINZA"]]}, {"text": "Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ", "triple_list": [["HDAC Inhibitors", "None", "HDAC inhibitors"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "NSAIDs"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "fluvoxamine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "beta blockers"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["aspirin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "fluvoxamine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "beta blockers"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["NSAIDs", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "fluvoxamine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "beta blockers"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "beta blockers"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluvoxamine", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "beta blockers"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["beta blockers", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "fluoxetine"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["fluoxetine", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "progestin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "benzodiazepenes"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["progestin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["benzodiazepenes", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["benzodiazepenes", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["benzodiazepenes", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["benzodiazepenes", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["corticosteroids", "None", "melatonin"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["corticosteroids", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["corticosteroids", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["melatonin", "None", "corticosteroids"]]}, {"text": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "triple_list": [["corticosteroids", "None", "corticosteroids"]]}, {"text": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "triple_list": [["sodium carboxymethylcellulose", "None", "carboxymethylcellulose-cysteine"]]}, {"text": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "triple_list": [["sodium carboxymethylcellulose", "None", "sodium fluorescein"]]}, {"text": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "triple_list": [["sodium carboxymethylcellulose", "None", "bacitracin"]]}, {"text": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "triple_list": [["carboxymethylcellulose-cysteine", "None", "sodium fluorescein"]]}, {"text": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "triple_list": [["carboxymethylcellulose-cysteine", "None", "bacitracin"]]}, {"text": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "triple_list": [["sodium fluorescein", "None", "bacitracin"]]}, {"text": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ", "triple_list": [["NaCMC", "None", "NaFlu"]]}, {"text": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ", "triple_list": [["NaCMC", "None", "NaCMC"]]}, {"text": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ", "triple_list": [["NaCMC", "None", "cysteine"]]}, {"text": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ", "triple_list": [["NaFlu", "None", "NaCMC"]]}, {"text": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ", "triple_list": [["NaFlu", "None", "cysteine"]]}, {"text": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ", "triple_list": [["NaCMC", "None", "cysteine"]]}, {"text": "Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. ", "triple_list": [["cysteine", "None", "NaFlu"]]}, {"text": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ", "triple_list": [["NaCMC", "None", "cysteine"]]}, {"text": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ", "triple_list": [["NaCMC", "None", "NaFlu"]]}, {"text": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ", "triple_list": [["NaCMC", "None", "NaCMC"]]}, {"text": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ", "triple_list": [["cysteine", "None", "NaFlu"]]}, {"text": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ", "triple_list": [["cysteine", "None", "NaCMC"]]}, {"text": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ", "triple_list": [["NaFlu", "None", "NaCMC"]]}, {"text": "Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ", "triple_list": [["bacitracin", "None", "insulin"]]}, {"text": "Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ", "triple_list": [["bacitracin", "None", "NaCMC"]]}, {"text": "Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ", "triple_list": [["insulin", "None", "NaCMC"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["NaCMC", "None", "cysteine"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["NaCMC", "None", "NaFlu"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["NaCMC", "None", "bacitracin"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["NaCMC", "None", "insulin"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["cysteine", "None", "NaFlu"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["cysteine", "None", "bacitracin"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["cysteine", "None", "insulin"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["NaFlu", "None", "bacitracin"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["NaFlu", "None", "insulin"]]}, {"text": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "triple_list": [["bacitracin", "None", "insulin"]]}, {"text": "It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ", "triple_list": [["sulfamethoxazole", "None", "anticoagulant"]]}, {"text": "Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "triple_list": [["antiretroviral medications", "None", "enfuvirtide"]]}, {"text": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "triple_list": [["SUTENT", "None", "sunitinib"]]}, {"text": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "triple_list": [["SUTENT", "None", "sunitinib"]]}, {"text": "The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. ", "triple_list": [["dofetilide", "None", "digoxin"]]}, {"text": "Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; ", "triple_list": [["dofetilide", "None", "digoxin"]]}, {"text": "therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.", "triple_list": [["dofetilide", "None", "digoxin"]]}, {"text": "- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio). ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ", "triple_list": [["contraceptive", "None", "norethindrone"]]}, {"text": "Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ", "triple_list": [["contraceptive", "None", "estradiol"]]}, {"text": "Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ", "triple_list": [["norethindrone", "None", "estradiol"]]}, {"text": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ", "triple_list": [["prednisone", "None", "prednisolone"]]}, {"text": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ", "triple_list": [["prednisone", "None", "prednisone"]]}, {"text": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ", "triple_list": [["prednisone", "None", "prednisolone"]]}, {"text": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ", "triple_list": [["prednisolone", "None", "prednisone"]]}, {"text": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ", "triple_list": [["prednisolone", "None", "prednisolone"]]}, {"text": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ", "triple_list": [["prednisone", "None", "prednisolone"]]}, {"text": "Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ", "triple_list": [["montelukast", "None", "montelukast"]]}, {"text": "In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ", "triple_list": [["montelukast", "None", "contraceptives"]]}, {"text": "Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ", "triple_list": [["montelukast", "None", "montelukast"]]}, {"text": "Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). ", "triple_list": [["transferrin", "None", "EGF"]]}, {"text": "Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). ", "triple_list": [["transferrin", "None", "insulin"]]}, {"text": "Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). ", "triple_list": [["EGF", "None", "insulin"]]}, {"text": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "triple_list": [["dexamethasone", "None", "retinyl acetate"]]}, {"text": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "triple_list": [["dexamethasone", "None", "transferrin"]]}, {"text": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "triple_list": [["retinyl acetate", "None", "transferrin"]]}, {"text": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "triple_list": [["transferrin", "None", "EGF"]]}, {"text": "Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ", "triple_list": [["dexamethasone", "None", "retinyl acetate"]]}, {"text": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "triple_list": [["dexamethasone", "None", "glucocorticoids"]]}, {"text": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "triple_list": [["trovafloxacin", "None", "ciprofloxacin"]]}, {"text": "1 hour after starting the oxycodone or levofloxacin 500 mg p.o. ", "triple_list": [["oxycodone", "None", "levofloxacin"]]}, {"text": "There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. ", "triple_list": [["levofloxacin", "None", "levofloxacin"]]}, {"text": "It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.", "triple_list": [["oxycodone", "None", "levofloxacin"]]}, {"text": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "triple_list": [["Antacids", "None", "kaolin"]]}, {"text": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "triple_list": [["Antacids", "None", "Antacids"]]}, {"text": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "triple_list": [["Antacids", "None", "kaolin"]]}, {"text": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "triple_list": [["kaolin", "None", "Antacids"]]}, {"text": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "triple_list": [["kaolin", "None", "kaolin"]]}, {"text": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "triple_list": [["Antacids", "None", "kaolin"]]}, {"text": "Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.", "triple_list": [["Cimetidine", "None", "Cimetidine"]]}, {"text": "Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.", "triple_list": [["cyclosporin", "None", "chloroquine"]]}, {"text": "Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.", "triple_list": [["potassium-depleting diuretics", "None", "ethacrynic acid"]]}, {"text": "Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.", "triple_list": [["salicylate", "None", "steroids"]]}, {"text": "Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.", "triple_list": [["salicylate", "None", "aspirin"]]}, {"text": "Monitor salicylate levels or the therapeutic effect for which aspirin is given;", "triple_list": [["salicylate", "None", "aspirin"]]}, {"text": "Observe the patient for possible diminished effect of steroid and increase the steroid dosage accordingly.", "triple_list": [["steroid", "None", "steroid"]]}, {"text": "When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.", "triple_list": [["estrogen", "None", "corticosteroid"]]}, {"text": "When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.", "triple_list": [["estrogen", "None", "estrogen"]]}, {"text": "When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.", "triple_list": [["corticosteroid", "None", "estrogen"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "cyclosporine"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "sulfonylurea agents"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "warfarin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["thiazides", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "sulfonylurea agents"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "warfarin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["cyclosporine", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "warfarin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["sulfonylurea agents", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["warfarin", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["methotrexate", "None", "phenytoin"]]}, {"text": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.", "triple_list": [["Simulect", "None", "azathioprine"]]}, {"text": "Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).", "triple_list": [["Simulect", "None", "azathioprine"]]}, {"text": "Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).", "triple_list": [["Simulect", "None", "mycophenolate mofetil"]]}, {"text": "Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).", "triple_list": [["azathioprine", "None", "mycophenolate mofetil"]]}, {"text": "A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)", "triple_list": [["carbamazepine", "None", "tetracyclines"]]}, {"text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "triple_list": [["apomorphine", "None", "apomorphine"]]}, {"text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "triple_list": [["apomorphine", "None", "5HT3 antagonist class"]]}, {"text": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "triple_list": [["apomorphine", "None", "neuroleptics"]]}, {"text": "Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. ", "triple_list": [["thyroxine", "None", "simeticone"]]}, {"text": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "triple_list": [["DZNep", "None", "DZNep"]]}, {"text": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "triple_list": [["DZNep", "None", "DZNep"]]}, {"text": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "triple_list": [["DZNep", "None", "DZNep"]]}, {"text": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "triple_list": [["DZNep", "None", "ABT-737"]]}, {"text": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "triple_list": [["DZNep", "None", "DZNep"]]}, {"text": "Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.", "triple_list": [["CRIXIVAN", "None", "indinavir"]]}, {"text": "Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.", "triple_list": [["CRIXIVAN", "None", "indinavir"]]}, {"text": "Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.", "triple_list": [["CRIXIVAN", "None", "protease inhibitors"]]}, {"text": "Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.", "triple_list": [["CRIXIVAN", "None", "atazanavir"]]}, {"text": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.", "triple_list": [["indinavir", "None", "CRIXIVAN"]]}, {"text": "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.", "triple_list": [["ritonavir", "None", "CRIXIVAN"]]}, {"text": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.", "triple_list": [["atorvastatin", "None", "HMG-CoA reductase inhibitors"]]}, {"text": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.", "triple_list": [["atorvastatin", "None", "rosuvastatin"]]}, {"text": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.", "triple_list": [["HMG-CoA reductase inhibitors", "None", "rosuvastatin"]]}, {"text": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "triple_list": [["rifabutin", "None", "CRIXIVAN"]]}, {"text": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "triple_list": [["rifabutin", "None", "rifabutin"]]}, {"text": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "triple_list": [["rifabutin", "None", "CRIXIVAN"]]}, {"text": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "triple_list": [["CRIXIVAN", "None", "rifabutin"]]}, {"text": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "triple_list": [["CRIXIVAN", "None", "CRIXIVAN"]]}, {"text": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.", "triple_list": [["estazolam", "None", "4-hydroxy-estazolam"]]}, {"text": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.", "triple_list": [["estazolam", "None", "triazolobenzodiazepines"]]}, {"text": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.", "triple_list": [["4-hydroxy-estazolam", "None", "triazolobenzodiazepines"]]}, {"text": "Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.", "triple_list": [["fluoxetine", "None", "estazolam"]]}, {"text": "When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.", "triple_list": [["INDOCIN", "None", "indomethacin"]]}, {"text": "Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "triple_list": [["non-steroidal anti-inflammatory drugs", "None", "cyclosporine"]]}, {"text": "Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "triple_list": [["INDOCIN", "None", "lithium"]]}, {"text": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "triple_list": [["INDOCIN", "None", "lithium"]]}, {"text": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.", "triple_list": [["INDOCIN", "None", "lithium"]]}, {"text": "As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.", "triple_list": [["INDOCIN", "None", "digoxin"]]}, {"text": "Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Therefore, when INDOCIN and INDOCIN.", "triple_list": [["INDOCIN", "None", "INDOCIN"]]}, {"text": "(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "triple_list": [["diuretics", "None", "diuretic"]]}, {"text": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.", "triple_list": [["non-steroidal antiinflammatory drugs", "None", "INDOCIN"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "TAXOL"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "TAXOL"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["cisplatin", "None", "TAXOL"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["cisplatin", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["cisplatin", "None", "TAXOL"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["cisplatin", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "TAXOL"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["cisplatin", "None", "TAXOL"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["cisplatin", "None", "cisplatin"]]}, {"text": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "triple_list": [["TAXOL", "None", "cisplatin"]]}, {"text": "Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.", "triple_list": [["paclitaxel", "None", "TAXOL"]]}, {"text": "Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.", "triple_list": [["doxorubicin", "None", "paclitaxel"]]}, {"text": "Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.", "triple_list": [["doxorubicin", "None", "doxorubicin"]]}, {"text": "Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.", "triple_list": [["cyclosporin", "None", "teniposide"]]}, {"text": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "triple_list": [["TAXOL", "None", "corticosteroids"]]}, {"text": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "triple_list": [["TAXOL", "None", "H2 antagonists"]]}, {"text": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "triple_list": [["TAXOL", "None", "cimetidine"]]}, {"text": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "triple_list": [["corticosteroids", "None", "H2 antagonists"]]}, {"text": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "triple_list": [["corticosteroids", "None", "cimetidine"]]}, {"text": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "triple_list": [["H2 antagonists", "None", "cimetidine"]]}, {"text": "To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ", "triple_list": [["GL", "None", "antibiotics"]]}, {"text": "To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ", "triple_list": [["GL", "None", "oxytetracycline"]]}, {"text": "To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ", "triple_list": [["antibiotics", "None", "oxytetracycline"]]}, {"text": "Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.\r\n", "triple_list": [["estradiol", "None", "progesterone"]]}, {"text": "The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. ", "triple_list": [["progesterone", "None", "noradrenaline"]]}, {"text": "injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. ", "triple_list": [["estradiol", "None", "progesterone"]]}, {"text": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "triple_list": [["noradrenaline", "None", "progesterone"]]}, {"text": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "triple_list": [["noradrenaline", "None", "progesterone"]]}, {"text": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "triple_list": [["progesterone", "None", "progesterone"]]}, {"text": "A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.", "triple_list": [["nimodipine", "None", "cimetidine"]]}, {"text": "A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.", "triple_list": [["nimodipine", "None", "nimodipine"]]}, {"text": "In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.", "triple_list": [["MTX", "None", "corticosteroids"]]}, {"text": "In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.", "triple_list": [["MTX", "None", "folic acid"]]}, {"text": "Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.", "triple_list": [["immunosuppressants", "None", "immunosuppressants"]]}, {"text": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.", "triple_list": [["infliximab", "None", "antibiotics"]]}, {"text": "In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ", "triple_list": [["vigabatrin", "None", "phenytoin"]]}, {"text": "In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ", "triple_list": [["phenylpropanolamine", "None", "ProAmatine"]]}, {"text": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ", "triple_list": [["ProAmatine", "None", "ProAmatine"]]}, {"text": "The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "triple_list": [["cocaine", "None", "desipramine"]]}, {"text": "Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05). ", "triple_list": [["mazindol", "None", "norepinephrine"]]}, {"text": "Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. ", "triple_list": [["norepinephrine", "None", "cocaine"]]}, {"text": "Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined. ", "triple_list": [["FLOMAX", "None", "alpha-adrenergic blocking agents"]]}, {"text": "The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated. ", "triple_list": [["cimetidine", "None", "FLOMAX"]]}, {"text": "Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive. ", "triple_list": [["tamsulosin HCI", "None", "warfarin"]]}]